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Antibiotic resistance is a critical global health care crisis, which requires urgent action to 
develop more effective antibiotics. This study has designed and tested two novel membrane 
targeting antimicrobials, which are effective against drug-resistant (DR) and multidrug-
resistant (MDR) resistant pathogens: amphiphilic xanthone derivatives and N-lipidated 
peptide dimers. Utilizing the hydrophobic scaffold of xanthone, a number of potent 
amphiphilic xanthone derivatives against Gram-positive bacteria were developed. In general, 
specific molecular components attached to a core molecule were required to mimic the 
membrane-targeting action of an antimicrobial cationic peptide: a hydrophobic core, cationic 
moieties with an appropriate spacer length and isoprenyl groups. Compound 9 (AM-0016), a 
xanthone derivative modified with N,N-diethylamine was first identified as a potent 
antimicrobial against Gram-positive bacteria. Compound 9 also killed bacteria rapidly and 
did not induce drug resistance. However, compound 9 was not effective in vivo. To further 
improve the activity, N,N-diethylamine was replaced with arginine, a cationic amino acid. 
Compounds 57 (AM-0052) and 61 (AM-0218), which contain a hydrophobic xanthone core, 
lipophilic chains and cationic amino acids, displayed very promising antimicrobial activities 
such as  rapid time-kill, avoidance of antibiotic resistance and low toxicity against multidrug-
resistant Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus 
(MRSA) and Vancomycin-Resistant Enterococci (VRE). The bacterial membrane selectivity 
of these molecules was comparable to that of several membrane-targeting antibiotics in 
clinical trials. Significantly, 57 and 61 were effective in a mouse model of corneal infection 
by S. aureus and MRSA. Evidences are presented and indicated that amphiphilic xanthone 
derivatives target the negatively charged bacterial membrane via a combination of 
electrostatic and hydrophobic interactions. 
X 
 
In addition to Gram-positive pathogens, selected amphiphilic xanthone derivatives were 
also used to investigate their anti-mycobacterial activities. The results showed that 
compounds 9, 19 (AM-0163) and 27 (AM-0009) were active against M. smegmatis, M. bovis 
and M. tuberculosis. Compounds 9 and 19 also displayed rapid bactericidal action against 
these mycobacteria. Biophysical studies have revealed that amphihilic xanthone derivatives 
also induced cell death via membrane targeting pathway. ATP leakage was detected, which 
implied that ATP starvation could be a reason for the bacterial death. 
The treatment of infections caused by multidrug-resistant (MDR) Gram-negative 
pathogens is challenging as only a few viable therapeutic options are available. In this study, 
a series of N-lipidated peptide-dimers (Cn-B2088) that displayed potent antimicrobial 
activities against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae 
(CRE) were identified. The optimized lipid length consisted of carbon numbers of 6 – 10. 
With these lipid lengths, the N-lipidated peptide-dimers showed strong outer membrane 
permeabilization. Interestingly, C8-B2088 displayed synergy with selected antibiotics in most 
of the combinations tested. Significantly, C8-B2088 and C8-B2099 were non-hemolytic at 
high concentration even up to 10 mg/mL, and were nontoxic in vitro and in vivo. N-lipidated 
peptide dimers also displayed potent activity against Gram-positive pathogens. 
Taken together the design principles presented here, it has led to successful and potent 
antimicrobials with desirable properties which include potent antimicrobial activity, rapid 
time-kill, promising selectivity, low toxicity and active in vivo render amphiphilic xanthone 
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1.1 Antibiotic resistance 
Today, antibiotic resistance is a critical global healthcare problem. In addition, it is also 
emerged as a global threat to humanity. Antibiotic resistance is widely associated with failure 
of clinical treatment, additional mortality and healthcare costs.
1
 Emergence of virulent and 
deadly multidrug resistance pathogens or superbugs, such as methicillin-resistant 
Staphylococcus aureus (MRSA) and carbapenem-resistant enterobacteriaceae (CRE) are 
continuing examples of the problem of resistance.
2
 For instance, Rice has identified that the 
“ESKAPE” pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species 
are the major cause of the majority of US hospital infections and effectively “escape” the 
effects of antibacterials.
3
 These infections could be classified into 2 major groups: Gram-
positive and Gram-negative infections. 
1.1.1 Gram-positive infections 
Gram-positive infections are the diseases caused by Gram-positive bacteria. For instance, 
methicillin-resistant S. aureus (MRSA) is a leading cause of nosocomial infections 
worldwide. MRSA is an emergent form of S. aureus, which confers resistance to β-lactam 
antibiotics.
4
 Expression of a unique penicillin binding protein (PBP2a) mediates the 
resistance against methicillin. PBP2a has very low affinity for all β-lactam antibiotics. 
Consequently, the bacteria could survive in the presence of high concentrations of β-lactam 
antibiotics.
5
 Gene mecA, located at staphylococcal cassette chromosome is found to encode 
the PBP2a.
6
 In addition to methicillin, several reports also have shown that, MRSA has 
acquired resistance against a wide range of antibiotic classes, including β-lactams (oxacillin 
and ampicillin), fluoroquinolones, tetracyclines, macrolides, lincosamides, aminoglycosides 





1.1.1.1 Methicillin-resistant S. aureus 
Diseases caused by MRSA include bacteremia, endocarditis, metastatic infection, sepsis 
and toxic shock syndrome, with an overall mortality rate of 11-43%
8
. MRSA infection is 
wide spread in hospitals, emergency departments and intensive care unit
9
, and has been 
identified as the main causes of soft tissue infection
10
, blood stream infection
11
 and prosthetic 
joint infection
12
. Furthermore, the death rate is higher than combine death rate of AIDs and 
tuberculosis in US and Europe, the situation may be more severe in developing countries
13
.  
In Singapore hospitals, 35 % of isolates of S. aureus are methicillin resistant.
14
 Since year 
1985, almost all MRSA infections are hospital-acquired (HA-MRSA),
14b, 15
 which  accounts 
for 0.31 bacteraemias/1000 inpatient days, or two to three MRSA bacteraemias per week at 
the largest hospital.
16
 HA-MRSA is widely associated with an outbreak of MRSA 
colonization among healthcare workers and patients in Singapore hospitals.
17
 ST239-MRSA-
III and EMRSA-15 are the two major MRSA strains isolated.
18
 In year 2006, emergence of 
community-associated MRSA (CA-MRSA) have been reported, including 2 cases of fatal 
bacteraemic pneumonia.
19
 According to Centers for Disease Control and Prevention, CA-
MRSA infections are the MRSA infections that are acquired by healthy people, who have not 
been hospitalized nor had a medical procedure (such as catheters or surgery) within the last 
year. CA-MRSA tends to infect skin and soft tissue. In addition, CA-MRSA also attributes 
Panton-Valentine leukocidin, which increase the virulence associated with MRSA.
19
 In 
general, similar to global healthcare problem, MRSA infections (HA-MRSA and CA-MRSA) 








1.1.1.2 Vancomycin-resistant enterococci 
In addition to MRSA, infections associated with vancomycin-resistant enterococci (VRE) 
are also increasing and difficult to treat.
20
 The major diseases caused by VRE are wound 
infections, urinary tract infections, bacteremia and endocarditis. VRE can have high level of 
resistance to the glycopeptides class of antibiotics such as vancomycin and teicoplanin.
21
 
Similar to MRSA, resistance among enterococcal isolates against other classes of antibiotics, 
such as linezolid
22
, β-lactams,23 daptomycin24 and tigercycline25 have been increasingly 
reported. DiaGranados et al has also reported that the mortality rate was significantly higher 
in patients infected by VRE.
26
  
These very current issues have created an urgent need for improved antimicrobial agents 
against multidrug resistant pathogens, because many antibiotics are no longer effective 
against bacterial infections that were once easily treated. Therefore, there is an urgent 
medical need for a sustainable supply of new, effective, safe antimicrobials without cross-
resistance with currently used antibiotics. In this thesis, I will describe a novel strategy to 
develop effective antimicrobials against multi-drug resistant Gram-positive pathogens, 
including MRSA and VRE. 
1.1.2 Gram-negative infections 
Since year 2000, four new classes of antibiotics have been approved by FDA: linezolid 
(2000), daptomycin (2003), retapamulin (2007), fidaxomicin (2010) and bedaquiline (for 
MDR tuberculosis, 2012).
27
 However, it must be noted that these newly approved antibiotics 
are only limited to the treatment of Gram-positive bacterial infections. In fact, multidrug-
resistant (MDR) Gram-negative bacterial infections are capable of causing serious infections 
such as bacteremia, pneumonia and urinary tract infections that are being encountered with 
increased frequency in hospitals.
28
 For instance, Gram-negative bacteria such as Escherichia 
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coli, K. pneunoniae, A. baumannii and P. aeruginosa have emerged as multi or extremely 
resistant strains rapidly.
29
 The treatment of infections caused by these MDR pathogens is also 
challenging as only few viable therapeutic options are available. 
1.1.2.1 P. aeruginosa 
P. aeruginosa is a Gram-negative pathogen, which is considered as “superbug” due to its 
enormous capacity to engender resistance. P. aeruginosa is also one of the leading causes of 
nosocomial infections and chronic lung infections in cystic fibrosis.
30
 P. aeruginosa 
infections account for 54.4% of the whole cystic fibrosis patients.
31
 Compared with Gram-
positive bacteria, P. aeruginosa has a very low permeable outer membrane, which consists of 
lipopolysaccharide (LPS). This outer membrane is a barrier to most of the antibiotics by 
limiting their rate of penetration into the cells. Moreover, Hancock el al has reported that the 
outer membrane permeability of P. aeruginosa is 12-100 times less than that of E. coli.
32
 
Thus, P. aeruginosa displays high intrinsic resistance to a wide variety of antibiotics, 
including β-lactam, fluoroquinolones and aminoglycosides.33 In addition to its high intrinsic 
resistance, P. aeruginosa also acquires resistance via horizontal transfer of genetic element 
and mutational resistance.
33
 These acquired resistance lead to reduced antibiotics uptake and 
efflux pump overexpression.
34
 P. aeruginosa is also capable of forming biofilm.
35
 
Accumulating evidence also suggests that biofilm bacteria are able to withstand antibiotic-
mediated killing in the presence of high concentrations of antibiotic.
36 
This biofilm lifestyle is 





Therefore, biofilm infections have been correlated with 
the failure of antibiotic treatment and infection recurrence or persistent infection.
38
 These 
high intrinsic and extrinsic resistance profiles of P. aeruginosa have rendered only a few 
antibiotic choices left for the treatment. 
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1.1.2.2 Carbapenem-resistant Enterobacteriaceae 
CRE has emerged as a new resistance threat to public health. E. coli and K. pneunoniae 
from the family Enterobacteriaceae are among the most common pathogens in human. They 
are also causing life threatening infections including pneumonia, peritonitis bacteremia and 
meningitis.
2b
 Historically, Enterobacteriaceae could be eradicated easily by wide range of 
antibiotics. However, in the past 30 years, a progressive increase in the number of multi-drug 
resistant Enterobacteriaceae has been reported as these pathogens are becoming more wide 
spread.
39
 Antibiotics from the carbapenem class have been used as the last resort in treating 
these infections. However, the emergence of novel β-lactamases with direct carbapenem-
hydrolyzing activity (carbapenemases) has increased the resistance of Enterobacteriaceae 
against carbapenem.
40
 CREs were rare but the incidence has been increasing. One of the most 
important and common carbapenemases in United State is Klebsiella pneumoniae 
carbapenemase (KPC).
41
 KPC-producing Enterobacteriaceae has spread globally to North 
Africa, Europe, China Canada, South America and India.
42
 First case of KPC-producing 
Enterobacteriaceae reported in Singapore was in year 2011.
43
 In Singapore, New Delhi 
metallo-beta-lactamase (NDM) is the most dominant carbapenemases found in CRE.
43
  
Subcontinent of India and Pakistan was the first recognized endemic region for NDM 
producing Enterobacteriaceae.
40
 To date, there is no reliable treatment available for infections 
caused by carbapenem-resistant Enterobacteriaceae.2b Several reports have shown that 
patients suffering from CRE infections require longer length of hospital stay, have poor 
functional status, greater intensive unit stays and an increase in mortality.
44
 As the spread of 
CRE has devastating consequences for global public health, development of a novel 
antibiotic that is effective against CRE should be addressed with urgency. In this thesis, I will 
describe my work to discover a novel antimicrobial, N-lipidated peptide dimer, which is 
active against a panel of multi-drug resistant P. aeruginosa and CRE. 
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1.1.3 Mycobacterial infections 
Every year, it is estimated that two million die from tuberculosis (TB) with approximately 
eight million people develop active TB.
45
 Mycobacterium tuberculosis is the causative agent 
of this deadly disease. To date, about one-third of the world’s population asymptomatically 
carry a latent form of M. tuberculosis. Accompanied by immune suppression, the latent TB is 
commonly activated. Therefore, reactivation of latent TB poses a high risk to those co-
infected with human immunodeficiency virus (HIV), or on an anti-tumour necrosis factor 
therapy or with diabetes.
46
 For instance, of the 9.4 million cases of TB infections in 2009, 11-
13% of them were HIV positive.
47
 Among HIV-positive patients, TB also accounts for about 
one in four deaths.
47
  
Drug-resistant TB has led to one of the greatest challenges in TB control. First-line anti-
TB drugs used in drug-susceptible-TB (DS-TB) includes ethambutol, rifampicin, isoniazid 
and pyrazinamide. Rifampicin, which was discovered in 1963, is the last drug with a new 
mechanism approved for TB treatment. However, emergence of multidrug-resistant strains 
(MDR-TB) has further complicated the effort to control TB. MDR-TB is resistant to at least 
rifampicin and isoniazid, the two most effective first-line anti-TB drugs. MDR-TB treatment 
is much more difficult and costly compared to DS-TB. The cure rates of MDR-TB are lower, 
in the range of 50-70%, in contrast to 95% cure rate for DR-TB.
48
 Unfortunately, the cases of 
extensively drug-resistant TB (XDR-TB) have also been reported.
49
 XDR-TB strains are 
resistant not only to rifampicin and isoniazid, but also to fluroquinolones and injectable 
second-line anti-TB drugs such as aminoglycosides. The cure rate of XDR-TB further 
reduces to 30%. In addition, a full course treatment for MDR-TB and XDR-TB requires at 
least 20 months therapy with highly toxic and costly medications.
50
 Serious side effects have 
been reported, including nephrotoxicity with aminoglycosides, heptatotoxicity with 





In addition to resistance, persistence and chronic infections are also great problems with 
TB. M. tuberculosis commonly undergoes physiological adaptations to grow slowly or stop 
growing in response to unfavourable conditions.
52
 A fraction of these non-growing 
specialized persister cells arises during this phase. These metabolically inactive persister cells 
are able to survive under high concentration of antibiotics during the treatment. Consequently, 
when the drug concentration falls below levels that kill or inhibit the growing cells, persister 
cells can reactivate to become active growing cells. The host will be infected and symptoms 
of disease are shown again. Most TB-drugs that are currently used clinically, target processes 
required for growth, such as biosynthesis of mycolic acid (ethambutol and isoniazid), enzyme 
inhibition (pyrazinamide), biosynthesis of protein (streptomycin) and DNA 
(fluoroquinolone).
52
 Therefore, these antibiotics are not effective for eradicating persistent 
infections in which bacteria are slow-growing. Therefore, TB persistence is widely associated 




In Southeast Asia, the incidence of tuberculosis in Singapore is the lowest.
48
 The 
incidence rate in Singapore is 38 cases per 100,000 resident population in year 2013. MDR-
TB cases in Singapore remained low, as it only comprised of 0.3% of new cases. Fortunately, 
to date, no XDR-TB has been reported among Singapore residents. A mortality rate of 1.2 
cases per 100,000 population was recorded in year 2013 among Singapore residents.
53
 
However, there is still a significant risk of MDR-TB or XDR-TB to be spread into Singapore 
from foreigners who come for work or study. Many of those foreigners originate from 
countries such as China, India, Philippines, Myanmar or Vietnam with a high risk of TB 
(MDR-TB and XDR-TB). In general, the current situation necessitates the immediate 




1.2 Antibiotics crisis 
1.2.1 Existing antibiotics scaffolds 
Emergence of drug-resistant superbugs and the dearth of new classes of antibiotics have 
drawn increasing awareness that we may return to the pre-antibiotic era. Many antibiotics 
used today share a common scaffold or molecular core. Aside of the introduction of 
carbapenems in 1985, almost all antibiotics currently approved were derived from existing 
scaffolds introduced between the mid-1930s and the early 1960s.
54
 From the early 1960s to 
1999, the innovative antibiotic pipeline dried up as no major classes of antibiotics were 
introduced. To date, most of the approved antibiotics today are still dominated by these old 
antibiotics scaffold or class discovered half a century ago. For example, cephalosporins, β-
lactams, quinolones and macrolides account for 73% of the new chemical entities launched 
between the years 1981-2005.
55
 Figure 1.1 shows the year of discovery of these antibiotic 
scaffolds. Figure 1.2 shows the chemical structure of selected antibiotic scaffolds discovered 
before the year 2000.  
In a Nobel Speech of Dr Alexander Fleming in December 1945, we are in a chemical age 
and penicillin may be changed by the chemists, so that all its disadvantages may be removed 
and a newer and a better derivative may be produced. Synthetic tailoring remains the major 
strategy to improve antibiotic properties to combat bacterial resistant. Synthetic tailoring 
involves modification of the chemical moieties at the periphery of an antibiotic scaffold, 
while the scaffold is left intact. For instance, nalidixic acid, ciprofloxacin, levofloxacin and 
moxifloxacin are derived from a quinolone scaffold, while oxytetracycline, doxycycline and 
tigecycline are tailored from a common tetracycline scaffold. Synthetic tailoring could design 
a new generation of compounds against pathogens that have become resistant to the previous 
generation. For example, a pathogen develops resistance against the 1
st
 generation of 
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cephalosporins by producing enzyme β-lactamese. Then, development of second- and third-
generations of cephalosporins, which are more resistant to destruction by the enzyme β-
lactamase allows renewed activity.
56
 Nevertheless, the effect of tailored antibiotics to fight 
for pathogen resistant is short. Third-generation cephalosporins were introduced into clinical 
practise in 1980, but resistant has emerged three years later in 1983.
57
 When new β-
lactamases (generation of extended-spectrum β-lactamases) emerged and rendered the third-
generation of cephalosporins inactive, the fourth-generation cephalosporins, which have 
greater resistance to β-lactamases than the third-generation cephalosporin, were developed.58 
Cefepime, a fourth-generation cephalosporin, has been introduced into clinical practice in 
year 1994.
59
 However, to date, many cases of cefepime-resistant pathogens have been 
reported.
59
 Similar problems are observed for quinolones, which pathogens emerged resistant 
rapidly, whenever a new generation of quinolone was introduced into clinical practise.
60
 In 
general, cross-resistance is a common phenomenon for antibiotics that share a similar 
mechanism of action.
61
 Therefore, discovery of new classes of antibiotics with novel 











Figure 1.1.  Existing scaffolds of antibiotic used in clinical treatment today. The arrow 





Figure 1.2. Scaffolds of selected antibiotics discovered in between mid-1930s to year 1999. 





1.2.2 New antibiotics scaffolds (since year 2000) 
In between years 2000 to 2012, twenty-two new antibiotics have been launched 
worldwide.
27a
 Seventeen of them are derived from existing scaffold such as macrolide, 
quinolone, carbapenem, tetracycline and cephalosporin backbones. However, the situation 
has improved as five new classes of antibiotic have been launched since year 2000: 
oxazolidinones, lipopeptides, mutilins, tiacumicin and diarylquinoline. Fidaxomicin is a 
tiacumicin with a macrocyclic-lactone structure (Figure 1.1).
62
  
The oxazolidinones are a novel chemical class of synthetic antimicrobial agents. 
Linezolid is an oxazolidinone, first used in clinical practise in 2000. Linezolid is approved for 
infections caused by Gram-positive pathogens, including MRSA and VRE. However, in 2001, 
emergence of linezolid-resistant S. aureus was already reported.
63
 Daptomycin is a cyclic 
lipopeptide antibiotic approved by US FDA in 2003 for the treatment of complicated skin and 
skin structure infections associated with S. aureus or MRSA.
64
 It is noteworthy that 
daptomycin is a bactericidal drug that could achieve a 3-log reduction (99.9%) of certain 
strains of S. aureus in 1 hour, but requires more than 12 hours to achieve than same level of 
killing for MRSA.
65
 However, it is noteworthy that daptomycin was not a new compound as 
it has been developed by Eli Lilly and Company in the late 1980s. Emergence of resistance 
against daptomycin has also been reported.
24, 66
 Retapamulin is the first in a new class of 
antibiotic known as pleuromutilin, which is approved by FDA in year 2007. Retapamulin is 
used for the topical treatment of impetigo, a highly contagious superficial skin infection 
caused by bacteria.
67
 Retapamulin is a semisynthetic derivative of pleuromutilin that has 
excellent in vitro activity against Gram-positive bacteria including S. aureus and 
Streptococcus pyogenes.
68
 Fidaxomicin is a narrow spectrum antibiotic used for the treatment 
of intestinal infections and diarrhea caused by Clostridium difficile (a pore-forming Gram-
positive pathogen).
69





addition, cross-resistance among fidaxomicin with macrolides, β-lactams, lincosamides, 
aminoglycosides, and rifampin has also not been observed.
70
 Bedaquiline will be discussed in 
detailed in Section 1.2.3: TB-drug development pipeline. Chemical structures of linezolid, 
daptomycin, retapamulin, fidaxomicin and bedaquiline are shown in Figure 1.3. 
1.2.3 TB-drugs development pipeline  
Before bedaquiline was approved by the FDA in 2012, rifampicin, discovered 50 years 
ago, is the last novel class of antibiotics used in clinical practise as a first-line agent for 
tuberculosis treatment. Bedaquiline (TMC-207), a diarylquinoline-antibiotic, was discovered 
using a high-throughput screening against Mycobacterium smegmatis.
71
 TMC-207 is an ATP 
inhibitor by targeting subunit c of mycobacterial ATP synthase.
72
 Bedaquiline is approved by 
FDA for as part of a combination therapy for MDR pulmonary TB treatment when other 
alternatives are not available. However, Bedaquiline interacts with CYP450-3A4, which 
carries considerable drug interaction and there were significantly more deaths in the treated 
than placebo group in some studies.
73
 In fact, bedaquiline was also approved with a black box 
warning that highlighted the possibility of severe cardiovascular side effects.
74
 
As of August 2014, all TB drugs in the developmental pipeline were engineered from 
existing scaffolds: fluoroquinolones, nitroimidazoles, oxazolidinones, rifamycin and 
ethylenediamines. Their chemical structures are shown in Figure 1.4. Currently, there are ten 
compounds in the clinical development pipeline for tuberculosis.
51
 Linezolid, rifapentine, 
gatifloxacin and moxifloxacin are four existing antibiotics that have been redeveloped for 
tuberculosis treatment. The others are new compounds that are specifically developed for 
tuberculosis (SQ-109, delamanid, PNU-100480, AZD-5847 and PA-824).  
Ciprofloxacin, ofloxacin, levofloxacin and sparfloxacin are fluoroquinolones used as 
second-line drugs for the treatment of MDR tuberculosis.
75
 Gatifloxacin and moxifloxacin are 
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the most recently developed fluoroquinolones, which display better in vitro activity against M. 
tuberculosis.
76
 Both gatifloxacin and moxifloxacin have completed phase 3 studies.
77
  
Nitroimidazoles are traditionally used to treat anaerobic bacteria and parasitic 
infections.
47
 It also represents an established scaffold for which synthesis modifications have 
been introduced to improve their activity against M. tuberculosis. PA-824 and delaminid are 
two nitroimidazoles in the clinical development. They are both bactericidal candidates and 
active against non-replicating or hypoxic induced dormant bacteria.
78
 This indicates that they 
have potential in shortening treatment for active disease.  
PNU-100480 and AZD-5874 are derivatives of oxazolidinones that are specifically 
developed for tuberculosis. Both compounds have completed phase 1 study.
77
 PNU-100480 
displays better in vitro and in vivo activity against M. tuberculosis than linezolid.
79
 Wiliams 
et al also reported that addition of PNU-100840 to isoniazid and pyrazinamide could shorten 
the treatment of drug-susceptible and drug-resistant tuberculosis.
80
 SQ-109 is an ethambutol 
analogue that has recently completed a phase 2 trial for patients with pulmonary TB.
27a
 SQ-
109 could interact synergistically with isoniazid and rifampicin.
81
 
Given the fact that the low success rate encountered in clinical development, there are 
still a worryingly low number of potential new chemical entities in the TB drug pipeline at 
the moment.
82
 Many more need to be discovered and developed. 
1.2.4 Future outlook  
The extremely serious threat of resistance to the current arsenal of antibiotics has started 
to capture the attention of the pharamaceutical industry, academic and small drug companies. 
There is a slow, but steady stream of new antibiotics with novel scaffolds entering the clinical 
pipeline for Gram-positive bacteria. However, this is not the case for Gram-negative bacteria 
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and M. tuberculosis. The current clinical pipeline for Gram-negative bacteria and tuberculosis 
are insufficient to address the unmet needs for better treatments. Therefore, the identification 
of structurally novel antimicrobial agents are likely to have different modes of action from 
existing antibiotics, should be a priority because this decreases the likelihood of cross 






















Figure 1.3 Chemical structures of antibiotics with new scaffold launched since year 2000: 












Figure 1.4. Structures of first-line TB drugs and TB drugs in clinical pipelines. For the TB 
drugs in the clinical pipelines, 4 major classes of scaffolds are fluoroquinolones, 









1.3 Conventional antibiotics: Mode of action and target 
Most of the antibiotics used in clinical today were developed during golden era of 
antibiotic drug discovery (1940s-1980s) (Figure 1.1). These conventional antibiotics are 
effectively inhibiting the growth of metabolically active bacteria.
83
 The major target of these 
antibiotics involves five main biosynthetic processes that occur in actively growing bacteria: 
biosynthesis of proteins, RNA, DNA, peptidoglycan and folic acid.
84
 Table 1.1 shows the 
mode of action and the targets of the major conventional antibiotics used today. Table 1.2 
shows the mode of actions of TB drugs. 
Table 1.1 Mode of action and targets of the major conventional antibiotics. The Table is 
adapted and updated from  a review.
84
 Lipopeptide class of antibiotic is not included. 












Sulfonamides Sulfamoxole Folic acid synthesis Dihydropteroate synthetase 
Tetracyclines Tigecycline Protein synthesis 30S ribosomal subunit 
Chloramphenicol Chloramphenicol Protein synthesis 50S ribosomal subunit 
Aminoglycosides Gentamicin Protein synthesis 30S ribosomal subunit 
Macrolides Telithromycin Protein synthesis 50S ribosomal subunit 
Glycopeptides Vancomycin Peptidoglycan synthesis Cell wall peptidoglycan 
Quinolones Moxifloxacin DNA replication/transcription Gyrase and topoisomerase IV 
Streptoglamins Pristinamycin Protein synthesis 50S ribosomal subunit 
Oxazolidinones Linezolid  Protein synthesis 50S ribosomal subunit 
Pleuromutilins Retapamulin Protein synthesis 50S ribosomal subunit 
Tiacumicin Fidaxomicin RNA transcription RNA polymerase 
a






Table 1.2. Mode of action and targets of selected anti-TB agents. 
Antibiotics/Class Drug Status Function inhibited Molecular target 
Rifampicin First-line agent RNA synthesis RNA polymerase 
Isoniazid First-line agent Cell-wall synthesis Fatty acid synthase  
Pyrazinamide First-line agent Fatty acid synthesis Fatty acid synthase  
Ethambutol First-line agent Cell-wall synthesis Arabinosyl transferase 
Aminoglycoside Second-line agent Protein synthesis 30S ribosomal subunit 
Cycloserine Second-line agent Cell-wall synthesis Alanine racemase and D-
alanine-D-alanine ligase 
Fluoroquinolones Second-line agent DNA 
replication/transcription 
DNA gyrase 
Bedaquiline Newly approved agent ATP production ATP synthase  
Nitroimidazoles Clinical pipeline DNA and cellular damage Many targets 









1.3.1 Mechanisms of antibiotic resistance 
Bacteria have developed resistance to all classes of conventional antibiotics (Table 1) 
discovered to date. Most of these conventional antibiotics are bacteriostatic agents.  
Bacteriostatic agents prevent the growth of bacteria, by keeping them in the stationary phase 
of growth.
85
 In term of microbiology, bacteriostatic agents could not achieve a 99.9% 
reduction in a viable bacterial density in an 18–24 h period.85 They must work together with 
the immune system to remove the pathogens. As the bacteria are not killed in the exposure of 
the conventional antibiotics, resistance could be developed. In addition, it is not difficult to 
make microbes resistant to penicillin in the laboratory by exposing them to concentrations not 
sufficient to kill them, and the same thing has occasionally happened in the body.  
Inhibition of bacterial growth via interference with an intracellular component in the 
biochemical pathway is the major targets of these conventional antibiotics. These targets 
seem to make it easier for the bacteria to develop resistance upon excessive prescription and 
misuse.
86
 Several reports have indicated that bacteria develop resistance via several pathways 
including bypassing the inhibited step, modifying the site of action, efflux mechanisms, target 
mutation and modifications of cell wall permeability.
87
 It is imperative to gain a good 
understanding of the molecular basis for the development of bacterial resistance, as it could 
provide a new strategy to develop new agents to overcome resistance. In general, there are 
two major mechanisms of bacterial resistance: Genetic and biological.
88
 
Genetic mechanisms of resistance involve genetic mutations or acquisition of resistant 
genes from other bacterial cells, called lateral gene transfer. In the presence of antibiotics, a 
potent stimulus could be produced to elicit a bacterial adaption response. Susceptible bacteria 
can acquire resistance to antibiotics via genetic mutations in response the micro-ecological 
pressure exerted by the presence of the antibiotics.
89
 The majority of bacteria cells in colonies 
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are inhibited or dead. However, resistant cells will survive and possess the genetic 
determinants to confer antibiotic resistance. Normally, these antibiotic resistance genes are 
located in specialized fragments of DNA known as transposons.
89
 Transposons can be 
transmitted, spread and propagated to other bacteria easily.
88-89
 Some transposons contain a 
special DNA fragment an “integrin”, which can integrate different antibiotic genes for 
resistance.
88
 Consequently, bacteria could confer multiple forms of antibiotic resistance, and 
multidrug resistant pathogen could emerge.  
When the resistant gene is transferred to a bacterium, antibiotic resistance is developed 
when the transferred gene is able to express itself to produce a tangible biological effect to 
render the antibiotic ineffective. There are three major biological mechanisms of resistance: 
Antibiotic destruction, antibiotic active efflux and receptor modification.
89
 Antibiotic 
destruction involves the synthesis of one or more enzymes that chemically degrade or modify 
the antibiotic. The degraded or modified antibiotic will be inactive against the bacteria. The 
most well-known example of this biological resistance is the production of β-lactamases to 
degrade β-lactam antibiotics.90 Another form of resistance, the antibiotic active efflux 
mechanism occurs when an efflux pump removes antibiotic molecule from the bacterium 
until the concentration of the antibiotic falls below the threshold to display antibacterial 
activity. This is a common mechanism of bacterial resistance against tetracycline, macrolides 
and fluoroquinolones.
89, 91
 Receptor modification involves the alternation of the target of 
receptor of an antibiotic. Consequently, the antibiotic could not bind to the receptor and exert 
its antibacterial effect. For instance, modification in the structural conformation of penicillin-
binding protein will confer penicillin resistance, ribosomal alternations that can make 
macrolides, aminoglycosides and tetracyclines inactive, or modification of DNA gyrase 





Bacterial biofilm is a critical global healthcare problem, as it accounts for over 80% of 
microbial infections in the body and can be up to 1000-fold more resistant to antibiotics than 
planktonic (free living) bacteria.
92 
A bacterial biofilm is defined as multicellular microbial 
communities that is embedded and protected by a self-produced extracellular matrix. 
Accumulating evidence also suggests that biofilm bacteria are able to withstand antibiotic-
mediated killing, even in the presence of high concentrations of antibiotic.
36 
This biofilm 
lifestyle is called “bacterial recalcitrance”. Bacterial recalcitrance is a very complex issue 
arose from bacterial tolerance (bacteria to avoid antibiotic-induced cell death in the presence 
of bactericidal antibiotic)
37a
 and resistance (the ability of a microorganism to grow in the 
presence of an antibiotic).
37b 
Therefore, biofilm infections are also widely associated with the 
failure of antibiotic treatment, infection recurrence or persistent infection and greater health 
care costs.
38
 S. epidermidis, P. aeruginosa, S. aereus and Enterobacteriaceae are most 
frequent causes of medically-relevant biofilm infections. Most of the developed antibiotics 
that are currently used in clinical use target processes required for growth: biosynthesis of 
proteins, peptidoglycan, folic acid, DNA and RNA.
52
 Therefore, these antibiotics are not 
effective for eradicating persistent infections in which bacteria are slow-growing, such as 
bacteria in biofilm. 
1.4 New drug target: Bacterial membrane  
At present, antibiotics are not developed for specific drug targets unless the modification 
was emerged from old drugs. When a new drug is discovered, the target is then elucidated 
and investigated. What is needed is a target for which drugs can be developed in an objective 
manner, and that can be further refined over time. Additionally, that target needs to show less 
susceptibility to mutation than existing targets. This approach would also minimize cross-
resistance developed with existing antibiotics. The bacterial membrane is promising as a new 
drug target.  
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In general, the bacterial membrane has two layers: outer membrane and inner membrane. 
Gram-positive bacteria, Gram-negative bacteria and mycobacteria have structurally very 
distinct outer membranes. In contrast, their inner membrane has similar structure and 
composition. Figure 1.5 shows schematic structures of the bacterial membrane in Gram-
positive bacteria, Gram-negative bacteria and mycobacteria. 
 
Figure 1.5. Schematic structures of bacterial membrane. From left to right: Gram-negative 











1.4.1 Outer membrane 
The outer membrane or cell wall is a critical component, which is responsible for cell shape 
maintenance, protection against osmotic lysis and acts an environmental barrier. There are 
three major types of outer membrane: peptidoglycan in Gram-positive bacteria, 
lipopolysaccharides in Gram-negative bacteria and mycolic acid in mycobacteria. 
1.4.1.1 Cell wall of Gram-positive bacteria 
Peptidoglycan is a major constituent of the outer membrane of Gram-positive bacteria. 
Peptidoglycan is a covalent macromolecule structure consisting of strong glycan chains that 
are cross-linked by flexible peptide bridges.
93
 N-acetyglucosamine and N-acetylmuramic acid 
residues are covalently linked by β-1-4 bonds to form a glycan strand. Then, each glycan 
strand is connected by peptide bridges. Peptide bridges are species specific and are the most 
variable components of peptidoglycan.
94
 It provides mechanical strength for structural 
support. Peptidoglycan is strong enough to withstand turgor pressure of up to 25 
atmospheres.
94
 However, peptidoglycan only impedes little resistance to the diffusion of 
small molecules such as antibiotics.
95
 Teichoic acids or lipoteichoic acid are also unique 
anionic polymers that are found in the peptidoglycan layer.  
1.4.1.2 Cell wall of Gram-negative bacteria 
The outer membrane of Gram-negative bacteria is an asymmetric bilayer of phospholipid 
and LPS, with the latter predominantly part of the outer leaflet of the cell wall with an 
interspaced peptidoglycan layer.
96
 In contrast to the coarse meshwork peptidoglycan of 
Gram-positive bacteria, the LPS-composed outer leaflet is a compact layer. The 
peptidoglycan layer of Gram-negative bacteria is much thinner than that found in Gram-
positive bacteria. LPS has an amphiphilic structure that can be divided into three parts: a 
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conserved lipid A, a highly variable polysaccharide or O antigen and a relatively short core 
oligosaccharide.
96
 Lipid A is negatively charged through carboxyl and phosphate groups, and 





97. This stable “tile 
roof” structure acts as a barrier to hydrophobic or relatively large hydrophilic antibiotics for 
Gram-negative bacteria.
97b, 98
 The LPS components of many bacteria are also referred to as 
endotoxins.
99
 The detailed LPS structure varies from one bacterium to another. The outer 
membrane of Gram-negative bacteria also contains porins, non-specific channel-forming 
protein to allow the transmembrane passage of small and hydrophilic nutrient molecules and 
extrusion of waste products.
100
 
1.4.1.3 Cell wall of mycobacteria 
The outer membrane of mycobacteria consists of two distinct layers: peptidoglycan, 
arabinogalactan and mycolic acid. Mycolic acid accounts for 60% of the weight of the 
mycobacterial cell wall. Mycolic acids are long-chain, α-branched, β-hydroxykated fatty 
acids containing 60-90 carbons.
101
 Long branch contains 40-64 carbons and short branch 
contains 22-24 carbons.
101
 Different species of mycobacterium produce different classes of 
mycolic acid. For instance, M. tuberculosis produces three classes of mycolic acids: α-
mycolates, ketomycolates and methoxymycolates.
102
 M. smegmatis produces α-mycolates, α’-
mycolates and epoxymycolates.
102
 Mycolic acid residues are covalently linked to 
arabinogalacan. Arabinogalactan layer is comprised exclusively of D-galactofuranoses and 
D-arabinofuranoses.
103
 Arabinogalactan is connected to peptidoglycan via a phosphodiester 
bridge. Mycobacterial peptidoglycan also consists of alternating units of sugar residues. 
However, instead of N-acetylmuramic acid, mycobacterial peptidoglycan contains N-
glycolylmuramic acid.
102
 Mycobacerial peptidoglycan is also resistant to lysozyme.
102
 The 
cell wall also contains several types of “extracable lipids”. These lipids are not linked to the 





Diffusion of lipophilic solutes through the lipid layer requires a fluid interior. In general, 
mycolic acids contain very few double bonds or cyclopropane groups, thus the mycolic acid 
layer has very low fluidity. In addition, fluidity also decreases when the membrane lipid 
contains longer hydrocarbon chains. Moreover, structure of mycolic, which contains two fatty 
acid chains that are connected to a single head group, further reduce the membrane fluidity.
104
 
Consequently, similar to LPS of Gram-negative bacteria, the mycolic acid layer also acts as 
an effective barrier for the penetration of lipophilic antibiotics.
101
 In addition, hydrophilic 
solutes are not able to traverse lipid bilayers either. Porins are needed for these hydrophilic 
molecules to penetrate through the outer membrane.
105
 However, mycobacterial porins have 
far lower permeability than the porins from Gram-negative bacteria.
105
 As the result, 
mycobacterial cell wall shows an unusually low degree of permeability to hydrophilic solutes. 
Thus, mycobacterial cell wall has long been regarded to act as a permeation barrier for 
antibiotics. 
1.4.2 Inner membrane of bacteria 
The bacterial inner membrane contains about one-third of the proteins in the cell and is 
critical for cellular processes, irrespective of the metabolic status of the cell. For instance, 
components required for ATP generation, bacterial respiration, active transport of nutrients 
and waste, and cell-cell communication can be found in the bacterial inner membrane. The  
inner membrane, composes of a phospholipid bilayer and proteins, encloses the contents of a 
bacterial cell.
106
 Three major phospholipid species present in the phospholipid bilayer are 
phosphatidylethanolamine (PE, 75%), phosphatidylglycerol (PG, 20%) and cardiolipin 
(diphosphatidylglycerol, CL, 1–5%). PG and CL are negatively charged, whereas PE is 
zwitterionic and neutral in charge. In contrast to the mammalian cytoplasmic membrane, the 





bilayers are also responsible for establishing the permeability barrier to protect intracellular 
organelles and to maintain the membrane potential..  
1.4.3. Membrane targeting antibiotics 
Traditional antibiotic discovery efforts have not focused on the membrane as an 
antimicrobial target. As bacterial membrane contains many components, membrane targeting 
would be expected to involve a multi-target mode of action. For instance, several groups have 
reported that membrane targeting agents could disrupt the architecture and functional 
integrity of bacterial membranes,
108
 alter the proton motive force and further lead to leakage 
of cytosolic content and induce cell death.
109
 It is noteworthy that the ability of bacteria to 
acquire resistance to membrane targeting agents is very limited, as multiple targets are 
involved.
52
 Multiple mutations are needed to acquire such mutations.
110
 Such multiple 
mutations may change the cellular environment drastically and bacteria cannot survive. In 
addition, as bacterial membrane has a universal role, membrane targeting agents are also 
expected to be active against dormant cells, including M. tuberculosis, bacteria in biofilms 
and quiescent cells or persisters. As a result, these membrane targeting agents have the 
potential to shorten the treatment period, reduce disease relapse and limit the emergence of 
antibiotic resistance arising from surviving bacteria.
52
 Unlike conventional antibiotics that are 
mainly bacteriostatic, membrane damaging agents could eradicate bacterial cells rapidly via 
bactericidal action. As “dead bugs don’t mutate”,111 the rapid bactericidal action of these 
membrane damaging agents would have an unique and important property, which would 
make this type of molecule a potential candidate for therapeutic use to combat with bacterial 
resistance. Figure 1.6 shows the chemical structures of selected membrane targeting 
antimicrobials.  
To date, several membrane targeting antimicrobials have been reported. Vooturi et al. has 





Benzophenone has a very narrow range of antimicrobial activity with MIC value of 0.5-1.0 
µg/mL against Gram-positive bacteria such as MRSA and VRSA (vancomycin resistant- S. 
aureus). However, benzophenone is not able to inhibit the growth of Gram-negative bacteria 
efficiently. Ooi et al also discovered and synthesized a novel porphyrin antibacterial agent, 
XF-73. XF-73 displays potent antibacterial activity by disrupting the membrane.
113
 In vitro 
studies show that XF-73 has very low range of MIC values for different species of Gram-
positive bacteria (0.25-2 ug/mL) including MRSA. XF-73 is able to kill 99.9% of bacteria 
within 5 minutes. XF-73 is also found to inhibit DNA, RNA and protein synthesis as a result 
of membrane disruption. In another study, Alhanout has performed extensive studies to 
investigate the antimicrobial action of squalamine, a natural aminosterol and found that 
squalamine is a membrane targeted antimicrobial.
114
 In addition to Gram-positive bacteria, 
squalamine also displays potent antibacterial activity against Gram-negative bacteria. 
Alhanout postulated that the positively charged amine groups interact with the negatively 
charged LPS layer of gram-negative bacteria by displacing divalent cations such as 
magnesium ion and calcium ion. Similar to other membrane targeting agents, squalamine also 
demonstrates rapid killing as 99.99% of S. aureus is killed within 30 minutes.  
Telavancin and dalbavancin are both semi-synthetic derivatives of vancomycin, which 
were approved by the FDA for complicated skin and skin structure infections (cSSSI) in 2009 
and 2014 respectively.
115
 Oritavancin is also a lipoglycopeptide derived from vancomycin. 
Oritavancin has completed clinical phase 3 trials for cSSSI. Similar to vancomycin, 
telavancin, dalbavancin and oritavancin are able to inhibit peptidoglycan biosynthesis by 
binding to the D-Ala-D-Ala termini. In addition to that, their fatty acid chain also allows 
them to induce membrane permeabilization and depolarization. In general, these 
lipoglycopeptides are effective against Gram-positive bacteria such as MRSA, VRSA, VISA 
(vancomycin intermediate resistance S. aureus) and VRE.
116
 MIC values for different 
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phenotypes is in the range of 0.25 – 2 ug/mL. The killing assay results show that 99.9% of 
VISA is killed rapidly within 30 minutes.  
Daptomycin is the first lipopeptide class antibiotic introduced into clinical practise in year 
2003 and is effective against Gram-positive bacteria including MRSA. Silverman et al has 
reported that daptomycin depolarizes bacterial membrane and further induce cell death.
117
 
Daptomycin also displays potent activity against bacteria in biofilms, including those 
endocarditis mediated by biofilm bacteria.
118
  
Nonetheless, resistance against membrane targeting antibiotics could emerge following 
theor widespread of clinical use. For instance, daptomycin resistant S. aureus has been 
reported recently.
66, 119
 Several groups reported that genetic mutations in mprF, yycG, rpoB, 
rpoC
120
 and cell wall thickening
121
  may play major roles in the emergence of daptomycin- 
resistant S. aureus. In one particular mutant strain, it has been shown that resistance is 
mediated by over production of lyslphosphotidyl glycerol, through the overproduction of 
phosphatidylglycerol lysyltransferase (MprF).
122
 The lyslphosphotidyl glycerol increases the 
net positive charge on the membrane surface thereby reducing the affinity of daptomycin.
123
 
Telavancin is found to be still active against daptomycin-resistant mutants of S. aureus 
containing mutations in MprF, suggesting that MprF does not affect telavancin activity.
124
 
Expression of the vanA gene clusters could confer resistance against lipoglycopeptides such 
as telavancin and dalbavancin. The expression leads to the production of peptidoglycam 
precursors ending in D-Ala-D-lactate instead of D-Ala-D-Ala.
125
 Consequently, the binding 
of glycopeptides to peptidoglycan reduces by up to 1000-fold.
125
 However, it is noteworthy 










Figure 1.6. Chemical structures of selected membrane targeting antimicrobials: Oriavancin 









1.5. Natural products 
As natural products include such a number of diverse bioactive compounds, they could be 
a major source of new antimicrobial core structures. To survive in more or less hostile 
environments, organisms will generate many new substances to equip themselves to 
overcome threats to survival. Thus, the percentage of biologically active substances in nature 
is expected to be high.
126
 In addition, the quality of useful compounds derived from natural 
products is normally better and more biologically friendly, as these compounds often interact 
with certain target sites in biological systems.
127
 Natural products are also abundant in 
different scaffolds for further modification, and they have been crucial for anti-infective drug 
discovery. For instance, doripenem, tigecycline, retapamulin, telavancin and monobactam 
aztreonam are natural products or natural product-derived antimicrobials that are approved by 
FDA.
127
 The large number of natural product-derived compounds in various stages of clinical 
pipelines signifies that natural products are a viable source for new drug discovery.  
1.5.1 Xanthones  
Mangosteen (Garcinia mangostana) is a tropical evergreen fruit tree from South East 
Asia, India and Sri Lanka with a long history of use as a source for traditional medicine for 
the treatment of infected wounds, chronic diarrhea, skin infections and dysentery.
128
 
Xanthones are natural polyphenolic compounds with a tricyclic scaffold. Xanthones are also 
the major bioactive secondary metabolites of mangosteen. Depending on the nature or 
position of the substituents, these xanthone derivatives could display potent pharmacological 
activities including antibacterial, antifungal, antioxidant, anti-tumoral, anti-inflammatory and 
anti-allergy properties.
128-129
 Chomnawang et. al has studied antibacterial activities using 
seventeen medicinal plant extracts. The results show that plant extract of G. mangostana is 
the most potent plant to inhibit growth of MRSA
130
. The main compound from the 
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mangosteen plant extract is further extracted and purified, which is identified as α-mangostin 
with minimum inhibitory concentration (MIC) of 1.95 ug/mL against MRSA. In addition, 
Panthong et al
131
 has isolated fifteen xanthones from Garcinia cowa and α-mangostin is the 
second best xanthone to inhibit growth of S. aureus and MRSA. The MIC values for both 












 has studied antimicrobial activity of α-mangostin and beta-mangostin with eight 
strains of Enterococci and nine strains of MRSA. Interestingly, although the chemical 
structure of beta-mangostin is very similar to α-mangostin, antimicrobial activity of β-
mangostin is eight times lower compared with α-mangostin. MIC values for α-mangostin 
were in the range of 3.13-6.25 ug/mL for all the strains tested. Kaomongkolgit et al. has also 
reported that α-mangostin had no cytotoxic effects on human gingival fibroblasts up to 4000 
µg/mL.
134
 From a review published by El-Seedi in year 2010, α-mangostin shows a very poor 
antimicrobial activity against Gram-negative bacteria.
129
  Boonnak et al also reported that α-
mangostin has significantly poorer MIC value against Gram-negative bacteria (18.7ug/mL 
against P. aeruginosa)
137
 Chemical structures of a xanthone core, α-mangostin and β-














Figure 1.7. Structures of a xanthone core, α-mangostin and β-mangostin. α-mangostin is one 











1.5.2 Antimicrobial peptides. 
Antimicrobial peptides (AMPs) are naturally occurring molecules that are known as 
evolutionarily ancient defensive weapons, which have remained effective against multiple 
classes of microbes including Gram-positive and Gram-negative pathogens.
138
 Hundreds of 
AMPs have been isolated and identified. AMPs usually range from 4 to 50 residues and can 
be classified into different structural classes, including α-helical amphiphiles, lipopeptides, 
glycopeptides, lantibiotics, and short cationic antimicrobial peptides.
139
  
Cationic antimicrobial peptides (CAMPS) are critical components of the mammalian innate 
immune system and provide protection against pathogen invasion.
140
 CAMPs have been 
identified as potential candidates of a new class of antibiotics with desired characteristics 
including a rapid time-kill, broad spectrum of activity and low rate in selecting resistant 
mutants in vitro.
141
 Interestingly, CAMPs are still effective agents against bacterial infection 
over evolutionary time.
142
 CAMPs are able to act directly on the bacterial cytoplasmic 
membrane via disruptive “lytic” or pore-forming “ionophoric” mechanisms.29 Therefore, 




Almost all active CAMPs are composed of hydrophobic and cationic groups that segregate 
into an amphipathic structure.
138
 This amphiphilic structure is important for CAMPs to exert 
its membrane targeting mechanism. The initial binding is thought to depend on electrostatic 
interactions between the cationic moieties and the anionic bacterial membrane surface. Then, 
the hydrophobic region allows the peptide to insert into the hydrophobic core of lipid 
membrane.
144
 There are three main mechanisms or models have been proposed for peptide 
permeation of the membrane:
145
 (i) barrel-stave model, (ii) toroidal pore model and (iii) 
carpet model. In barrel-stave model, peptides interact laterally with one another to form 
transmembrane pores in a voltage-dependent manner. Non-polar parts of the peptides facing 
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the membrane lipids and forming the hydrophilic pore spanning the membrane, that is 
reminiscent of a membrane protein ion channel.
146
 Toroidal pore model involves the 
alternation of the bilayer curvature such that a toroid-shape pore through the membrane forms, 
lines by lipids and peptide.
145b
 A carpet model describes the covering of the bacterial 
membrane by a carpet of peptides. Then, the integrity of the membrane is disrupted by the 
formation of holes.
147
 Pexiganan (MSI-78) is an example of CAMP drug that is developed as 




CAMPs have shown to display more desirable antimicrobial properties than conventional 
antibiotics, including a rapid bacterial killing, good selectivity toward the bacterial membrane, 
and a low propensity for bacterial resistance.
140a
 However, CAMPs still have unresolved 
issues such as systemic toxicity, high cost of productions and poor stability, limiting them to 
iv or topical use and a loss of activity in the presence of salts.
149
 These issues have posed 
significant challenges to the therapeutic development of CAMPs. Consequently, the 
development of small-molecule-based membrane-targeting antimicrobials that maintains the 
essential key characteristics of CAMPs has received considerable attention.
150
 These small 
molecule-based membrane targeting antimicrobials are of interesting as they have therapeutic 
potentials to combat multidrug resistance pathogen infections and also overcome the 
limitations of the CAMPs. Peptidomimetics are a new generation of small-molecule 
antimicrobial that mimics the structure and antibacterial action of CAMPs. Peptidomimetic 
design involves the introduction of amide bond isosteres or peptide backbone modifications 
via non-natural side chains to mimic a peptide structure or function.
149, 151
  
To date, there are several classes of antimicrobial peptidomimetics have been reported: β-
peptides, peptoids, arylamides, AApeptides and γ-peptide-based oligomers.151 It is 
noteworthy that nonpeptidic small molecule membrane-targeting agents that are facially 
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amphiphilic have also been derived from other scaffolds. For instance, ceragenins are semi-
synthetic antimicrobial cationic amphiphiles with a steroid scaffold derived from cholic 
acid.
152





 scaffolds to obtain peptidomimetics.  
Currently, there are several peptidomimetics in clinical trials:
52
 LTX-109, a synthetic 
antimicrobial peptidomimetic;
155





 LTX-109 is developed by Lytix Biopharma, which focus on topical treatment of 
skin infections and nasal eradication of staphylococcus. Brilacidin has completed two phase 2 
studies for acute bacterial skin and skin structure infections (ABSSSI). CSA-13 is developed 
as a topical agent and for biofilm prevention on medical devices.
52
 Chemical structures of 
brilacidin, LTX-109 and CSA-13 are shown in Figure 1.8. However, the major limitations of 





















































The major limitations of current membrane targeting antibiotics or peptidomimetics, 
including those in clinical pipelines are their membrane selectivity, toxicity, complex 
synthesis, and high cost of production. Significantly, there is still no general design principle 
to improve selectivity for membrane targeting of small antimicrobial molecules to the 
bacterial membrane as this issue has only received less attention. The development of 
effective small-molecule-based membrane-targeting antimicrobials with high membrane 
selectivity from simple scaffolds and synthetic routes would have an important positive 
impact on antibiotic development.  
The aim of this PhD project is to provide design principles for membrane targeting 
antimicrobial that will avert bacterial resistance. Rationally designed compounds would 
display promising antimicrobial activity against drug resistant and multidrug-resistant 
pathogens, rapid time-kill, avoidance of antibiotic resistance and low toxicity.  
In this study, two natural-derived compounds were used as starting compounds: α-
mangostin and an antimicrobial peptide derived from human β-defensin. Then, a number of 
antimicrobials derived from these two compounds were synthesized to determine the 
appropriate structural parameters to fulfill the design requirements. Their antimicrobial 
activities against Gram-positive bacteria, Gram-negative bacteria and mycobacteria were 
determined. Their antibacterial actions were also investigated using a combination of 
biophysical, biochemical and computational studies. Understanding the antibacterial action 
and structural relationships would provide critical information for design of more potent 
antimicrobials. In vitro and in vivo toxicity profiles and in vivo efficacy models of the 
selected potent compounds were also evaluated. This study will provide new insights toward 




























3.1.1 Bacterial strains and growth condition 
All strains used were not more than four passages removed from the original master stock 
obtained from the American Type Culture Collection (ATCC) or from our clinical isolate 
collection. Inoculum suspensions were prepared from isolated colonies using the direct 
colony suspension method as described by the Clinical & Laboratory Standards Institute 
(CLSI). The colonies were selected from an 18-20 h Tryptic Soy Agar (TSA) plate. The 



















Table 3.1. Gram-positive and Gram-negative strains used in this study. For clinical isolates, 
their sources are also indicated. 
Strains Sources 
Gram-positive bacteria  
S. aureus 29213 ATCC 
S. aureus 6538 ATCC 
S. aureus 29737 ATCC 
S. aureus 25923 ATCC 
S. aureus DM4400R  Corneal 
S. aureus DM4001  Eye 
S. aureus DM4583R Eye 
S. aureus DB6506  Blood 
MRSA 700699 ATCC 
MRSA 43300 ATCC 
MRSA DM21455  Eye 
MRSA DM09808R  Eye 
MRSA DB57964 Blood 
MRSA DM21595  Wound 
MRSA DR42412  Sputum 
MRSA DR68004  Blood 
Streptococcus faecium 10541 ATCC 
Staphylococcus epidermidis 12228 ATCC 
B. cereus 11778 ATCC 
E. faecalis 29212 ATCC 
Gram-negative bacteria  
P. aeruginosa 27853 ATCC 
P. aeruginosa 9027  Outer ear infection 
P. aeruginosa DR4877  Sputum 
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P. aeruginosa DR5790  Wound 
P. aeruginosa DU14476  Urine 
P. aeruginosa DM23376  Eye 
P. aeruginosa DM23257  Eye 
P. aeruginosa DM4150R  Eye 
P. aeruginosa DM23155  Eye 
K. pneumonia 10031 ATCC 
K. pneumoniae DM4299 Eye 
K. pneumoniae DS07955 Stool 
K. pneumoniae DU31158 Urine 
K. pneumoniae DS16260 Stool 
K. pneumonia DB55301 Blood 
E. coli 8739 ATCC 
E. coli 25922 ATCC 
E. coli DS11804 Stool 
E. coli DS19963 Stool 
E. coli DS17232 Stool 













3.1.2 Susceptibility testing 
MIC determinations of xanthone derivatives were performed in Mueller Hinton Broth 
(MHB) using the broth macro-dilution method following CLSI guidelines. All xanthone 
derivatives were first dissolved in N,N-dimethylformamide (DMF) to make up the stock 
solutions of 1000 µg/mL. Serial twofold dilutions of the compounds were prepared in Cation 
Adjusted MHB in test tubes. The concentration of the above-mentioned inoculum suspension 
was adjusted in MHB. After inoculation, each tube contained approximately 5 x 10
5
 Colony 
Forming Units (CFU)/mL. The tubes were then incubated at 35 
o
C for 20 to 22 hours. The 
most potent compound was also sent to Quotient Bioresearch Ltd, United Kingdom for 
further antimicrobial screening. The list of bacterial strains tested by Quotient Bioresearch 
Ltd is shown in Table 3.2. For peptides, serial dilutions of all peptides were prepared in 
distilled water with concentrations ranging from 3 – 80 µM. MIC of daptomycin (Tocris 
Bioscience) was performed in MHB supplemented with 50 mg/mL free Ca
2+
. Vancomycin 
was first dissolved in sterile water to make up a 1000 µg/mL stock solution. Then, the MIC 
was determined using the broth macro-dilution method as described above. Vancomycin was 
the 2nd ASEAN Reference Substances (ARS) and obtained from the ARS Singapore 
representative. Other antibiotics such as gatifloxacin, levofloxacin and gentamicin were 
prepared using the same protocol to prepare peptides. The MIC was defined as the lowest 
concentration of a compound that resulted in zero growth after incubation. The experiments 
were performed in duplicate. To determine the antimicrobial activity of the compounds in the 
presence of BSA, BSA was added to bacterial suspensions at a final concentration of 4% w/v. 





Table 3.2. Strains tested in Quotient Bioresearch Ltd (UK). Description of each strain and 
resistance is also indicated.  
Strains Description 
S. aureus MU50 VISA 
S. aureus MRSA SSC mec type 2 
S. aureus EMRSA3 MRSA SSCmec type 1 
S. aureus EMRSA1 SSCmec type 3 
S. aureus EMRSA15 SSCmectype 4 
S. aureus HT2001254 MRSA PVL pos 
S. aureus Teicoplanin- resistant intermediate 
S. aureus MDR isolate 
S. aureus MRSA ATCC BAA-38 
E. faecium Van-susceptible 
E. faecium Van A- resistant 
E. faecium Van B- resistant 
E. faecium Susceptible-strain 
E. faecium ATCC 29212- susceptible index strain 
E. faecium VRE isolate Van A 
E. faecium VRE VanB 
E. faecium High level of gentamicin- resistant 
Enterococcus gallinarum Van C- resistant 
Streptococcus pyogenes MLS- resistant 
Streptococcus bovis Macrolide-resistant 
Streptococcus pyogenes Macrolide- resistant 
Streptococcus constellatus Susceptible-strain 
Corynebacterium jeikeium MDR 







3.1.3 Hemolysis assay  
The hemolytic activity of antimicrobials was determined by the amount of hemoglobin that 
was released from rabbit erythrocytes.
158
 Fresh red blood cells (RBCs) isolated from New 
Zealand white rabbits, approved by the IACUC of SingHealth and were in accordance to the 
standards of the Association for Research in Vision and Ophthalmology, were used for this 
experiment. In brief, the RBCs were centrifuged at 3000 rpm for 10 min and the serum was 
removed. Thereafter, the RBCs were washed twice with sterile PBS buffer (20 mM, 100 mM 
NaCl, pH 7). For xanthone derivatives, they were dissolved in DMSO or DMF. The 
compounds solutions were mixed with RBCs to prepare the desired concentration of 
compounds in RBCs (final v/v= 4%). Final DMSO% or DMF% in the mixture was controlled 
at < 1%, which had negligible effect on hemolytic activity. For peptides, all peptides were 
dissolved in PBS buffer, except for C14-B2088, C16-B2088, C14-B2099 and C16-B2099, which 
were dissolved in DMF. The desired concentrations of the peptides were then mixed with 
RBCs (final v/v= 4%) and incubated at 37 
º
C for 60 min. For peptides dissolved in DMF, the 
final DMF% in the mixture was controlled at 0.5%, which had a negligible effect on the 
hemolytic activity. After incubation, the mixtures were centrifuged at 3000 rpm for 3 min and 
the supernatant (100 µL) was transferred into a clean 96-well plate (SPL Life Sciences Inc. 
Korea). The amount of hemoglobin released was determined by measuring the absorbance 
(abs) at 576nm with a TECAN infinite M200Pro micro-plate reader. 2 % Triton X-100 was 
used as the positive control. PBS or 0.5% DMF was used as the negative control. The amount 
of hemoglobin released was calculated using the following equation: 
            
                               
                                       
      




3.1.4 Time-kill kinetics 
A time-kill kinetics assay was used to determine the rate at which specific concentrations of 
the antimicrobial agents could kill bacteria isolates. The bacterial strains used were prepared 
from isolated colonies on a 18 – 22 h tryptic soy agar (TSA) plate and suspended in a 0.31 




 CFU/mL was 
obtained. The inoculum was then treated with antimicrobial of desired concentrations (1/2×, 
1×, 2×, 4× MIC). The mixtures were incubated at 35 ºC and culture aliquots were collected at 
desired time points to measure the viable plate counts. The aliquots were diluted ten-fold 
serially using phosphate buffer and 100 µL of each dilution was plated with Mueller-Hinton 
Agar (MHA) using the surface-spread plate method. The plates were then incubated at 35 ºC 
for 48 to 72 h. The number of viable bacteria was determined by counting the colonies grown 
on the plates. The detection limit of the reliable viable count was 100 CFU/mL. Bactericidal 
activity was defined as a 3-log reduction of the viable count in a sample treated with 
antimicrobial peptides as compared to an untreated control. 
3.1.5 Multipassage resistance selection studies 
A dilution series of eight concentrations of desired compound was prepared. The resistance 
of the strains against the tested compounds was determined based on the progressive increase 
in the MIC of the bacteria over passages. Bacterial growth in each dilution was checked after 
20 to 22 hours of incubation. The bacteria that grew in the 0.5x the MIC of the tested 
compounds were re-passaged in a fresh dilution series of eight concentrations. The tested 
compounds were re-passaged for at least 17 passages in each culture. In this study, resistance 







3.1.6 Synergistic studies 
The synergistic interaction was determined using checkerboard microdilution methods with 
MHB as described previously.
160
 Briefly, MICs of each antibiotics used in synergy studies 
were determined by broth microdilution method. The range of concentrations was prepared 
according to the MIC of each compound and each antibiotic which were determined earlier. 
Bacterial strains used in this study were P. aeruginosa DM23155, P. aerugonosa ATCC 
27853, E. coli ATCC25922 and E. coli ATCC 8739. For xanthone derivatives, two-fold 
dilutions of xanthone derivatives and antibiotics were prepared and mixed in sterilized test 
tubes. The following antibiotics or compounds were used in the synergism assays: eugenol, 
daptomycin (Tocris Bioscience), vancomycin, gatifloxacin (Tocris bioscience), polymyxin B, 
gentamicin and polymyxin B nonapeptide. For synergistic study involved peptide and Gram-
negative bacteria, antibiotics used in the study were nalidixic acid (Fluka), gentamicin, 
erythromycin, streptomycin and kanamycin. Serial 2-fold dilutions of peptides and antibiotics, 
ranging from 0.0625× MIC to 1× MIC were prepared and mixed. The inoculum suspension 
was prepared by adding selected isolated colonies from a 18 – 20 h TSA plate into phosphate 
buffer (0.31 mM, pH 7.2), adjusted to a turbidity equivalent to 0.5 McFarland Standard. Each 
tube contained a final bacterial concentration of approximately 5 × 10
5
 colony forming units 
(CFU)/mL. All tubes were covered and incubated at 35 °C. After 24 h, an aliquot of the 
mixture was removed and the OD600 was measured using a TECAN Infinite 200Pro micro-
plate reader to determine the MIC90 of each antimicrobial combination. The fractional 
inhibitory concentration indexes (FICIs) for the combinations of two antimicrobials were 
calculated using the following formula as previously described by Oo et al.: 
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Σ FIC values were interpreted as follows:  Σ FIC of values ≤ 0.5 denoted synergy, Σ FIC 
values of 0.5 – 0.75 denoted partial synergy and 0.75 to 4 denoted indifference and Σ FIC 
values of ≥ 4 denoted antagonism.160a 
3.1.7 Luminescent cell viability assay 
Human corneal fibroblast cells were plated at a density of 10,000 cells per well in a 96-well 
opaque white plate (SPL Life Sciences Inc. Korea).  Then, desired concentrations of xanthone 
derivatives or peptides were added. Xanthone was dissolved in DMSO or DMF. The final 
volume of each well was 100 µL. The final DMSO% or DMF% in the mixture was controlled 
at < 1%, which had negligible effect on cell viability. Then, the mixtures were incubated for 4 
h. After incubation, the plate was equilibrated to 22 ºC for 30 minutes. A CellTiter-Glo 
reagent (Promega Inc. USA) was added to each well and the cell viability assay was 
performed according to the manufacturer’s instructions. Luminescence was assessed using a 
TECAN infinite M200Pro micro-plate reader. The cells exposed with 1% Triton X-100 was 
used as a positive control and treated as the minimal viability. PBS was used as a negative 
control. Cell viability was determined using the formula below: 
% Cell viable  
                             
                                   
      
where L is the intensity of luminescence measured. 
3.1.8 Cytotoxicity evaluation using Lactate Dehydrogenase (LDH) assay  
Human corneal fibroblasts were prepared and treated with the desired concentration of 
xanthone derivatives or peptides as described above in the luminescent cell viability assay. 
After 4 hours of incubation, 100 µL of Cyto-TOX One reagent (Promega Inc. USA) was 
added to each well and the LDH assay was performed according to the manufacturer’s 
instructions. Fluorescence was assessed at an excitation wavelength of 560 nm and an 
emission wavelength of 590 nm using a using a TECAN infinite M200Pro micro-plate reader. 
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The cells exposed with 1% Triton X-100 was used as a positive control and treated as the 
minimal viability. PBS was used as a negative control. The cytotoxicity of each compound 
was determined using the formula below: 
% Cytotoxicity  
                              
                                   
      
where I is the measured intensity. 
3.2 Physical parameters 
3.2.1 Molecular hydrophobicity analysis 
The molecular hydrophobicity of the synthesized analogs was characterized in terms of 
retention time and %ACN by HPLC (Waters 2695 separation module) on a Waters Delta-Pak 
CA 300 Å column. The experiments were conducted under the same conditions for all 
analogs. The samples were injected at a concentration of 10 μg/mL with an injection volume 
of 20 μL and a flow rate of 1 mL/min. The gradient profile was 5 − 55% ACN over 5 min, 
followed by 55-95% over the next 15 min. 
3.2.2 Self-aggregation assay 
8-(phenylamino)-1-naphthalenesulfonic acid (ANSA) is a fluorescent probe that can be 
used to detect hydrophobic clusters. The binding of ANSA to non-polar regions leads to an 
increase in its steady-state fluorescence emission.
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  This assay was only applied to peptide 
studies. 40 µM ANSA was prepared by first dissolving the solid in methanol and diluting 
with 20 mM PBS buffer at pH 7. Equal volumes of peptide at desired concentrations were 
added into the ANSA solution. An aliquot of the mixture was transferred to a 96-well black 
immunological plate. The emission spectrum was collected from 410 to 700 nm at a fixed 
excitation wavelength of 350 nm using the Perkin Elmer Enspire multimode plate reader. The 
minimum concentration of C16-B2088 or C16-B2099 to achieve the highest fluorescence 
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emission intensity was determined. Then, the relative degree of aggregation of the peptide 
was determined using the formula below: 
Degree of aggregation  
F     
Fmax    
  100  
where F0 is the fluorescence intensity of ANSA without the peptide, Fmax is the highest 
achievable fluorescence intensity of ANSA and F is the fluorescence intensity in the presence 
of the peptides. 
3.3 Biophysical studies of bacterial inner membrane function 
3.3.1 Cytoplasmic membrane depolarization assay 
3,3’-dipropylthiadicarbocyanide iodide (DiSC3-5), a cytoplasmic membrane potential 
sensitive probe, is self-quenched when it partitions onto polarized cytoplasmic membrane. 
The addition of a membrane active antimicrobial that dissipates the membrane potential will 
lead to the release of DiSC3-5 and the increase in fluorescence can be observed. The effect of 
the antimicrobial on the membrane potential of bacteria was studied based on a modified 
method of Wu and Hancock.
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 To test xanthone derivatives, S. aureus was harvested at an 
early exponential growth phase and washed with buffer (5 mM HEPES at pH 7) and 
resuspended in the same buffer until an optical density of 0.09 at 620 nm (OD620) was 
obtained. The cell suspension was incubated with 0.4 μM DiSC3-5 (Invitrogen) and 0.1 M 
potassium chloride (KCl) solution at 37 
o
C until DiSC3-5 uptake was maximal. For peptides, 
the incubation condition was slightly modified to optimize the condition for peptide studies. 
In brief, bacterial strains at an early exponential growth phase was also harvested and washed 
in HEPES buffer (5 mM HEPES, 0.1 M KCl, pH 7). Instead of OD620 of 0.09, the bacteria 
were suspended in HEPES buffer until an OD620 of 0.2 was obtained. Then, the suspension 
was incubated with 10 µM DisC3-5 and 0.1 M KCl at 37 ºC for 20 min. The fluorescence of 
DiSC3-5 in the suspension was monitored using a fluorescence spectrophotometer until the 
fluorescence intensity was stable. Desired concentrations of xanthone derivatives or peptides 
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were added into the stirred cuvette and the change in the fluorescence intensity was measured. 
For xanthone derivatives, the fluorescence reading was monitored for 500 seconds with a 
Photon Technology International Model 814 fluorescence spectrophotometer, at an excitation 
wavelength of 660 nm and an emission wavelength of 675 nm. For peptides, the fluorescence 
reading was taken for 1 h at an excitation wavelength of 622 nm and an emission wavelength 
of 670 nm. Fresh bacteria suspension was used for each measurement. Experiments were 
repeated at least twice and were reproducible. Data from one experiment is presented. 
3.3.2 EtBr uptake assay 
Cytoplasmic membrane disruption was determined by using ethidium bromide (EtBr). EtBr 
is a membrane impermeable dye and intercalates into DNA. When the integrity of the inner 
membrane was disrupted, EtBr is able bind to DNA and fluoresces more strongly when 
exposed to UV light. In this project, this assay was only done using α-mangostin and selected 
antibiotics, as a preliminary assay to investigate the membrane targeting property of the 
xanthone. This assay was then replaced with Sytox green uptake assay, which will be 
described in the next section. First, S. aureus was harvested at an early exponential growth 
phase and washed with buffer solution (5 mM HEPES at pH 7) and resuspended in the same 
buffer until OD620 of 0.09 was obtained. The cell suspension was incubated with 17 nM EtBr 
at 37 
o
C until the fluorescence reading was stable. Then, the desired concentration of 
antimicrobial was added and the fluorescence reading was monitored for 500 s at an 
excitation wavelength of 360 nm and an emission wavelength of 616 nm using Photon 
Technology International Model 814 fluorescence spectrophotometer. DMF alone had no 
effect on EtBr fluorescence and membrane permeability. Triton X-100 (40%) was used to 
maximize the permeabilization effect. Daptomycin and vancomycin were used as 
comparators in this study. Experiments were repeated at least three times and yielded 
reproducible results. Results from one experiment are presented. 
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3.3.3 Sytox green uptake 
Sytox Green is a high-affinity nucleic acid stain that is able to penetrate into cells with 
compromised plasma membranes, but will not cross the intact membranes of live cells. The 
protocol was modified from the method of Rathinakumar et al.
140b
 Briefly, bacterial cultures 
were harvested in exponential phase. Bacteria were then suspended and washed twice with 
sterile 20 mM PBS buffer (pH 7) until an optical density of 0.09 at 620 nm was obtained. 
Then, 3 µM of Sytox Green was added to the bacterial suspension. The mixture was 
incubated in the dark and the fluorescence signal was monitored in a stirring cuvette at an 
excitation wavelength 504 nm and an emission wavelength of 523 nm until the fluorescence 
signal was stabilized. Then, desired concentrations of the xanthone derivatives were added, 
and the increase in Sytox green fluorescence intensity was measured. Melittin at 10 µg/mL 
was used as a positive control. Experiments were repeated at least three times. Data from one 
experiment is presented.  
3.3.4 Visualization of bacterial membrane permeation 
The clinical isolate S. aureus DM4001 was harvested and suspended in HEPES buffer 
(5mM) until an OD620 of 0.4 was obtained. The suspension was incubated with desired 
concentrations of α-mangostin for 20 minutes with 3 µM of Sytox green. Then, the 
incubation mixtures were immobilized on poly(L-lysine)-coated glass slides. The slides were 
examined by a fluorescence microscope (ZEISS Model Axioplan 2 IE) with an excitation 
wavelength of 485 nm. Bacterial treatment with vancomycin (6.25 µg/mL) was used as a 





3.3.5 Live/Dead Baclight Assay 




 bacterial viability 
kits (Molecular Probes, Invitrogen) with minor modifications to the manufacturer’s protocol. 
In this assay, green-fluorescent SYTO-9 stain and red-fluorescent propidium iodide stain 
were employed to distinguish the intact and damaged bacterial cell membrane. SYTO-9 stain 
labels both cells with intact and damaged membrane. In contrast, propidium iodide stain only 
penetrates and labels bacteria with damaged membrane. Thus, bacteria with intact 
membranes fluoresces green, whereas bacteria with damaged membranes fluoresces red. 
Briefly, a bacterial strain was grown overnight and harvested at exponential phase. The 
culture was washed twice with 0.9% saline (live culture). A portion of the culture was re-
suspended in 70% 2-propanol to prepare a dead culture with fully permeabilized membrane. 
Both live and dead cultures were incubated at room temperatures for 1 h. For studies using 
xanthone derivatives, both cultures were washed twice and re-suspended with 0.9% saline 
until OD670
 
of 0.3 was obtained. For studies involved peptides, bacterial suspension with 
OD600 of 0.20 was prepared. Bacterial suspensions of live culture were incubated with desired 
concentrations of xanthone derivatives at room temperature for 10 min. For peptides, the 
incubation period was 1 h. At the end of the incubation period, the suspension was 
centrifuged at 4000 g for 5 min. The cells were re-suspended with the same volume of 0.9% 
saline and a volume of 100 uL of the bacterial suspension was added to a 96-well plate. An 
equal volume of the baclight reagent (10 µM of SYTO 9 stain and 60 µM of propidium 
iodide) was added into each well. Then, the plate was incubated at dark for 15 min. At an 
excitation wavelength of 485 nm, emission intensity from 500 nm – 700 nm was recorded 
using TECAN infinite M200Pro microplate reader. Green to red ratio (G/R) was determined 
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% of membrane damage was quantified using a G/R ratio standard curve generated using 
bacterial mixture of 0, 10%, 50%, 90% and 100% dead culture. 
3.3.6 ATP leakage assay 
An ATP determination kit (Molecular Probes, Invitrogen) was used to measure 
extracellular ATP levels released by the bacteria. In this assay, luciferase in the medium 
requires ATP released from bacteria to produce light, which could be detected by a 
luminometer. The measurement was performed as described by the manufacturer’s 
instructions, with the following modification. Briefly, bacterial strain was grown to 
exponential phase and washed twice with 20 mM PBS buffer (pH 7). The bacterial culture 
was then re-suspended in the same buffer until an OD620 of 0.3 was obtained. Following 
addition of each xanthone derivative with desired concentration, the suspensions were 
incubated at 37 
o
C for 10 min. After the incubation period, the treated cells were centrifuged 
at 4000 r.p.m. for 5 mins. An aliquot of the supernatant was transferred to a sterile white 
immuno-96-well plate (SPL Life Sciences). Then, enzyme mixture (1× reaction buffer, 1 mM 
of dithiothreitol, 0.5 mM of D-luciferin and 1.25 µg/mL of firefly luciferase) was added. The 
sample volume was controlled at 10% of total assay volume. The concentration of 
extracellular ATP was measured with a TECAN Infinite M200Pro microplate luminometer. 
3.3.7 Calcein leakage assay 
In this experiment, all phospholipids were purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL) and used without further purification. Phospholipids used in this study were 
1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-
glycero-3-phospho-(1’-rac-glycerol) (sodium salt) (DOPG), 1,2-di-(9Z-octadecenoyl)-sn-
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glycero-3-phosphocholine (DOPC), 1',3'-bis[1,2-dioleoyl-sn-glycero-3-phospho]-sn-glycerol 
(sodium salt) (18:1 cardiolipin; Cl) and 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-
myo-inositol) (ammonium salt) (DOPI). DOPE/DOPG= 75/25 and pure DOPC were used to 
mimic the bacterial membrane and mammalian membrane respectively. Cl/DOPG/DOPI= 
4/3/3 was used to mimic the mycobacterial membrane. The calcein loaded large unilamellar 
vesicles (LUVs) were prepared using a film hydration method. In brief, the lipids 
(DOPE/DOPG= 75/25) were dissolved in methanol/chloroform (1:2, by volume). The solvent 
was dried gently using a constant stream of nitrogen gas. Then, the lipid film was placed 
under vacuum for at least two hours. The dried lipid film was hydrated with calcein solution 
(80 mM calcein, 50 mM HEPES, 100 mM NaCl, 0.3 mM EDTA, pH 7.4) to a final lipid 
concentration of 30 mM. The hydrated vesicles were frozen in liquid nitrogen and warmed in 
a water bath for 7 cycles. Homogeneous LUVs with 100 nm diameter were then prepared by 
the extrusion method using a mini-extruder (Avanti Polar Lipid, Inc.), as described in the 
Avanti Polar Lipid Inc website.
164
 The extrusion was done for 10 cycles using a 
polycarbonate membrane (Whatman, pore size 100 nm). Calcein encapsulated vesicles were 
separated from free calcein with gel filtration column using Sephadex G-50. The 
concentration of eluted liposomes was determined using a total phosphorus determination 
assay as described by Avanti Polar Lipids, Inc website.
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An aliquot of the calcein encapsulated LUVs was transferred to a 96-well black 
immunological plate. Desired concentrations of xanthone derivatives or peptides were then 
added to obtain compound to lipid ratios of 1/2, 1/4, 1/8, 1/16, 1/32, 1/64 and 1/128. The final 
concentration of the liposome was fixed at 50 µM. Triton X-100 (0.1 %) was used as a 
positive control to induce a complete leakage. The fluorescence emission intensity was 
monitored using a TECAN Infinite 200Pro micro-plate reader at an excitation wavelength of 
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490 nm and an emission wavelength of 520 nm for 30 minutes. The percentages of leakage (% 
L) were calculated using the following formula: 
 L  
      
Imax    
  100  
where Io and It are intensities before and after the addition of the peptides respectively, and 
Imax is the intensity after the addition of 0.1% Triton X-100. 
3.3.8 Scanning electron microscopy (SEM) 
For electron microscopy analysis, S. aureus DM 4001 was grown on TSA Plates overnight 
and a suspension of 10
8
 CFU/ml was prepared in United States Pharmacopeia Buffer (USP 
Phosphate buffer). The suspension was centrifuged at 3000 rpm for 20 minutes and the pellet 
was washed with the same buffer. An aliquot of the bacterial suspension was incubated with 
desired concentrations of xanthone dervatives at 35 
o
C for 30 minutes. After incubation, the 
bacterial suspension was again centrifuged, washed and prefixed in 0.5 ml of a mixed 
aldehyde fixative (2% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate 
buffer, pH 7.2) for 24 hours. Then the suspension was washed once again in sodium 
cacodylate buffer (Electron Microscopy Sciences, Washington, USA) and subsequently 
mounted on poly-L-Lysine coated cover-slips and post-fixed in 1% osmium tetroxide 
(Electron Microscopy Sciences). Following dehydration in a graded series of ethanol, the 
samples were critical-point-dried and sputter coated with 10 nm of gold. All samples were 
viewed and photographed on a Philips XL30-FEG-SEM (FEI Electron Optics BV, Eindoven, 
The Netherlands) at an accelerating voltage of 10 kV at the Electron Microscopy Unit, 
National University of Singapore. Bacteria incubated in USP phosphate buffer without the 





3.4 Biophysical studies on outer membrane 
3.4.1 Limulus Amebocyte Lysate (LAL) assay for LPS neutralization 
The LPS neutralization study was conducted using a pierce LAL chromogenic endotoxin 
quantitation kit (Thermo Scientific). This kit employs an endotoxin or LPS activated 
proenzyme in the LAL assay, which then catalyzes the splitting of p-Nitroaniline (pNA) from 
the colorless substrate. Peptides at desired concentrations were incubated with 10 ng/mL of 
LPS from E. coli serotype 0111:B4 and P. aeruginosa serotype 10 for 1 h at 37 ºC. Then, the 
assay was performed according to the manufacturer’s specifications using a gamma-sterilized 
and non-pyrogenic 96-well transparent plate (SPL Life Sciences Inc. Korea). The absorbance 
of the released pNA was measured at 405-410 nm using a TECAN infinite M200Pro micro-
plate reader. The relative change in the endotoxicity of the LPS was measured by comparing 
with the peptide-free LPS samples. The extent of neutralization of the endotoxicity of LPS in 
the presence of peptides was calculated using the formula: 
  Neutralization  
Abspeptide free  Abspeptide 
Abspeptide fre 
  100  
where Abs peptide free is the endotoxicity of LPS solution and Abs peptide is the endotoxicity of 
the solution in the presence of the peptide. Then, the peptide concentration to neutralize 50% 
of LPS was determined. 
3.4.2 Bodipy TR Cadavarine (BC) displacement assay  
Bodipy TR cadaverine (BC) is a fluorescent probe that binds tightly to the lipid A moiety 
of the LPS and forms a complex via ionic bridges. Complex formation quenches the 
fluorescence of BC. When molecules that interact with LPS are added, BC will be displaced 
from the complex, with concomitant de-quenching of its fluorescence emission. In this study, 
50 µg/mL of LPS from E. coli serotype 0111:B4 and 10 µM of bodipy TR cadaverine were 
mixed in HEPES buffer (5 mM, pH 7). Then, serial 2-fold dilutions of all peptides 
concentrations ranging from 250 µg/mL to 0.49 µg/mL were added to the mixture. After 5 
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min of incubation at 37 °C, the mixture was added into a 96-well black immunological plate 
(SPL Life Sciences). Fluorescence readings were measured using a TECAN infinite M200Pro 
micro-plate reader at an excitation wavelength of 580 nm and an emission wavelength of 620 
nm. Polymyxin B at 40 µM was used as a positive control in the experiment. The 
displacement of BC relative to polymyxin B was calculated based on the equation:  
 Displac ment of BC  
      
 pmxb    
  100  
where F0 is the fluorescence intensity of LPS-BC complex, Fpmxb and F are the fluorescence 
intensities after the addition of 40 µM polymyxin B and peptides respectively. Then, the 
displacement curve of each peptide was fitted with Dose-response function using OriginPro 
8.5.1. The maximum achievable displacement of BC (Dmax) of each peptide was then 
determined. 
3.4.3 1-N-phenylnaphthylamine (NPN) uptake assay  
In vitro LPS permeabilization or NPN uptake was performed based on a modified method 
from Helandar and Mattila-Sandholm.
166
 In brief, P. aeruginosa DM23155 was collected at 
an early exponential growth phase and suspended in 5 mM HEPES buffer solution at pH 7 
until an optical density of 0.4 at 600 nm (OD600) was obtained. An equal volume of NPN at 
40 µM was added into the bacterial suspension. Then, desired concentrations of peptides 
were added and mixed thoroughly. The mixture was then incubated at 37 ºC for 1 h. 
Fluorescence readings were measured by a Perkin Elmer Enspire multimode plate reader at 
an excitation wavelength of 355 nm and an emission wavelength of 405 nm. Polymyxin B at 
300 µM was used to induce a maximal NPN uptake. The percentage of NPN uptake of the 
peptide was calculated based on the formula below: 
  NPN uptake  
F     
Fmax    
  100  
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where F0 is the fluorescence intensity of NPN uptake in the absence of peptide or polymyxin 
B, Fmax and F are the fluorescence intensities after the addition of 100 µM polymyxin B and 
peptides respectively. 
3.5 In vivo studies 
After xanthone derivatives and peptides were screened for their antibacterial activities and 
membrane targeting properties, in vivo toxicity and in vivo efficacy were further evaluated. 
In vivo studies were performed by Dr Thet Tun Aung from Prof. Roger’ microbiology group. 
All animal studies obtained IACUC (SingHealth) approval and were conducted in 
compliance with the ARVO statement for the Use of Animals in Ophthalmic and Vision 
Research, the guide for the Care and Use of laboratory animals (National Research Council) 
and under the supervision of Singhealth Experimental Medical Centre (SEMC). 
3.5.1 In vivo topical toxicity 
Wild type C57BL6 mice (6-8 weeks old) purchased from National University of Singapore 
was used for this study. All animals were utilized after 1 week of acclimatization and were 
kept in air-conditioned rooms with a controlled temperature (23 ± 2 °C), 12 h light-dark 
cycles, and a humidity of 55–60%. Desired concentrations of tested antimicrobials were 
dissolved in 10 mM PBS. To investigate corneal toxicity, three normal, healthy wild-type 
mice were selected randomly and treated with desired concentrations of tested antimicrobial. 
The respective antimicrobials were applied topically 5 times/day for 4 days. At the end of the 
experiment, cornea clarity was checked by slit lamp microscopy. 
3.5.2 In vivo toxicity test for rabbit corneal wound healing model 
New Zealand white rabbits (weighing 2 to 3 kg) purchased from National University of 
Singapore was used in this study. In this study, 3 rabbits were assigned randomly for each 
treatment group. Rabbits were tranquilized by intra-peritoneal injection of 1 mL of ketamine 
(100 mg/mL) and 0.5 mL of xylazil (20 mg). Then, corneas were anesthetized by topical 
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administration of 1% xylocaine. A 5-mm trephine was used to outline the wound margin, and 
epithelial cells were removed mechanically using a sterile mini-blade (BD-Beaver) while 
leaving the basal lamina intact.
167
 Each treatment group was treated by topical administration 
of respective antimicrobials 3 times per day. The cornea wound was visualized by staining 
with fluorescein sodium, which is used in ophthalmology clinics to visualize wounds on the 
ocular surface, with the help of a slit-lamp biomicroscope equipped with a cobalt-blue 
filter.
168
 All photographs were taken at a fixed focal length with the help of slit-lamp 
microscopy. All the images were processed in Image-J 1.44o version and outlines of the 
defect area were calculated. Mann-Whitney Test was employed to determine if a difference in 
re-epithelialization existed among the three different groups. The statistical calculations were 
performed using PASW statistic 18. 
3.5.3 In vivo acute toxicity test 
Wild type C57BL6 mice (6-8 weeks old; 20-30 gram weigh) purchased from National 
University of Singapore was used in this study. All animals were utilized after 1 week 
acclimatization and put in air conditioned rooms with controlled temperature (23 + 2 
o
C), 12 
hours light-dark cycle and humidity at 55–60%. Normal and healthy wild type mice were 
chosen and weighed. Desired concentrations (mg/kg) of antimicrobials were dissolved in PBS 
and delivered through bolus injection via intra-peritoneal route. Concentrations (mg/kg) used 
for intra-venous route was determined based on the intra-peritoneal results. Two animals 
were used for each administration and they were carefully monitored through 24 hours. Any 
mortality, morbidity or toxicity signs were recorded.  
3.5.4 In vivo therapeutic efficacy of experimental corneal infections 
Bacterial strains were grown overnight on TSA plates at 35 °C. A few colonies were 




CFU/mL and used for the animal study. All mouse eyes were examined previously under slit-
lamp examination. Eight healthy mice were chosen for each treatment group. The 
antimicrobials and concentrations used in this study were gatifloxacin (0.3% solution). 
Vancomycin was used as a 5% solution in the MRSA ATCC700699 treatment. Xanthone 
derivatives or peptides were used at a specific concentration. The animals were anesthetized 
subcutaneously with 0.2 mL of ketamine (100 mg/mL) and 0.1 mL of xylazine (20 mg/mL) 
mixed with 0.7 mL of normal saline (0.08 mL/mice). Superficial scratches of the cornea (n=3, 
each 1 mm long) were created with a sterile mini-blade (BD-Beaver) under the microscope 
on one eye and did not penetrate beyond the superficial stroma, whereas the other eye 
remained uninvolved.
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 Then, 10 µL of the bacterial suspension was applied topically to the 
surface of the wounded eye. All animals were treated with the respective antimicrobials five 
times/day starting from day 1 post-infection. At days 1, 2, and 3 post-treatment, four animals 
from each group were sacrificed. The wounded corneas were dissected, and the number of 
viable bacteria was quantified after plating. For this purpose, individual corneas were 
homogenized in sterile 0.9% NaCl containing 0.25% BSA
170
, serially diluted, and plated in 
duplicate on TSA plates. The plates were incubated for 48 h at 35 °C. The number of viable 
bacteria in an individual cornea was determined by counting individual colonies on plates 
from the various dilutions and multiplying the number of colonies by the appropriate dilution. 
The results were reported as log10 CFU/cornea. The data were examined statistically by one-
way analysis of variance (ANOVA) and a post-hoc test (Bonferroni test, PASW Statistics 18). 
The Kruskal-Wallis non-parametric test was employed, and a post-hoc test (pair-wise 
comparison test) was performed to determine if a difference in colony forming units existed 





3.6 Molecular dynamic (MD) simulations 
MD simulations were used to predict the interactions of antimicrobials with the bacterial 
membrane. MD simulations were also alternative approaches to investigate antimicrobial 
action. MD simulations were performed by Dr Li Jianguo from Prof Roger’s group. 
Computational facilities were provided by Bioinformatics Institute, A*STAR Computational 
Resource Center and CSC in Finland. In this study, both bacterial and mammalian 
membranes were modelled using 128 lipids. The bacterial membrane composed of 96 
zwitterionic POPE (1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) and 32 anionic 
POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol) lipid molecules (a ratio of 
POPG/POPE = 3/1).
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 The human membrane was modelled with 96 POPC (1-palmitoyl-2-




3.6.1 Interaction of xanthone derivatives with membrane at different concentrations  
All xanthone derivatives and lipid molecules were modelled using the Gromos53a6 force 
field
172
 and solvent water molecules were modelled using the simple point charge model 
(SPC).
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 The parameters of xanthone derivatives were generated using the aAutomated force 
field Topology Builder (ATB).
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 The AM1 charges was used for the electrostatic 
interactions.
175
 Desired number of xanthone molecules with random orientations was put 
close to the model bacterial membrane. Then the system was solvated with 6000 - 7200 water 
molecules and neutralized with sodium ions. The system was first subjected to 500 steps of 
energy minimization using the steep descent algorithm, followed by 10 ps NVT simulation. 
Then, MD simulations of 200 – 400 ns were then conducted. During all MD simulations, a 
cut-off distance of 1.2 nm was used for both the LJ and real-space electrostatic interactions. 
The particle-mesh Ewald algorithm was employed to calculate the long-range electrostatic 
interactions in reciprocal space. The Nose-Hoover method was used to maintain the target 
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temperature at 310 K and Parrinello-Rahman method with semi-isotropic coupling was used 
for maintaining the pressure at 1 atm in the NPT ensemble. To enhance sampling of the 
conformations of α-mongostin at a certain distance from the bilayer center, a series of 
distance-restrained simulations were carried out by fixing the distance between one α-
mangostin and the bilayer center, using the pull module of gromacs.
176
 For peptidic-xanthone 
derivatives, the surface potential of the model membranes was calculated using the APBS 
plugin for PYMOL.
177
 During the simulations, the covalent bonds involving hydrogen atoms 
were constrained using the LINCS algorithm, which enabled a time step of 2 fs to be used in 
all simulations. A cut-off distance for real-space electrostatic interactions and LJ potentials 
were 0.9 nm and 1.44 nm respectively.  
3.6.2 Aggregation study using molecular dynamic simulation 
The aggregation behaviors of N-lipidated peptide-dimers with carbon unit of 4, 8 and 16 
were also studied using coarse-grained molecular dynamics simulations. The N-lipidated 
peptide-dimers were modeled using MARTINI force field 1 and the simulations were 
performed using GROMACS 4.52.  In each simulation, 27 N-lipidated peptide-dimers were 
solvated in a cubic simulation box of 15 nm in xyz dimension and then neutralized with 
counter ions. The system first underwent 5000 steps of energy minimization, and then a 100 
ps of equilibrium using time step of 0.2 fs. Thereafter, 2000 ns MD run were performed with 
a time step of 30 fs. Non-bonded potentials were calculated using a cutoff distance of 1.2 nm, 
with the Lennard-Jones potential being switched from 0.9 to 1.2 nm. During the MD 
simulations, temperature and pressure are maintained at 300K and 1 bar, respectively. 
3.7 Biophysical studies on anti-mycobacteria actions 
3.7.1 Mycobacteria: Sytox Green uptake and Baclight assay 
Sytox Green uptake and baclight assays were done to investigate the membrane 
permeability of xanthone derivatives on mycobacterium. The method used was similar and 
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optimized from section 3.3.3 for study of mycobacteria. Bacterial strains used in this study 
were M. bovis and M. smegmatis. The washing and suspending buffer was 20 mM PBS at 
pH7.0 or 0.9% saline, containing 0.025% tyloxapol. Tyloxapol is a detergent to prevent the 
aggregation of mycobacterial cells. Bacterial culture with an OD600 of 0.2 was prepared. For 
baclight assay, an aliquot of mixture was removed at a specific time for measurement. The 
measurement procedures were same as section 3.3.3 for Sytox Green assay and 3.3.5 for 
baclight assay respectively. In this study, ethambutol, isoniazid, rifampicin, streptomycin and 
pyrazinamide at 60 µM were used as comparators.  
3.7.2 Mycobacteria: CMFDA membrane integrity assay 
5-Chloromethylfluorescein diacetate (CMFDA) is a cell tracker that freely passes through 
cell membranes, and is converted to cell-impermeant and fluorescent reaction products. The 
emission at 520 nm is pH in-sensitive at excitation wavelength of 450 nm and is pH-sensitive 
at excitation wavelength of 490 nm. The fluorescence emission decreases at lower pH. This 
assay was modified using previously established protocol from Purdy et al.
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 First, M. bovis 
was washed and suspended in 20 mM PBS at pH7.0, containing 0.025% tyloxapol. An OD600 
of 0.2 was prepared. Then, the M. bovis was labeled and incubated with 5 µM of CMFDA for 
30 min. Thereafter, the culture is re-suspended using the same buffer of pH 5.5. Desired 
concentrations of xanthone derivatives were added. An aliquot of mixture was removed at a 
specific time. The fluorescence reading was monitored at an emission wavelength of 520 nm 
at excitation wavelengths of 450 nm and 490 nm using a TECAN infinite M200Pro micro-
plate reader. Then, the ratio of emission intensity at excitation wavelength of 490 nm to 450 
nm (EI490/EI450) was determined. To generate a standard curve, M. bovis suspended in same 
buffers at known pH of 5, 5.5, 6, 7, 7.5 and 8 were prepared. Then, an ionophore, nigericin at 
10 nM was added. Nigericin completely interfered membrane integrity and therefore H
+
 from 
the buffer could enter into the cells. The standard curve was generated by plotting EI490/EI450 
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against pH of the buffer. Then, the pH shift induced by the xanthone derivatives, were 
estimated based on the standard curve. In this study, ethambutol, isoniazid, rifampicin and 
streptomycin were used as comparators. 
3.7.3 Mycobacteria: ATP inhibition assay 
M. bovis and M. smegmatis were grown in 7H9 Middlebrook broth until an OD620 of 0.2 
was reached. Then, desired concentrations of antimicrobials were added to 50 mL of the 
culture (50 mL), incubated at 37 
o
C and shook at 300 r.p.m. 10 mL of culture aliquots were 
removed at 1 h, 3h, 6h, 9h, 24 h, and placing them immediately on ice. All subsequent 
manipulations were conducted at 4 ºC. The cells were harvested by centrifugation at 4000 
rpm for 10 min. The supernatant was collected and put on ice. ATP content in the supernatant 
was determined as extracellular ATP. The harvested cells were re-suspended with ATP 
extraction buffer (100 mM Tris, 4 mM EDTA, pH 7.5). The cells were than disrupted by 
sonication using a Diagenode Biorupter UCD-200. Thereafter, the cellular debris was 
removed by centrifugation at 13000 g for 15 min. The ATP-containing supernatant was 
collected, which is regarded as intracellular ATP. Extracellular and intracellular ATP 













































4.1: α-Mangostin is a potent membrane targeting antimicrobial 
4.1.1 Antibacterial activity of natural products extracted from fruit hull of mangosteen 
1,5,8-trihydroxy-3-methoxy-2-(3-methyl-2-butenyl)xanthone (1), γ-mangostin (2), 
garcinone E (3), α-mangostin (4) and mangostenone D (5) are 5 natural xanthones extracted 
from the hull of the mangosteen fruit (Figure 4.1). The extraction was done by Prof 
Shengxiang Qiu from South China Botanical Garden, Guangzhou, China. The details of the 
isolation of these compounds have been reported previously.
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Table 4.1 demonstrates that compound 4 was the most potent of the plant extracts after 
screening against Gram-positive bacteria. MIC values of 4 were 0.78-1.56 µg/mL. In contrast, 
2 and 3 had higher MIC values (MICs 3.125-12.5 µg/mL), while 1 and 5 were not active even 
at 12.5 µg/mL. MIC levels of 4 were comparable to vancomycin for B. cereus, S. aureus as 
well as several isolates of MRSA (MIC= 1.56 µg/mL for all the strains tested). MIC values 
for vancomycin were within CLSI published ranges. Comparing structures 1 to 5, the 
presence of an isoprenyl group at the carbon-8 position was thought to have an important role 
in conferring antimicrobial activity since molecules that lack this moiety 1 or cyclized to the 
adjacent carbon 5 displayed poor antimicrobial properties. The role of isoprenyl groups will 
be discussed in later section. These mangosteen compounds were inactive against Gram-








Figure 4.1 Chemical structures of plant extracts from mangsteen fruit hull. 1,5,8-trihydroxy-
3-methoxy-2-(3-methyl-2-butenyl)xanthone (1), γ-mangostin (2), garcinone E (3), α-
mangostin (4) and mangostenone D (5). 
 
 
Table 4.1 In vitro antimicrobial activities of mangosteen extracts (1 - 5) and vancomycin 
(Van) against Gram-positive bacteria. 
Bacteria 
MIC (µg/mL) 
1 2 3 4 5 Van 
S. aureus DM21455 > 12.5 3.125 3.125 1.56 > 12.5 0.78 
S. aureus DM09808R > 12.5 12.5 3.125 1.56 > 12.5 1.56 
B. cereus ATCC11778 > 12.5 1.56 3.125 1.56 > 12.5 1.56 
MRSA DB57964/04 ND
a
 1.56 ND 1.56 ND ND 





4.1.2 Antimicrobial properties of α-mangostin 
As compound 4 displayed lower MIC values overall, its antimicrobial activity was 
further explored. First, to understand the nature of the action against Gram-positive bacteria, 
time killing analyses were carried out using ATCC strains and clinical isolates of S. aureus. 4 
displayed rapid, concentration-dependent killing of MRSA (09808R), at concentrations of 2× 
MIC or 4× MIC and achieving 3-log and 5-log reductions respectively in viable counts within 
5 minutes (Figure 4.2A). At concentrations below 1x MIC, less than a 3-log reduction of 
viable counts (99.9% of cell death) was attained. Similar findings were observed when 
another MRSA (DM21455) and B. cereus (ATCC11778) were tested. Rapid killing of over > 
3 log-reduction was found at 2× MIC in 5 minutes (Figure 4.2B). In contrast, vancomycin 
had notably poorer bactericidal activity against MRSA (DM21455) and B.cereus 
(ATCC11778) at 2 x MIC or 8 x MIC. There was no significant ≥ 3-log reduction in viable 
cells even after 300 minutes of incubation with vancomycin at 8x MIC (Figure 4.2C). A 
previous report found that 16-20 h are needed for vancomycin to achieve a 3-log reduction in 
viable counts.
180
 It is generally accepted that vancomycin inhibits biosynthesis of the 
bacterial cell wall by binding to the D-Ala-D-Ala terminus of the growing peptidoglycan 
component, which is the substrate for crosslinking of peptidoglycan via the transpeptidation 
reaction, suggesting an inherently slower antibacterial action.
181
 The results suggest that 4 is a 
stronger bactericidal agent than vancomycin.  
Next, the ability for bacteria to develop resistance against 4 was also tested. To examine 
this issue, a laboratory simulation of resistance using E. faecalis ATCC29212 and MRSA 
DM21455 was carried out and these organisms were individually incubated with α-mangostin. 
Antibiotic resistance is defined as more than a 4 fold increase in original MIC.
159
 Figure 4.2D 
shows that resistance was not seen to develop for E. faecalis which had less than a > 4-fold 
MIC increase for α-mangostin (MIC at passage 0, 0.78 µg/mL; MIC at passage 20, 1.56 
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µg/mL). 2-fold increased in MIC was observed for MRSA DM21455 from passage 10-19. 
However, the 2-fold increased was not stable throughout the experiment and was within the 
error margin for MIC testing. Overall, there was no evidence of the emergence of mutational 






















Figure 4.2 Time kill kinetics: (A) Concentration-dependent bactericidal killing curve of 
MRSA 09808R using α-mangostin. Effect of (B) α-mangostin and (C) vancomycin on the 
survival of MRSA and B. cereus and (D) Multistep resistance selection studies of α-
mangostin against Gram-positive bacteria. Vancomycin was used as a comparator in the 









4.1.3 Membrane targeting properties of α-mangostin 
Compound 4 showed rapid killing and no evidence of the emergence of mutational 
resistance from bacteria. These properties are similar to the natural antimicrobial peptides.
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From this observation it was considered possible that 4 may kill bacteria via membrane 
targeting pathway. First, membrane depolarization induced by 4 was investigated. DiSC3-5 is 
a cytoplasmic membrane potential sensitive dye. Partitioning of DiSC3-5 onto the surface of a 
polarized cell self- quenches its fluorescence. Depolarization prevents dye partitioning on the 
cell surface and releases the dye into the media with a concomitant increase in fluorescence 
intensity. Thus, the increase in fluorescence intensity of DiSC3-5 would be proportional to the 
degree of membrane potential reduction.
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 Addition of 4 to the clinical isolate S. aureus 
DM4001 caused a rapid, concentration-dependent increase in fluorescence intensity of 
DiSC3-5, indicating loss of membrane potential (Figure 4.3A). Fluorescence signals from 
bacteria exposed to higher concentrations of 4 at 2×, 4× and 8× MIC concentrations showed a 
sharper, immediate increase. The extent of depolarization at 8× MIC was very similar to 4x 
MIC. The result signified that 4 at 4× MIC, compound 4 was able to completely dissipate the 
membrane potential. Cells exposed to 1x MIC lost membrane potential gradually. In contrast, 
no depolarization was observed at concentrations less than the MIC value. These results 
confirmed that 4 altered the proton motive force and caused structural damage to the 
cytoplasmic membrane. 
Next, the membrane interaction study was continued using EtBr, a membrane 
impermeable dye which is generally excluded from bacteria with intact membranes. The dye 
intercalates into double-stranded nucleic acids with enhanced fluorescence in the visible 
region. Membrane disruption by 4 allowed the influx of the dye to complex with intracellular 
nucleic acids with increased fluorescence intensity. Figure 4.3B shows that addition of 4 at 
concentrations of 2× MIC, 4× MIC and 8× MIC to the clinical strain of S. aureus resulted in a 
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strong increase in the fluorescence emission of EtBr at 616 nm. Similarly as for the 
membrane depolarization assay, addition of 4 at concentrations lower than MIC did not 
display a significant enhancement of EtBr fluorescence emission. Controls without 
antimicrobial treatment, membrane-targeting antibiotics such as daptomycin and vancomycin 
did not result in an increased intensity of EtBr fluorescence (Figure 4.2C). As expected, 
addition of Triton X-100 (40%) as a positive control (Bio-rad laboratories) rapidly 
permeabilized the bacterial membrane allowing entrance of EtBr, which complexed with 
nucleic acids and fluoresced. Therefore, cytoplasmic membrane disruption is shown to be the 
dominant action mechanism to explain the rapid bactericidal properties of 4. 
Membrane disruption action of 4 was further investigated using Sytox green dye. Figure 
4.2D shows that addition of 4 to the clinical isolate S. aureus DM4001 caused concentration-
dependent increase in fluorescence intensity of Sytox green indicating membrane was 
permeabilized. Addition of 4 at concentrations of 2× MIC and 4× MIC resulted in a strong 
increase in the emission intensity of Sytox green fluorescence emission. Cells exposed to 
0.5× and 1× MIC increased the Sytox green fluorescence emission gradually. Melittin is a 
principal peptide of bee venom with strong membrane lytic properties.
183
 Addition of 10 
µg/mL of melittin caused a rapid increase in fluorescence intensity of Sytox green, indicating 
the bacteria were permeabilized rapidly. The result further demonstrated that 4 had similar 
membrane permeabilization effect to melittin.  
Next, calcein loaded liposomes, mimicking bacterial membranes, containing 75/25 
DOPE/DOPG were constructed. Dye leakage from the LUVs showed that 4 could induce ~37% 
leakage at a lipid-to-compound (L/C) ratio of 2. The lytic activity was ~28% and ~16% at the 
L/C ratio of 4 and 8 respectively (Figure 4.2E). In general, all these assays strongly support 
the notion that the antibacterial action of 4 was membrane targeting. Interestingly, α-
mangostin is also found as a membrane active agent to depolarize the mitochondrion 
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membrane potential in eukaryotic cells.
184
 In fact, the mitochondrion membrane has similar 
lipid composition to the bacteria membrane such as cardiolipin and 
phosphatidylethanolamine.
185
 In addition, mitochondrion and bacteria are closely related. 
Therefore, a similar mechanism of action should be involved against the bacteria. Our data 
supports this statement as the antibacterial mechanism of α-mangostin is to disrupt cell 
membrane. 
The extent of membrane damage varied when bacteria were exposed to different 
membrane targeting antimicrobials. It has been suggested that the degree of membrane 
disruption is a continuous graduation.
186
 The antimicrobial activity of α-mangostin appears to 







 These agents elicit bactericidal action by 
forming ion channels or transmembrane pores without causing direct disruption of the 
membrane integrity.
152, 188
 However, it is important to note that membrane targeted action 
without causing lysis does not impede the emergence of drug resistant S. aureus. For instance, 
daptomycin-resistant S. aureus has been reported recently.
66, 119a
 Therefore, interaction of α-
mangostin with cytoplasmic membrane causing cell lysis via non-electrostatic interactions 
may represent a novel way of diminishing the probability of developing resistance in 
susceptible pathogens. In support of this, an in vitro multipassage resistance selection study 







Figure 4.3 Membrane targeting properties of α-mangostin. Membrane targeting property of 
α-mangostin was investigated using different biophysical approaches: (A) Membrane 
depolarization of 4 on the clinical isolate S. aureus DM4001. (B) Effects of 4 with different 
concentration on the fluorescence intensity of EtBr incubated with clinical isolate S. aureus 
DM4001 at 0.25x, 0.5x, 1x, 2x, 4x and 8x MIC. (C) Effects of different antibiotics on the 
EtBr fluorescence intensity: red line, 1 µL DMF; black line, α-mangostin, 8x MIC; blue line, 
daptomycin, 12.5 µg/mL; light blue line, vancomycin, 8x MIC; purple line, 15 µL triton X-
100. (D) Membrane permeabilization of 4 at 0.25x, 0.5x, 1x, 2x and 4x MIC to the clinical 
isolate S. aureus DM4001 incubated with Sytox green. Dark blue line: Melittin (10 µg/mL). 
Addition of DMF (green line) and 0.25x MIC (purple line) had no effect on the Sytox green 
fluorescence emission. (E) Percent released of calcein from artificial bacterial membrane with 
composition of 75/25 DOPE/DOPG LUVs upon addition of lipid to α-mangostin ratio of 4 




4.1.4 Visualizing the permeation of bacterial membranes  
The cationic dye Sytox green (Invitrogen) is a membrane impermeable dye. When the 
bacterial membrane is disrupted, the Sytox green increases cytoplasmically resulting in bound 
fluorophore to intracellular nucleic acids, which can be visualized using fluorescence 
microscope. Figure 4.4 shows that when the clinical isolate, DM4001 of S. aureus was 
exposed to 3.125 µg/mL (2x MIC) and 6.25 µg/Ml (4x MIC) of α-mangostin, in the presence 
of Sytox green, a marked fluorescence signal within the bacteria could be observed. The 
results suggested that α-mangostin disrupted the bacterial membrane rapidly. Untreated 
controls or bacteria treated with vancomycin at 6.25 µg/mL did not show similar levels of 
fluorescence.  
Next, morphological changes of α-mangostin treated bacteria were also visualized with 
SEM. S. aureus (DM4001) treated with α-mangostin were compared with untreated controls. 
Untreated cells had intact, smooth and spherical morphology (Figures 4.5A and 4.5C). In 
contrast, bacteria exposed to 10 µg/mL of α-mangostin showed significant morphological 
changes. For instance, numerous lysed cells accompanied by cellular debris and release of 
intracellular components were observed. In addition, some cells had burst with deep craters 
on the cell membrane (Figures 4.5B and 4.5D). This observation was compatible with the 











Figure 4.4. Visualizing the permeation of bacterial membranes using Sytox Green dye. . 
Cells fluoresced in green when treated with 4 at 2× and 4× MIC as the consequent of 
membrane disruption. In contrast, cells treated with vancomycin (6.25 µg/mL) did not show 
significant amount of stained cells (upper right). Control without treatment: bacteria with 








Figure 4.5 Visualizing the morphological change of α-mangostin treated cells. Scanning 
electron microscopy showed that α-mangostin induced cell lysis and membrane disruption 
after 30 min of incubation. (A) and (C): Control without treatment at magnification of 5000x 
and 20000x, respectively. (B) and (D): S. aureus incubated with 10 µg/mL α-mangostin after 
30 minutes at magnification of 5000x and 20000x, respectively. White arrow indicated 







4.1.5 Hemolysis study of α-mangostin 
Compound 4 was proven to be membrane targeting. Next, the effect of 4 on mammalian 
membrane was investigated. Hemolysis assay using rabbit red blood cells showed that it 
induced lytic percentage of 7.7 ± 2.4%, 8.1 ± 1.9% and 10.5 ± 4.8% at 1× MIC, 2× MIC and 
4× MIC respectively. However, concentration required to hemolyse 50% of red blood cells 
(HC50) was only 9 µg/mL. Therefore, the selectivity (HC50/MIC) of 4 was only 5.77, which 
signified that 4 had poor selectivity to discriminate bacterial and mammalian membrane.  
In summary, we have shown that the main target of α-mangostin is bacteria inner. It 
displayed potent antimicrobial activities against Gram-positive pathogens, rapid time kill and 
resistance was not formed in laboratory simulations using E. faecalis and a MRSA. However, 
membrane selectivity was not satisfactory. Therefore, compound 4 may not be a potential 
candidate for further therapeutic development. Further modification is required. 
4.2: Design and synthesis of amphiphilic xanthone derivatives  
In the previous chapter, I have shown that that α-mangostin, a natural xanthone extracted 
from a common South East Asian fruit, disrupts the cytoplasmic membrane of Gram-positive 
organisms including MRSA. α-Mangostin displays desirable antimicrobial properties such as 
low minimum inhibitory concentration, rapid bactericidal action and avoidance for 
development of resistance. However, α-mangostin does not show adequate selectivity 
between bacteria and mammalian cell membranes. To overcome these issues, design and 
synthesis new xanthone analogues with improved membrane selectivity are required.  
4.2.1 Rationale and design: Amphiphilic xanthones 
CAMPs contain hydrophobic and cationic residues and are able to adopt facial amphiphilic 
topologies. Cationic groups are preferentially attracted to the anionic phospholipid head 
groups of the bacterial membrane driven by electrostatic interactions. In contrast, the CAMPs 
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have relatively weaker interactions with neutral or zwitterionic amphiphiles present in 
mammalian membranes at physiological pH.
189
 CAMPs selectively inhibit and kill bacteria 
without inducing significant cell cytotoxicity.
190
 Inspired by this, new derivatives of α-
mangostin were designed by incorporating cationic groups with different pKa values to tune 
the amphiphilic properties of the hydrophobic xanthone scaffold to afford compounds with 
better selectivity.  
The design strategy for amphiphilic xanthone is based on a pharmacophore model for short 
CAMPs that contains an amphiphilic topology in which hydrophilic and hydrophobic regions 
are segregate into opposing regions.
110
 In general, α-mangostin can be conceptually divided 
into four distinct portions: spacer length, cationic end groups, varied lipophilic chains and 
trivalent functionalization. The structure-activity relationships that emerged from these 
portions in this study are summarized in Figure 4.6. A series of xanthone derivatives were 





















Figure 4.6. Conceptual structural breakdown of α-mangostin. A, B, C and D indicate 
different portions of α-mangostin used in this study to investigate the SARs of amphiphilic 















4.2.2 Structure activity relationships: Cationic moieties 
Amine groups are organic compounds and functional groups that contain a basic nitrogen 
atom with a lone pair. Therefore, amine groups are good moieties to provide cationic charge 
to α-mangostin. Three types of amines were used for functionalization: aliphatic amines, 
cyclic amines and aromatic amines. Structures of amine used, antibacterial activity, HC50 and 
selectivity of amphiphilic xanthone derivatives are shown in Table 4.2. 
First, the effect of introducing primary amine group, compound 6 was explored. As shown 
in Table 4.2, this modification resulted in significant improvements in hemolytic activity 
(HC50= 80.2 µg/mL) while also maintaining a good in vitro antibacterial activity (MIC= 1.56 
µg/mL). Selectivity of 6 was 51.4. Replacements using guanidine (7), N,N-dimethylamine (8) 
and N,N-methylethylamine (11) did not seem to provide benefit, as both compounds showed 
less potency and selectivity (10.3 – 20.5). Amination using N,N-diethylamine (9) resulted in 
the interesting compound 9, which had very potent antimicrobial activity with a MIC value of 
0.39 µg/mL, a 4-fold improvement as compared to α-mangostin. In addition, the HC50 was 
19.6 µg/mL, so the selectivity of this compound was 50.4. The effect of introducing two 
hydroxyl groups to N,N-diethylamine, compound (10) was also explored. The pKa of the 
moiety was dramatically reduced to 5.8 due to an induction effect, and no improvement in 
MIC values or selectivity was observed. A similar effect was observed for compound 13, as 
the MIC and selectivity were both significantly reduced to 6.25 µg/mL and 1.3 respectively. 
The N,N-diethylamine was replaced with its isomer, N-methylpropylamine (12). Surprisingly, 
this replacement was very negative for the MIC, with a 64-fold reduction of antibacterial 
activity, from 0.39 µg/mL to 25 µg/mL.  
Further modification of the N,N-dialkylamine with carbon number of > 4, significantly 
lowered the potency. For instance, xanthones coupled to N,N-butylmethylamine (14), N,N-
ethylpropylamine (15), N,N-ethyllisopropylamine (16), N,N-pentylmethylamine (17), and 
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N,N-butylmethylamine (18), N,N-dipropylamine (19) and N,N-hexylmethylamine (20) 
displayed poor MIC values of 12.5 – 50 µg/mL. The loss of activity (MIC > 50 µg/mL) 
observed for 21 and 22 also clearly showed that substituents at carbon number 8 were 
deleterious. Careful evaluation of the potency of these compounds signified that N,N-diethyl-
substitution was the optimized alkyl length of the cationic moieties for potent MIC values 
(0.39 – 3.125 µg/mL). Any substitution of N-propyl or longer alkylamine diminished the 
antibacterial activities (MIC ≥ 12.5 µg/mL).   
Attention turned to heterocyclic cationic moieties (compounds 23 – 33). Results were 
disappointing, as maximum attainable selectivity achieved was < 25 for all the compounds 
studied. In general, pyrrolidine (23) and piperidine (25) coupled xanthone derivatives 
displayed the most potent antimicrobial properties, with MIC values of 0.78 – 1.56 µg/mL. 
When a hydroxyl group was introduced to the para-position of piperidine (26), a 8-fold 
reduction of potency was observed. This result further suggests that substitution of hydroxyl 
groups could reduce the activity of amphiphilic xanthone derivatives. Replacement of the 
piperidine with a lower pKa morpholine (27) and thiomorpholine (28) led to a loss of activity 
(MIC > 50 µg/mL). Piperazine coupled derivative (29) showed a 8-fold reduction of potency 
compared to 25. A more hydrophobic analogue, 30, with 1-methylpiperazine also displayed 
similar antibacterial activities (MIC= 6.25 µg/mL). An increase in the alkyl length to 1-
ethylpiperazine (5i), further reduced the activity to 25 µg/mL. Other heterocyclic substituted 
analogues, 24 and 32 displayed moderate MIC values of 6.25 µg/mL. Compound 33 was 
inactive at 50 µg/mL.   
Next, aromatic amine substitutions were explored. Table 4.2 shows that derivatives in this 
series were inactive at the highest concentration tested (> 50µg/mL). No hemolytic effects 
were observed. The results suggest that delocalization of electrons into the aromatic greatly 
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Compounds 6 – 37 were tested for their inner membrane targeting properties against S. 
aureus DM4001 at 1× MIC. Membrane permeabilization properties using Sytox Green 
uptake assay was first investigated (Table 4.3 and Figure 4.7). Permeabilization reached a 
very high level for substituents with N,N-dialkylamine with carbon number of 4 – 5 (c.p.s. of 
80,000 – 115,000). When the carbon number further increased to 6 – 7 (compounds 17 – 20), 
the extent of membrane permeabilization was slightly reduced c.p.s. of 45,000 – 85,000. 
When the carbon number reached 8 (compounds 21 and 22), poor permeabilization was 
observed. The leakage of ATP from bacteria using ATP determination kits in ATP-free PBS 
buffer was determined. Table 4.3 shows that strong ATP leakage could be observed when S. 
aureus was incubated with xanthone analogues coupled with N-alkylamine with a carbon 
number of 4 or above. Similar to the Sytox Green uptake assay, only low levels of ATP 
leakage were detected when bacteria were incubated with xanthone derivatives modified 
using a N,N-alkylamine with a carbon number of 8.  
Next, statistical analysis to determine correlations were performed. Figures 4.8A and 4.8B 
show that a significant positive correlation was observed between MIC and cLogP and 
carbon number of aliphatic amine modified xanthone derivatives for compounds 6 – 22, with 
rs value of 0.7098 (p= 0.0014) and 0.7948 (p= 0.0001) respectively. Carbon number emerged 
as an important parameter influencing in vitro MIC value, suggesting that these compounds 
with high carbon numbers could not approach the negatively charged bacterial membrane 
efficiently. A possible reason was that long alkyl chain on N,N-alkylamine hinders the ability 
of the cationic nitrogen to approach negative charged membrane. Increasing the carbon 
number also increased cLogP (rs= 0.9083, p< 0.0001), as moieties with more carbon units are 
more hydrophobic. For example, as shown in Figure 4.7, compounds 14, 17, 19 and 20 
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induced membrane permeabilization more slowly. Therefore, higher concentrations were 
needed to reach adequate high surface concentration in the outer leaflet of the membrane. In 
addition, there was also a significant positive correlation between ATP leakage and carbon 
number for compounds 6 – 20 (Figure 4.8D, rs= 0.746, p= 0.0014). Once an adequate 
concentration of an active compound was achieved on the bacterial membrane, analogues 
with higher carbon numbers could induce stronger membrane permeabilization or pore 
formation. In support of this, Liu et al. reported that membrane destabilization through 
transmembrane pore formation requires alkyl chain with sufficient length.
191
 In addition, Lin 
et al. showed that alkylation of a membrane-perturbing peptide induced pores with larger size 
relative to those formed by a non-alkylated peptide.
192
 Thus, these xanthone derivatives with 
larger carbon number induced stronger ATP leakage at their MIC values.  
For xanthone derivatives coupled with a N,N-alkylamine of carbon number >8, overall 
amphiphilic conformation of the xanthone analogues was disrupted as the N,N-alkylamine 
was too hydrophobic. Therefore no antibacterial activity was observed for 21 and 22. No 
significant correlation was observed between pKa and MIC and ATP leakage. 
Table 4.4 shows that cyclic amine coupled xanthone derivatives, in general displayed 
weaker membrane permeabilization. The data suggests that cationic moieties with cyclic 
structures are relatively bulkier than N,N-dialkylamine and may hinder the amphiphilic 
xanthone to disrupt bacterial membrane. Figure 4.8E shows that, examination of potential 
correlations revealed that pKa displayed a significant negative correlation with MIC values 
(rs= -0.7335, p= 0.0028). No correlation was observed between carbon number and MIC and 
ATP leakage. 
As expected, Figure 4.8F shows that there was a significant positive correlation between 
Sytox Green uptake and ATP leakage (rs= 0.6525, p= 0.0001) for all compounds tested (6 – 
37). This observation was in accordance with a previous report that to a large extent  
88 
 
membrane perturbation is frequently followed by leakage of larger cellular constituents such 
as ATP and DNA.
193
  
Overall, the findings suggested that cationic moieties of xanthone derivatives are important 
to selectively interact and further perturb the negatively charged microbial cytoplasmic 
membrane. The data also further support the earlier postulation
194
 that the amphiphilic 
xanthone derivatives disrupt the bacterial membrane via interfacial activity model as 
described by Wimley.
145b
 Carbon number of high pKa aliphatic N,N-dialklyamine is also an 
important factor to affect the antimicrobial activity. For heterocyclic coupled xanthone 
derivatives, pKa is more crucial to exhibit good antimicrobial property. This SAR effort has 















Table 4.2. In vitro antibacterial activity, HC50 and selectivity of amphiphilic xanthone 
derivatives modified with aliphatic amines, cyclic amines and aromatic amines. Bacterial 
strain tested was a clinical isolate S. aureus DM4001. pKa of each branched substituent is 












Aliphatic amines  
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10.2±0.1 4.90 1.56 80.2 ± 2 51.4 
7 
 
13.4±0.7 4.04 3.125 64.1 ± 2 20.5 
8 
 
9.6±0.3 6.73 3.125 32.1 ± 3 10.3 
9 
 
10.4±0.3 8.56 0.39 19.6 ± 3 50.4 
10 
 
5.8±0.5 4.22 6.25 60.6 ± 2 9.7 
11 
 
9.7±0.5 7.84 1.56 25.1 ± 2 16.1 
12 
 





8.8±0.5 6.54 6.25 31.8 ± 3 5.1 
14 
 
9.7±0.5 9.32 50 60.5 ± 3 1.2 
15 
 
9.7±0.5 9.32 12.5 63.3 ± 4 5.1 
16 
 
9.8±0.5 9.10 25 54.6 ± 2 2.2 
17 
 
9.7±0.5 11.16 25 >200 > 8 
18 
 
9.7±0.5 10.18 12.5 >200 > 16 
19 
 
9.7±0.5 10.18 25 >200 > 8 
20 
 
9.8±0.5 11.88 50 >200 > 4 
21 
 





8.6±0.5 9.68 >50 >200 NA 
Cyclic amines  
23 
 
10.4±0.2 7.60 1.56 25.0 ± 2 16.0 
24 
 
9.7±0.4 6.74 12.5 28.9 ± 2 2.3 
25 
 
9.6±0.1 8.84 0.78 19.3 ± 3 24.7 
26 
 





7.4±0.1 6.60 >50 >200 NA 
28 
 
7.7±0.2 7.82 >50 >200 NA 
29 
 
9.2±0.1 6.31 6.25 72.1 ± 4 11.51 
30 
 
7.7±0.1 5.87 6.25 32.3 5.2 
31 
 
7.9±0.1 6.72 25 138.5 ± 8 5.5 
32 
 
9.5±0.3 5.64 6.25 35.9 ± 3 5.7 
33 
 
7.2±0.1 8.58 >50 >200 NA 
Aromatic amines  
34 
 
7.0±0.1 6.65 >50 >200 NA 
35 
 
3.0±0.1 5.52 >50 >200 NA 
36 
 
2.2±0.1 6.88 >50 >200 NA 
37 
 
ND 8.85 >50 >200 NA 
a 
Calculated using ACD/Percepta predictors software. 
b 









Table 4.3. Effect of xanthone derivatives coupled with aliphatic amines on the inner 
membrane measured by Sytox Green uptake (S.G.U.) assay and ATP leakage at 1× MIC. 
Carbon number indicates total carbon atoms of the aliphatic amines coupled. Bacterial strain 
tested for S.G.U. and ATP leakage was clinical isolate S. aureus DM4001. Values represent 










6 0 1497.3 ± 65 210.0 ± 25 
7 1 68378.0 ± 2647 2236.8 ± 322 
8 2 23924.7 ± 2076 3769.1 ± 201 
9 4 61678.8 ± 3582 2235.0 ± 218 
10 4 59694.1 ± 2511 3741.2 ± 38 
11 3 12456.1 ± 1019 1734.4 ± 222 
12 4 87537.3 ± 4686 3944.7 ± 616 
13 4 112771.8 ± 4400 5027.1 ± 16 
14 5 114095.1 ± 6913 8861.9 ± 117 
15 5 82176.4 ± 5653
 
12735.7 ± 218 
16 5 97823.9 ± 4587 5406.8 ± 308 
17 6 47165.7 ± 2635 8949.4 ± 509 
18 6 64789.5 ± 3656 12480 ± 476 
19 6 53637.1 ± 4876 5122.8 ± 437 
20 7 74047.1 ± 3285 8545.2 ± 1009 
21 8 1768.3 ± 30 763.3 ± 46 
22 8 1778.4 ± 69 573.8 ± 35 
a








Table 4.4 Effect of xanthone analogues coupled with a cyclic amine or aromatic amine on the 
inner membrane measured by Sytox Green uptake (S.G.U.) assay, ATP leakage assay and 
calcein leakage assay at 1× MIC. Bacterial strain tested for S.G.U. and ATP leakage was 
clinical isolate S. aureus DM4001. Values represent the means and standard deviation 
obtained from two independent experiments. 
Compound 
a




23 814.3 ± 67 465.1 ± 12 
24 58190.9 ± 1858 7962.4 ± 199 
25 2797.4 ± 120 626.3 ± 94 
26 50250.4 ± 1484 5937.9 ± 596 
27 6357.5 ± 311
 
228.7 ± 17 
28 7128.9 ± 285 4.5 ± 1 
29 24629.2 ± 2462 3153.7 ± 211 
30 7128.9 ± 610 3726.8 ± 322 
31 15095.3 ± 416 7821.7 ± 312 
32 5850.4 ± 446 2974.7 ± 78 
35 1979.4 ± 124 415.7 ± 35 
36 3444.8 ± 120 309.8 ± 46 
a











Figure 4.7. Sytox Green uptake of aliphatic amine modified xanthone derivatives was used to 









Figure 4.8. Plot of correlations of xanthone derivatives with different cationic moieties. (A) 
MIC versus cLogP of aliphatic amines modified xanthone derivatives 6 – 22. (B) MIC versus 
carbon number of aliphatic amines modified xanthone derivatives 6 – 22. (C) Carbon number 
versus cLogP of aliphatic amines modified xanthone derivatives 6 – 22. (D) ATP leakage 
versus carbon number of aliphatic amines modified xanthone derivatives 6 – 20. (E) MIC 
versus pKa for cyclic amine modified xanthone derivatives 23 – 32. Significant positive 
correlations were observed for (A), (B) and (C). A significant negative correlation was 
observed for (D). (F) Sytox green uptake versus ATP leakage of all compounds 4 - 32 and 35 





4.2.3 Structure activity relationships: Spacer length 
The previous study has shown that N,N-diethylamine modified xanthone, compound 9 
displayed desired antibacterial activity. On the basis of these results, next, the effect of spacer 
length was investigated by preparing new compounds with spacer length (n) of 2, 3, 5, 6, 8, 
10 and 12. MIC values of these xanthone derivatives against clinical isolate S. aureus 
DM4001were shown in Table 4.5. Similar to compound 9 with spacer length of 4, 
compounds 39 – 41 (n= 3 – 6) also displayed potent antimicrobial activities, with MIC values 
of 0.78 – 1.56 µg/mL. At spacer length of n= 2 and n ≥ 8, no bacterial inhibition was 
observed at the highest tested concentration at 50 µg/mL. Next, the cytoplasmic membrane 
targeting properties were investigated using Sytox Green assay. Figure 4.9 shows that S. 
aureus DM4001 treated with compounds 9, 39 – 41 at 10 µM showed significant Sytox 
Green influx in 200 s. In contrast, 43 and 44 caused only a very small amount of dye influx. 
Compounds 38 and 42 also promoted dye uptake but at a slower rate. These data correlates 
well with the MIC values, signifies that membrane permeabilization of 9, 39 – 41 was crucial 
to induce cell death.  
The effects of spacer length and pKa of the xanthone derivatives on membrane integrity 
were also evaluated using the Live/Dead BacLight bacterial viability kit. The Baclight 
reagent is using two nucleic acid stains with different properties to distinguish cells with 
damaged cell membranes from the intact cell membranes. SYTO-9 is a green-fluorescent 
nucleic acid that stains both bacteria with intact or damaged membrane. In contrast, 
propidium iodide is a red-fluorescent nucleic stain that penetrates only bacteria with damaged 
membranes and reducing the fluorescence intensity of the SYTO-9. It is clear from the results 
presented in Table 4.5 that N,N-diethylamine modified xanthone analogues with spacer 
length of n= 3 – 6 significantly reduced membrane integrity of bacterial membrane to < 50%. 
Compound 9 (n= 4) was found to be the most effective compound to reduce the membrane 
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integrity to 37.8 ± 5.1%. In accordance to Sytox Green uptake assay, compound 38 (n=2) was 
less efficient to reduce the membrane integrity to 64.1 ± 1.2%. In contrast, for bacteria 
exposed to 42 – 44, no reduction of membrane integrity was detected. The results suggest that 
active amphiphilic xanthone derivatives kill the bacteria via membrane disruption.
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The potent activity of xanthone derivatives with spacer length from n= 3 to 6 were clearly 
defined. Spacer length with either too short (n= 2) or too long (n ≥8) were detrimental to 
antibacterial activity, and the reason is not known. Compounds 9, 38 – 44 were all modified 
with same N,N-diethylamine, suggesting that the spacer length may play an important role in 
antibacterial action. For 38 (n= 2), I postulate that the distance between oxygen atoms at C3 
and C6 positions with the terminal nitrogen atoms are short enough for oxygen atoms to cause 
inductive effect. The effects of the spacer length on electron density were studied by 
1
H NMR 
spectra, as shown in Figure 4.10. At spacer length of n= 5 and above, the signal of protons H
2
 
could be observed at 2.40 – 2.48 ppm, and the signal of H1 protons are at downfield of 2.50 – 
2.60 ppm. At spacer length of n= 4, signal of H
2
 protons shifted to lower field and merged 
with the signal of H
1
 protons at 2.50 – 2.65 ppm. The signal of proton H2 was further shifted 
to lower field when the spacer length decreased from n= 4 to n= 2. For 38 with spacer length 
of n= 2, the signals of the proton H
2
 were shifted significantly to down field region (3.00 
ppm). In contrast, sinal of H
1
 protons did not show significantly shifted. The results clearly 
show that the inductive effect of the oxygen atom has significant effect to the electron 
distribution of the proton H
2
 attached to the carbon that is adjacent to the amine group when 
the spacer length is n< 5. The pKa value of the diethylamine is expected to be lower and 
shifted from 10, which cause the antimicrobial properties of compound 38 is much weaker 
than 9 and 39 – 41. In support of this, Table 4.6 was presented to show the effect of the 
spacer length between amine and alcohol group on the pKa values. pKa values of 
alkanolamine with n=3 (1,3-propanolamine, dimethylpropanol amine and 
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diethylpropanolamine; pKa values of 9.91, 9.27 and 10.14, respectively) are higher than their 
respective alkanolamine with n= 2 (monoethanolamine, dimethylethanolamine and 
diethylehtanilamine; pKa values of 9.16, 8.88 and 9.79 respectively).
195,196
 The shifting of 
pKa is -0.76, -0.39 and -0.35, respectively. Therefore pKa of diethyalmine at n= 2 might be 
shifted to a value of < 10. Indeed, Table 4.5 shows that calculated pKa of N,N-diethylamine 
of 38 was only 9.5. Calculated pKa of 9, 39 – 44 were in the range of 10.1 – 10.6. As cationic 
charge is important to membrane targeting antimicrobials to distribute on the surface to 
disrupt the bacterial membrane,
140a
 the poorer antimicrobial activity of the 39 could be 
attributed to the pKa shifting. Consequently, 38 had weaker ability to disrupt the inner 
membrane as shown in Sytox Green uptake and membrane integrity studies.  
Inductive effect and pKa profile could not explain the reduction of antimicrobial properties 
of the compounds with longer spacer length (n≥ 8) as no significant different was observed 
from their NMR spectra. Other factors must be involved. One of the possible explanations to 
this observation is likely aggregation. A number of studies report that longer alkyl chain 
facilitate aggregation.
144, 192, 197
 For instance, Malina and Shai have reported that the enhanced 
oligomerization of a compound endows them with a large volume, which limit their access to 
penetrate into cytoplasmic membrane via bacterial cell wall such as peptidoglycan.
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Aggregation also reduced the effective concentration of xanthone derivatives with longer 
spacer length in the solution, so hemolytic activity also reduced with spacer length.  To 
examine whether this was the case, we examine the ability of these compounds to disrupt 
calcein-loaded liposome (DOPE/DOPG= 75/25), which mimicking bacterial membrane. It is 
noteworthy to mention that the liposome is a good model to mimic lipid membrane, but not 
the real bacteria model as the bacterial membrane also consists of outer membrane. In 
contrast to Sytox Green uptake and baclight assays that utilizes whole cells in the study, 
calcein leakage study (Figure 4.11) shows that lytic activities of 42 (n= 8) and 43 (n= 10) 
99 
 
were similar to 9 (n=4), the most potent compound in this series in inducing calcein leakage 
from LUV. At compound to lipid ratio of 0.125 – 0.5, 9, 42 and 43 all induced > 70% leakage. 
44 (n= 12) had a slightly weaker lytic activity with % leakage of about 60%. This observation 
was contradicted to the to the whole cells assay using Sytox Green and baclight studies that 
42 – 44 were much less potent in disrupting bacterial membrane. Combining these 
biophysical approaches signified two important issues. First,  the amine moieties with high 
pKa value are crucial to interact with negatively charged bacterial membrane via electrostatic 
interaction, as suggested by the surface activity model.
145b
 Electrostatic interactions are 
crucial to attract the cationic charged xanthone derivatives to the membrane surface, 
regardless of their spacer length. High surface concentration in the outer leaflet is then result 
in membrane disruption. Second, in order to perturb the inner membrane, amphiphilic 
xanthone derivatives must be able to penetrate the peptidoglycan layer of the Gram-positive 
bacteria effectively. Derivatives with longer spacer length tended to aggregate and more 
difficult to pass through the peptidoglycan layer. Hence, despite of strong leakage in 
liposome could be observed for the analogs with spacer length of ≥ 8, they were not able to 
exhibit antibacterial activity.  
In general, SAR on spacer length suggests that n= 4 is the optimized spacer length for N-
diethylamine modified xanthone. If the spacer length is too short, the induction effect will 
affect the cationic distribution of the cationic moieties. In contrast, at longer spacer length, 







Table 4.5. The effects of spacer length of compound 9 on MIC values (µg/mL), HC50 
(µg/mL), selectivity and bacterial membrane integrity. Hydrophobicity, calculated logP and 






















38 2 >50 >200 NA 
f
 64.1 ± 1.2 8.67 57.02 6.94 9.5±0.2 
39 3 0.78 16.3 ± 2 20.9 46.2 ± 9.2 8.97 58.82 7.75 10.1±0.3 
9 4 0.39 19.6 ± 3 50.4 37.8 ± 5.1 9.30 60.80 8.56 10.4±0.3 
40 5 1.56 14.0 ± 2 9.0 43.0 ± 5.3 9.78 63.68 9.16 10.5±0.3 
41 6 1.56 26.5 ± 2 17.0 45.1 ± 7.3 10.24 66.40 9.93 10.6±0.3 
42 8 >50 53.1 ± 3 NA 95.5 ± 9.9 11.29 72.74 11.95 10.6±0.3 
43 10 >50 > 200 NA 100.0 ± 6.8 12.43 79.58 13.56 10.6±0.3 
44 12 >50 > 200 NA 99.9 ± 2.3 13.79 87.74 14.98 10.3±0.3 
a
 Strain tested= clinical isolate S. aureus DM4001.  
b 
Extracellular ATP leakage induced by xanthone analogues at 10 µM relative to nisin (8 




Measured by Live/Dead® BaclightTM bacterial viability kits. Concentration of xanthone 
derivatives used was 10 µM. 
d
 Rt= retention time. Standard deviation is ±0.02 min 
e
 Calculated using ACD/Percepta predictors software 
f
 Not applicable, as an exact value of MIC or HC50 could not be determined. 
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Table 4.6. Variations of pKa values at 298 K of HO-(CH2)n-NR2 as function of amine 
substituent, R and spacer length, n 




monoethanolamine 2 H 9.5 
195
 9.16 ± 0.10 
1,3-propanolamine 3 H 9.96 
195
 9.91 ± 0.10 
dimethylethanolamine 2 CH2 9.23 
196
 8.88 ± 0.28 
dimethylpropanolamine 3 CH2 NA
b 
9.27 ± 0.28 
diethylethanolamine 2 CH2CH3 9.76 
196
 9.79 ± 0.25 
diethylpropanolamine 3 CH2CH3 NA 10.14 ± 0.25 
a
 Reported values 
b 
Calculated using Advanced Chemistry Development (ACD/Labs) software V11.02 
c
 Not applicable 
Figure 4.9. Fluorometric determination of bacterial membrane permeabilization induced by 
xanthone derivatives with different spacer lengths. Increased fluorescence intensity indicates 
cytoplasmic membrane permeabilization was measured with Sytox Green stain.  Inner 
membrane permeabilization of clinical isolate S. aureus DM4001 induced by diethylamine 






Figure 4.10. Partial 
1
H NMR spectra (400 MHz) of N-diethylamine modified xanthone 
derivatives (compounds 9, 38 – 44) with different spacer lengths. Shifting of H1 and H2 as 











Figure 4.11 Percent leakage of calcein from LUV, 30 min after the addition of a xanthone 
derivative with spacer lengths n= 4, 8, 10 and 12. Composition of liposomes used was 
DOPE/DOPG= 75/25 to mimic bacterial membrane. Values represent the means and standard 











4.2.4 Structure activity relationships: Lipophilic chains 
N,N-diethylamine coupled xanthone with spacer length of n= 4 displayed the most potent 
antibacterial activity. Next, the role of lipohiphilic chains was investigated. Table 4.7 shows 
that removal of the isoprenyl group (compounds 45, 46 and 47; R1 and R2= H) resulted in a 
loss of potency in antibacterial activity (MIC> 50 µg/mL) and hemolysis decreased (HC50> 
200 µg/mL). The data strongly suggested that removal of isoprenyl groups was not well 
tolerated for amphiphilic xanthone derivatives. To examine the effect of planarity of overall 
xanthone scaffold with isoprenyl groups, the two isoprenyl groups of compounds 4, 9, 8 and 
23 were also reduced via hydrogenation and yielded compounds 48 – 51 with 2 isopentyl 
groups respectively. The isopentyl group is more flexible. In general, 48 – 51 exhibited 
decreased potency; in particular, 48 lost its antibacterial activity. In addition, these 
compounds also displayed less hemolytic activity as compared to their analogues without 
hydrogenation.  
To investigate their membrane targeting properties, calcein loaded liposomes with different 
compositions, DOPE/DOPG= 75/25 and DOPC to mimic bacterial membrane and 
mammalian membrane respectively were tested. Calcein leakage induced by 4, 8 and 9, with 
their corresponding derivatives with varied isoprenyl groups was investigated (Figure 4.12). 
Figure 4.12A and 4.12D show compound 4 induced 29.4±3.0% and 33.6±11.0% leakage 
from liposomes with a composition of DOPE/DOPG=75/25 and DOPC respectively at lipid 
to compound (L/C) ratio of 4. The observed leakage reduced to 16% and 14.1±4.5% at L/C 
ratio of 8. Further increasing the L/C ratio to 16 and above resulted in leakage of < 10%. 
Notably, 45 and 48 only induced negligible calcein leakage from both types of liposomes at 
all L/C ratios tested, consistent with their loss of potency with MIC> 50 µg/mL and non-
hemolytic activity with HC50> 200 µg/mL. Figure 4.12B shows that both 8 and 50 had 
similar lytic activity against DOPE/DOPG= 75/25 liposome, while 8 induced stronger lytic 
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activity at L/C ratios of 16 – 64 as compared to 50 against DOPC liposome. Taken together, 
the lytic activities correlated well with the MICs and HC50s of these analogues with modified 
isoprenyl groups. The results further proved that isoprenyl groups are found to be crucial and 
enhance the interaction with biological membrane of amphiphilic xanthone derivatives. 
Similar trends could be observed for lytic activities for derivatives of compound 9 (Figure 
4.12C and 4.12F). 9 induced significant leakage against both types of liposomes up to L/C 
ratios of 16, as leakage of >70% was detected. 49, hydrogenated analogue of 9, displayed 
decline in lytic potency relative to 9. For instance, 149 only induced 78.0±0.7%, 58.6±4.3% 
and 20.1±2.9% against a bacterial mimicking membrane at L/C ratios of 4, 8 and 16. 
Consistent with MIC and HC50, no detectable leakage was observed for 46 in both liposomes.
 
In summary, Table 4.7 and Figure 4.12 show that antibacterial activities and membrane 
targeting activities increased in the following manner: Derivatives without isoprenyl groups< 

















Table 4.7. In vitro antibacterial activity, HC50 and selectivity of amphiphilic xanthone 
derivatives with varied lipophilic chains. The bacterial strain tested was clinical isolate S. 
aureus DM4001. Compounds 4, 8, 9 and 23 were used as comparators. Values represent the 
means and standard deviation obtained from two independent experiments. 
 
Compound R1 R2 R3 MIC HC50 Selectivity 
4 
 















12.5 28.9 ± 2 2.3 
45 H H H >50 >200 NA
a 
46 H H 
 
>50 >200 NA 
47 H H 
 
>50 >200 NA 
48 
 















25 34.8 ± 3 1.4 
a 










Figure 4.12. Calcein leakage induced by xanthone derivatives with modified lipophiphlic 
chains. Calcein leakage induced  by (A) α-mangostin derivatives (B) Compound 8 analogues 
and (C) Compound 9 derivatives against liposomes with composition of DOPE:DOPG= 
75/25 and (D) α-mangostin derivatives (E) Compound 8 derivatives and (F) Compound 9 
derivatives against liposomes with composition of DOPC. DOPE:DOPG= 75/25 mimicks the 
bacterial membrane and DOPC mimicks the mammalian membrane. Values represent the 









4.2.5 Structure activity relationships: Trivalent modification 
Finally, the trivalent functionalization of compound 9 was explored by conjugating a N,N-
dietylamine at C1 position. The hydroxyl group at C1 position is relatively inert because of the 
potential for intramolecular hydrogen bond formation between the C1 hydroxyl group and the 
C9 carbonyl group.
194, 200
 Therefore, a more drastic condition was needed to obtain a trivalent 
form of 9 yielding compound 53 via 52.  
Table 4.8 showed that 53 displayed a MIC value of 12.5 µg/mL against S. aureues, which 
was 32-fold weaker MIC than 9. Interestingly, HC50 value of 53 was > 200 µg/mL. Figure 
4.13 shows that 53 induced much weaker membrane permeabilization (Sytox Green uptake= 
4305.1±46 c.p.s) than 9 (Sytox Green uptake= 43558.4±6488 c.p.s). The results suggest that 
the intramolecular hydrogen bond between the C1 hydroxyl group and the C9 carbonyl group 
was important to form a “pseudo-ring”, which is rigid and co-planar to the 3-membered ring 
xanthone enhancing membrane disruption. This 4-membered ring structure is similar to the 4-
membered sterol core of the cationic steroidal antimicrobial (ceragenin),
201
 which also 
displays potent antimicrobial activity via membrane targeting (Structure see Figure 4.13). 
Taken together, the 4-membered ring structure of amphiphilic xanthones was crucial for 









Table 4.8. In vitro antibacterial activity, HC50 and selectivity of compound 9 and its trivalent-
form, compound 53. Bacterial strain tested was clinical isolate S. aureus DM4001. Values 
represent the means and standard deviation obtained from two independent experiments. 
 
Compound R1 R2 MIC HC50 Selectivity 
9 
 
H 0.39 19.6 ± 3 50.4 





12.5 > 200 NA 
a 
Not applicable, as an exact value of MIC or HC50 could not be determined. 
 
Figure 4.13. The 4-membered ring xanthone core is important to induce strong membrane 
disruption (9). When the hydroxyl group at the C1 position is used to conjugate N,N-
diethylamine, the formation of “pseudo-ring” is prohibited and membrane permeabilization 
was reduced (compound 53). Ceragenins are membrane active agents with a 4-membered 
sterol core. Structure of CSA-13 is shown.
201
 S. aureus DM4001 was used in this study. 





4.2.6 Properties of compound 9 (AM-0016) 
The SAR studies have clearly revealed that amphiphilic modifications with aliphatic amine 
moieties that have high pKa values and low carbon number are essential to retain and 
improve antimicrobial properties and selectivity. Compound 9 was identified as a potential 
compound to be further evaluated for its therapeutic potential against Gram-positive 
infections. Compound 9 is also coded as AM-0016 based on my group’s xanthone library. 
4.2.6.1 Antibacterial properties of compound 9 
Encouraged by these results, we screened the antibacterial activity of 9 against a panel of 
Gram-positive bacteria (Table 4.9). Compound 9 exhibited excellent antimicrobial properties 
against all bacteria tested (MIC = 0.095 – 1.56 µg/mL; selectivity index, HC50/ MIC99 = 12.6 
– 206.3), including three clinical isolates of S. aureus, four ATCC strains of S. aureus, four 
clinical isolates of MRSA, one ATCC strain of MRSA, one vancomycin intermediate -
resistant (VISA) strain of S. aureus, two ATCC strains of Streptococcus faecium and one 
ATCC strain of E. faecalis. In addition, 9 also demonstrated comparable or superior 
antibacterial activities to vancomycin and daptomycin (currently the most widely used 
antibiotics for MRSA infection) against 5 selected MRSA strains (Table 4.10). Compound 9 




Next, time-kill kinetic of 9 was investigated. Generally, small-molecule antibiotics kill 
bacteria slowly (over the course of hours),
203
 whereas membrane-active amphiphilic 
antimicrobials and natural antimicrobial peptides are known to kill bacteria rapidly in hour. 
189a, 204 
Compound 9 exhibited concentration-dependent, rapid killing of MRSA, achieving 3-
log reductions (99.9% reduction) in viable counts within 5 and 10 mins at 2× and 4× MIC, 
respectively (Figure 4.14). At 0.5× and 1× MIC, 3-log reductions were achieved in 2 h. The 
time-kill kinetics of 9 were compared with those of daptomycin and vancomycin against 5 
111 
 
MRSA strains (Figure 4.14). Daptomycin achieved a 3-log reduction in approximately 8 h, 
and vancomycin was only minimally active at 24 h). The rapid time-kill for 9 demonstrated 
the advantage of a membrane-directed molecule over vancomycin and daptomycin. The rapid 
time-kill eliminates the production of subsequent generations of bacteria decreasing the risk 
of a resistant mutation.   
An important characteristic of natural CAMPs is that they have not been shown significant 
amounts of resistance, a problem that is shared among essentially all antibiotics in current 
use.
138
 We simulated the development of resistance using an in vitro multipassage resistance 
selection study with S. aureus and E. faecalis to determine whether spontaneous resistance 
against 9 would emerge during prolonged passages at sub-inhibitory concentrations. 
Resistance is formally defined as a >4-fold increase in the original MIC.
159
 Figure 4.15 shows 
that there was no evidence of resistance or cross-resistance against 9 for any of the 4 strains 
tested. Our strategy of modifying α-mangostin to adopt the amphiphilic topology of CAMPs 
allowed 9 to retain the ability to avert resistance like the natural CAMPs and α-mangostin. 
Because “dead bugs don’t mutate”,111 the rapid bactericidal action of 9 and improved 
selectivity make this molecule a good candidate for therapeutic use against MRSA. 
Morphological changes to S. aureus after treatment with 9 were examined using scanning 
electron microscopy. Structural effects were rapid, and membrane changes were apparent 
within minutes after incubation of S. aureus; these findings agreed well with the results of the 
time-kill assays and all the membrane targeting assays performed in the previous section. The 
bacterial membrane exhibited extensive damage, and intracellular components were released 
(Figure 4.16). Untreated cells remained as intact spheres with smooth morphology. This 
shows that 9 had a profound effect on the bacteria; most membrane depolarizing agents, such 
as β-defensins (CAMPs)205 and daptomycin,188 have not been shown to induce cell lysis. To 





This would be very unlikely because it would drastically affect 
cell viability. The membrane-targeting action of 9 is expected to play an important role in its 
rapid time-kill kinetics (Figures 4.14) and in minimizing the development of resistance, as 

























Table 4.9. MIC values of 9 against a panel of Gram-positive bacteria including 6 strains of 
clinical isolates MRSA 
Gram-positive Strains  MIC Selectivity 
MRSA ATCC 700669 0.095 206.3 
MRSA DM09808R  1.56 12.6 
MRSA DB57964/04 0.78 25.1 
MRSA DM21595  0.39 50.3 
MRSA DR42412  0.39 50.3 
MRSA DR68004  1.56 12.6 
VISA 10:DB6506 0.78 25.1 
Staphylococcus aureus ATCC29213 0.39 50.3 
Staphylococcus aureus ATCC 6538 1.56 12.6 
Staphylococcus aureus ATCC 6538P 0.78 25.1 
Staphylococcus aureus ATCC 29737 1.56 12.6 
Streptococcus faecium ATCC 10541 0.195 100.5 
Streptococcus epidermidis ATCC 12228 0.78 25.1 











Table 4.10. MIC values of compound 9, vancomycin and daptomycin against selected 
MRSA strains. 
Bacteria strains MIC (µg/mL) 
9 Daptomycin Vancomycin 
MRSA DM21455 0.39 0.78 0.78 
MRSA DM09808R 1.56 0.195 0.39 
MRSA DM42412  0.39 0.195 0.78 
MRSA ATCC700699
a 
0.095 0.78 6.25 
MRSA DM21595 0.39 0.78 0.39 
a









Figure 4.15. Multipassage resistance selection study of compound 9. Plot of MICs (µg/mL) 
of 9 against E. faecalis ATCC29212, S. aureus DM21455 (MRSA), vancomycin 
intermediate-resistant S. aureus (VISA) and S. aureus ATCC 700699. The 4-fold increase in 
MIC was transient. No > 4-fold increase in MIC was observed in any of the strains tested.  
 
Figure 4.16. Scanning electron micrograph of S. aureus DM4001 treated with 9, which 
induced a large amount of membrane leakage after the treatment. In contrast, an untreated 





4.2.6.2 In vivo toxicity profile of compound 9 
Animals such as mice and rabbits have been widely used in ocular research and toxicity 
studies due to their easy manipulation, low cost and biological similarity to humans.
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Although anatomical and physiological differences exist between mice and rabbits, toxicity 
potential is comparable in both species.
58
 In vivo toxicity is a major challenge in the use of 
membrane-targeting antimicrobials. Thus, this study was initially conducted to test for 
potential toxicity of 9 to the cornea. 
In vivo topical studies showed that 9 had no deleterious effects on mouse or rabbit eyes 
when 9 was applied topically in PBS. First, initial testing was carried out in the mouse eye, 
using five applications per day at a concentration of 400 µg/mL (513 – 1026 × MIC). Slit 
lamp photography showed no clinical signs of toxicity or corneal opacity (Figure 4.17). To 
further investigate the biocompatibility of 9, a corneal epithelial abrasion, 5 mm in diameter, 
was made by lightly impressing a sterile 5-mm-diameter trephine onto the corneal surface, 
and the epithelium was removed with a mini blade (BD-Beaver) and treated either with 
saline, vancomycin (50 µg/mL) or 9 (50 µg/mL; 64-128× MIC). The time course of wound 
closure was determined from fluorescein-stained photographs of the defect size over time. 
The wound defect area (p value = 0.376) decreased in both control and treated eyes in a 
similar manner throughout the healing process (Figure 4.18). In fact, vancomycin also had no 
effect on wound healing at this concentration. Short application periods have shown toxicity 





 and loss of corneal transparency.
208
 These 
observations suggest that 9 offered acceptable biocompatibility with delicate tissues such as 
the cornea. 
Next, in vivo acute toxicity of compound 9 was evaluated. Studies with animals showed no 
evidence of toxicity after bolus injection at 50 mg/kg i.p. and 25 mg/kg i.v. for 24 hours 
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(Table 4.11). These data are comparable to results for other new antimicrobials such as 
cathelicidin peptides and those for commercially available antimicrobials such as 
aminoglycosides and gentamycin.
209 
Moreover, the excellent bacterial killing efficacy and 
low MIC values may help to achieve a therapeutic index with significantly low concentration 
in future clinical development studies. However, the in vivo efficacy of compound 9 in a 
corneal infection model was not satisfactory. The result and discussion for the in vivo 





















Table 4.11. In vivo acute toxicity of 9: Toxicity studies using bolus injection of 9 applied via 
i.v. and i.p. routes. 
Route Concentration 















 Not determined 
d 
Numbers of animals survived/ numbers of animals tested. 
 
Figure 4.17. Topical application of compound 9 at 400 µg/mL onto mouse eyes. Slit lamp 












Figure 4.18. Effect of compound 9 on wound healing in rabbit cornea. Slit lamp images show 
that topical application of 9 at 50 µg/mL on rabbit eyes does not interfere with wound 
closure. 9 results in a very similar wound closure percentage as treatment with vancomycin 












In summary, a series of novel antimicrobials have been designed and prepared by cationic 
modification of α-mangostin, a natural xanthone that has a planar hydrophobic core, to yield 
amphiphilic structures that exhibit improved selectivity for bacterial membranes and disrupt 
the hydrophobic-water interface. The present chapter has also shown that spacer length, 
cationic moieties, lipophilic chains and hydroxyl group at C1 position of amphiphilic 
xanthone derivatives were important in their membrane targeting property. The antimicrobial 
activities of cationic xanthone derivatives can be generally predicted based on the pKa values 
and carbon number of the corresponding amines. The efforts on SAR analysis has identified 
compound 9 as the most potent compound in the series. This compound exhibits potent 
antimicrobial activity against Gram-positive bacteria including MRSA and displays other 
desirable properties such as improved selectivity, rapid time-kill and avoidance of antibiotic 
resistance.  
4.3: Design and synthesis of peptidic xanthone derivatives  
In the previous section, α-mangostin and its synthetic derivative, compound 9 (AM-0016), 
which are characterized by a hydrophobic xanthone core and an amphiphilic structure 
displayed potent antimicrobial activity against a panel of Gram-positive pathogens, and they 
can disrupt the inner bacterial membrane. However, these compounds exhibited 
unsatisfactory toxicity and not effectiven in a mouse model of corneal infection. For 
compound 9, the selectivity value is good but the absolute value of HC50 was still low (only 
19.6 ± 3 µg/mL). Hence, the tolerated concentration for compound 9 was only 400 µg/mL. In 
this chapter, design and synthesis of peptidic xanthone derivatives to improve the absolute 
toxicity profile is presented. Therefore, higher concentration of xanthones could be applied 




4.3.1: Rationale and design: Peptidic xanthone derivatives with peptidomimetic 
properties 
Peptidic xanthone derivatives are defined as using cationic amino acid as the cationic 
moieties to couple on hydrophobic xanthone scaffold. In this present study, the aim was to 
identify a set of components that mimic the action of an antimicrobial cationic peptide that 
would further decrease toxicity, increase bacterial membrane selectivity while maintaining 
satisfactory antimicrobial activity in vitro and in vivo. In this study, a xanthone core was also 
used as a template to understand and design effective membrane-targeting small-molecule 
antimicrobials with promising membrane selectivity. Effects of a second component, 
isoprenyl groups or lipophilic chains on antimicrobial activities were investigated in last 
chapter. Lastly, a series of amino acid modified xanthone-based membrane-targeting 
molecules were designed to investigate the role of cationic amino acid residues (component 
3) in antimicrobial activity and toxicity. Cationic amino acids were used to improve 
selectivity because we previously demonstrated that these amino acids improve the 
membrane selectivity of CAMPs.
140a
 Finally, the antimicrobial activity, in vitro time-kill 
kinetics, multipassage resistance selection, membrane selectivity and efficacy in a mouse 
model of corneal infection of these molecules were systemically studied. The results reported 
herein are the first to provide guidelines for the design and synthesis of xanthone analogues 
with CAMP properties that target bacterial membranes with high selectivity and therapeutic 
levels of antimicrobial activity in vitro and in vivo. The design of amino acid modified 














Figure 4.19. Components required for the design of a peptidic xanthone derivatives. Each 
component is highlighted using different colors. Red: hydrophobic core; blue: lipophilic 










4.3.2: Antimicrobial properties of peptidic xanthone derivatives 
The antibacterial activities of 55 – 61 were tested against a panel of Gram-positive bacteria, 
including clinical strains of MRSA (Table 4.12). Coupling high pKa amino acids (55, lysine, 
pKa of ϵ-NH2 = 10.54; 57 (also coded as AM-0052; arginine, pKa of guanidine = 13.6) 
yielded antimicrobials with MICs of 6-12 µg/mL for 55 and 2-3 µg/mL for 57 respectively. A 
histidine-containing analogue (46, pKa of side chain histidine = 6.10) exhibited greatly 
reduced antibacterial activity (MIC> 50 µg/mL). In general, arginine-containing derivatives, 
exhibited less hemolytic activity than lysine-containing analogue and 9. The positive charge 
of the guanidinium group of arginine is more dispersed than that of the single -amino group 
of lysine (55) and the diethylamino group (9), increasing the selectivity of 57 – 59 toward the 
anionic bacterial membrane.
191, 210
 Because 57 exhibited potent antimicrobial activity, the 
structure of the arginine-containing form was further modified (58-60), and the effect of 
hydrophobicity on the interaction with mammalian membranes was determined by measuring 
the concentration needed to induce lysis in 50% of red blood cells (HC50). In general, the 
selectivity of arginine-containing analogues for bacterial membranes increased as the 
hydrophobicity decreased (Table 4.13). For example, 57 had a higher HC50 value (232 ± 8 
µg/mL) than the more hydrophobic derivatives, such as 58 and 60, which caused hemolysis at 
lower concentrations (HC50 of 56 ± 6 and 79 ± 6 µg/mL, respectively), as shown in Table 
4.12. These results suggest that increasing the hydrophobicity of the arginine-containing 
analogues induced stronger hemolytic activities. This observation was consistent with 
previous reports that the introduction of hydrophobic substituents confers hemolytic activity 
on cationic antimicrobial peptides and peptidomimetics.
211
 Compound 54, a xanthone 
derivative coupled with two carboxylic acids, was not active against any of the bacterial 
strains tested. This observation further indicated the crucial role of cationic moieties in 
increasing the selectivity of membrane-targeting xanthone derivatives. 
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An additional set of arginines was coupled to 57 to yield 61. Compound 61 (also coded as 
AM-0218) was obtained through a two-step process in which 5c was first hydrolyzed using 
lithium hydroxide and then coupled with H-Arg-OMe•2HCl in the presence of DIC and 
HOBt. Compound 61 exhibited excellent antimicrobial activity (MIC = 0.5-3 µg/mL) against 
a panel of Gram-positive bacteria with reduced hemolytic activity (HC50 = 277 ± 4 µg/mL), 
as shown in Tables 4.12 and 4.14. By contrast, MSI-78,
212 
an analogue of magainin 
containing a 23-residue helical peptide, exhibited a HC50 value of 120 µg/mL. Notably, the 
selectivities (HC50/MIC) of 5c (selectivity = 77-116) and 6 (92-554) (Table 4.13) were 
significantly improved compared to α-mangostin (Selectivity = 5) and 9 (Selectivity = 7-40) 
(Table 4.14). In addition, the selectivities of 57 and 61 were also comparable or superior to 
those of other membrane-active drugs in clinical trials, such as LTX-109, CSA-13 and MSI-















Table 4.12. In vitro antibacterial (µg/mL) and hemolytic activities (µg/mL) of 54 – 61 
compared to MSI-78. 
Compound Bacterial Strains 
a 
 
A B C D HC50 
b 
54 > 50 > 50 > 50 > 50 > 400 
55 6 12 6 12 39 ± 1 
56 > 50 > 50 > 50 > 50 > 400 
57 2 3 3 2 232 ± 8 
58 6 6 12 12 56 ± 6 
59 6 1 6 6 128 ± 5 
60 12 12 12 12 79 ± 6 
61 0.5 2 3 3 277 ± 4 
4 2 2 2 2 9 ± 2 
9 2 0.5 2 3 20 ± 3 




Clinical Isolates S. aureus DM4001 (A), MRSA DM21455 (B), MRSA DM09809R (C), 
Bacillus cereus ATCC 11778 (D). MIC values were rounded for ease of comparison.  
b
 The HC50 value is the concentration required to lyse 50% of red blood cells after 1 h.                                                                        
c 









Table 4.13. Hydrophobicity, MIC range, HC50, and selectivity range of compounds 
containing arginine derivatives. 
Compound 
a 





57 7.96 ± 0.01 66.9 2-3 232 77-116 
58 8.38 ± 0.01 68.5 6-12 56 5-9 
59 7.40 ± 0.01 64.6 1-6 128 13-128 
60 9.51 ± 0.01 73.0 12 79 7 
61 6.49 ± 0.01 61.2 0.5-3 277 92-554 
a
 Only compounds containing arginine analogues were tested for molecular hydrophobicity. 
 
Table 4.14. Selectivity of xanthone derivatives and selected membrane-active antimicrobials 
in clinical trials. 




4 - 2 9 5  
9 - 0.5-3 20 7-40   
57 - 2-3 232 77-116  
61 - 0.5-3 277 92-554  
LTX-109 Lytix Biopharma, Norway 4 175 44
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4.3.3: Antibacterial properties of compounds 57 (AM-0052) and 61 (AM-0218) 
Compounds 57 and 61 displayed the most potent antibacterial activities among all the 
peptidic xanthone derivatives. These were further examined as small-molecule membrane-
active antibiotics against a panel of 37 Gram-positive pathogens, including MSSA, MRSA 
and vancomycin-resistant enterococci (VRE) (Table 4.15). The MIC values of these 
compounds were determined by Quotient Bioresearch Ltd (UK). 57 and 61 were effective 
against Gram-positive bacteria exhibiting resistance to vancomycin, teicoplanin, and 
macrolides and against multi-drug resistant (MDR) strains. The MICs of 57 and 61 were 2-4 
µg/mL against all strains tested, with the exception of Streptococcus, Corynebacterium 
jeikeium and Listeria monocytogenes (MIC = 4-8 µg/mL). More importantly, because the 
MICs of 57 and 61 were not significantly higher for strains with known resistance to 
established antibacterial agents, cross resistance would not be anticipated to develop.   
Binding to plasma proteins such as albumin may reduce the effective concentration of most 
cationic antimicrobial peptides or peptoids.
216
 Therefore, the antibacterial activities of 57 and 
61 in the presence of bovine serum albumin (BSA) were further investigated. A 2-fold 
increase in the MIC was observed, indicating weak binding of 57 to BSA (Table 4.16). A 4- 
to 8-fold reduction in the antibacterial activity of 61 was observed in the presence of BSA. 
By contrast, a 16-fold increase was observed in the MICs of MSI-78 and daptomycin. A 
relatively weak binding to plasma proteins is clearly an important consideration for the 
therapeutic use of 57 and 61. 
Next, Time-kill kinetic studies of 57 and 61 against MRSA and VRE were performed to 
confirm and explore the membrane-targeting characteristics of these small molecules. Time-
kill kinetics revealed that 57 killed bacteria rapidly, achieving a 3-log reduction (99.9% of 
bacteria killed) in 1 h at 1× MIC and in 30 min at 2× MIC against MRSA DM21455 (Figure 
4.20A). 61 also induced rapid bacterial cell death; a 3-log reduction was achieved in 2 h at 4× 
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MIC (Figure 4.20B). 61 also induced rapid killing of VRE; a 3-log reduction was achieved in 
1 h at 2× and 4× MIC (Figures 4.20C and 4.20D, respectively). By contrast, 2048 µg/mL 
vancomycin induced negligible log reductions at 2 h and 24 h. 
The ability of 57 and 61 to avoid endogenous mutational resistance during prolonged 
passages at sub-inhibitory concentrations of S. aureus was investigated. Fluoroquinolones are 
among the most prescribed antibiotics in the United States. Norfloxacin and gatifloxacin are 
two broad-spectrum fluoroquinolones to which resistance has been reported.
148
 Therefore, 
these two antibiotics served as useful comparisons to investigate the potential of 57 and 61 to 
induce resistance. Figure 4.21 shows that resistance to 57 and 61 did not develop over 17 
passages. By contrast, a 64- to 128-fold increase in the MIC values of gatifloxacin and 
norfloxacin was observed. Resistance is usually defined as a > 4-fold increase in the original 
MIC.
124
 The results of this multistep passage resistance study clearly demonstrated that 57 
and 61 averted the induction of antibiotic resistance, an important characteristic of an 
antimicrobial peptide.  
The selectivity of 56 and 61 for bacterial or mammalian model membranes was first 
evaluated. The levels of leakage of calcein encapsulated in large unilamellar vesicles (LUV) 
with a membrane lipid composition of DOPE/DOPG = 75/25 (mimicking a negatively 
charged bacterial cytoplasmic membrane) or DOPC (mimicking a neutral mammalian 
cytoplasmic membrane) was analyzed. As shown in Figure 4.22, 57 induced strong calcein 
leakage in DOPE-DOPG vesicles, as indicated by a leakage value of 68 ± 3% at a compound 
to lipid (C/L) ratio of 1/16. At the same C/L ratio, a leakage value of 32 ± 2% was observed 
in DOPC liposomes. Striking differences were observed in the ability of 61 to induce leakage 
in DOPE-DOPG and DOPC liposomes. At C/L ratios of 1/16, 1/32, and 1/64, 99.2 ± 8.1%, 
67.9 ± 6.4%, and 24.6 ± 0.5% leakage, respectively, were observed in the DOPE-DOPG 
vesicles, while the leakage was less than 15% in DOPC vesicles at all C/L ratios tested. These 
130 
 
results strongly suggest that the higher cationic charge density of xanthone analogues 57 and 

























Table 4.15. MIC (µg/mL) values of compounds 57 and 61 against a panel of Gram-positive 
bacteria (37 strains). The MICs were determined by Quotient Bioresearch Ltd (United 





57 61 Vancomycin  
S. aureus  MSSA ATCC 25923 2 4 1 - 2  
S. aureus MU50 VISA 2 2 2  
S. aureus  MRSA SSC mec type 2 4 2 1  
S. aureus  EMRSA3 MRSA SSCmec type 1 2 2 8  
S. aureus  EMRSA1 SSCmec type 3 4 2 1  
S. aureus  EMRSA15 SSCmectype 4 2 2 1  
S. aureus  HT2001254 MRSA PVL pos 2 2 1  
S. aureus  Teicoplanin- resistant intermediate 2 2 2  
S. aureus  MDR isolate 2 2 2  
S. aureus  MSSA DM4583R  2 3 2  
S. aureus  MSSA DM4400R 3 2 1  
S. aureus  MSSA ATCC 29213 3 3 2  
S. aureus  MSSA ATCC 6538 3 2 1  
S. aureus  MSSA ATCC 29737 3 3 1  
132 
 
S. aureus  MRSA DB6506 3 2 1  
S. aureus  MRSA DB68004 (source: blood) 3 2 2  
S. aureus  MRSA DB57964 3 2 1  
S. aureus  MRSA DR42412 (source: sputum) 3 3 1  
S. aureus  MRSA DB21595 (source: wound) 3 3 2  
S. aureus  MRSA ATCC 43300 3 2 1  
S. aureus  MRSA ATCC 700699 3 2 2  
S. aureus  MRSA ATCC BAA-38 3 2 2  
E. faecium Van-susceptible 2 2 1  
E. faecium Van A- resistant 2 1 >32  
E. faecium Van B- resistant 2 2 16  
E. faecium Susceptible-strain 4 4 1  
E. faecium ATCC 29212- susceptible index strain 2 2 2  
E. faecium VRE isolate Van A 4 2 >32  
E. faecium VRE VanB 2 2 >32  
E. faecium High level of gentamicin- resistant 4 8 1  
Enterococcus gallinarum Van C- resistant 2 2 8  
Streptococcus pyogenes MLS- resistant 4 8 0.5  
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Streptococcus bovis Macrolide-resistant 4 4 0.5  
Streptococcus pyogenes Macrolide- resistant 8 8 0.5  
Streptococcus constellatus Susceptible-strain 8 2 2  
Corynebacterium jeikeium MDR 8 4 0.5  
Listeria monocytogenes Susceptible-strain 4 2 1  
 
 
Table 4.16. Antimicrobial activities of compounds 57 and 61 in the presence and absence of 
4% BSA. Vancomycin, MSI-78 (antimicrobial peptide) and daptomycin (lipopeptide) were 
used as comparators in this study. 
Compounds MIC (µg/mL) 










57 1.56 3.125 2-fold 3.125 6.25 2-fold 
61 3.125 12.5 4-fold 1.56 12.5 8-fold 
MSI-78 12.5 200 16-fold 12.5 200 16-fold 
Vancomycin 0.78 0.78 1-fold 0.78 1.56 2-fold 











Figure 4.20. Time-kill kinetics of (a) 57 and (b) 61 against MRSA and 6 against (c) vanA 
VRE and (d) vanB VRE. MIC against MRSA DM21455: 57 = 3 µg/mL, 61 = 2 µg/mL. MIC 
against VRE: 61 = 2 µg/mL, vancomycin (VAN) > 32 µg/mL. Test concentration of VAN = 












Figure 4.21. Multi-step passage resistance selection studies of 57 and 61 against S. aureus. 
The ability of 57 and 61 to avoid endogenous mutational resistance was investigated in 
multipassage resistance selection studies. The fourth- and first-generation fluoroquinolones 
gatifloxacin and norfloxacin were selected as reference antibiotics. MICs against S. aureus 
ATCC29213: 57 = 3 µg/mL; 61 = 2 µg/mL; gatifloxacin = 0.1 µg/mL; norfloxacin = 2 













Figure 4.22 Leakage (%) induced by compounds 57 and 61 in calcein-loaded liposomes. 
Liposome compositions of 75:25 DOPE:DOPG and DOPC only were used to mimic the 
bacterial and mammalian membranes, respectively. For all measurements, each point 










4.3.4: MD simulations: Antibacterial actions of amphiphilic xanthones 
Next, the antibacterial action was investigated using MD simulations. To understand the 
possible detail in membrane disruption of xanthone derivatives, MD simulations were first 
used to provide information on membrane penetration pathways of the xanthone core using 
compound 4. The penetration properties of α-mangostin into a model bacterial membrane, 
POPE/POPG (75/25) bilayers using all-atom MD simulations were determined. When 4 was 
placed close to the bacterial membrane, a rapid absorption of the molecule into the membrane 
was observed. At a low drug/lipid ratio (1/128), the distance between 4 and the lipid bilayers 
(Figure 4.23A) decreased sharply by 100 ns and reached an equilibrium distance of 1.5 nm, 
locating just below the head groups of the lipid molecules. As the number of compound 4 
molecules was increased, some 4 molecules penetrated deeper into the lower leaflet of the 
modeled bacterial membrane during the course of the simulation (Figure 4.23C). This was 
accompanied by perturbation of the integrity of the membrane with a large number of defects 
(filled with water molecules; Figure 4.23C) and the increased of average lipid area (Figure 
4.23B). Although some of these defects were transient, there were several occurrences of 
defects that evolved into water translocation across the membrane. At longer time and length 
scales, the increased permeability may allow large molecules to permeate through the 
membrane resulting in the leakage of intracellular components. It is likely that the strong 
affinity of 4 to hydrophobic alkyl chain perturb the integrity and packing density, thus 
leading to the leakage of intracellular components. These observations were strong indication 
of increased membrane perturbation induced by 4, and which tended to corroborate the data 
from both the biophysical studies as well as the SEM results. Figure 4.23D shows that the 
conformation of 4 at different distances from the bilayer center. During penetration, the 
isoprenyl group first entered into the hydrophobic region of the membrane, which is driven 
by hydrophobic interactions. Then, the compound 4 was entropically driven and its long axis 
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was orientated in parallel to the lipid tails. The isoprenyl groups conjugated to the xanthone 
scaffold as short lipid tails were found to trigger the penetration into the hydrophobic region 
of the membrane. The isoprenyl groups would act to reduce the free energy barrier of 
penetration. In addition, the presence of isoprenyl groups further increased the 
hydrophobicity of 4, thus enhancing the tendency to partition into the membrane. In support 
of this, the role of isoprenyl group was also studied using compound 45 (α-mangostin 
derivative without isoprenyl group). In this study, no penetration of 45 was observed, and all 
molecules remained on the membrane surface (Figure 4.24). MD simulations suggested that 
two isoprenyl groups or lipophilic chains enhanced the interaction with the bacterial 
membrane, which further facilitated the penetration of the molecule into the lipid membrane. 
In summary at this point, the presence of isoprenyl groups produced more potent 
antibacterial activity. The results suggested that the largely hydrophobic 4 prefers to be 
solvated by the hydrophobic portion of membrane lipids. Lack of one isoprenyl group in 1 
and 5 diminished antimicrobial properties as the free energy barrier for bacterial membrane 
penetration increased. These results are also in accordance with a recent report showing that 
presence of at least two isoprenyl groups conjugated to the xanthone scaffold are important to 
confer potent antimicrobial properties.
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Calculations using MD simulation of amphiphilic xanthone, compound 9 on modeled 
membrane were also performed. Consistent with the surface activity model, 9 had a strong 
tendency to partition into the bacterial membrane.
145b
 The high affinity of 9 to the bacterial 
membrane arises from the electrostatic interactions of the two cationic diethylamine groups 
with the head groups of anionic lipids, which results in a high surface concentration in the 
outer leaflet of the membrane. Moreover, similar to 4, the hydrophobicity, particularly the 
planarity of the central xanthone core further drives 9 to penetrate deeper into the lipid tail 
region of the membrane. However, different from 4, 9 was forming an amphiphilic 
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conformation with the cationic groups located at the hydrophobic-water interface (Figure 
4.25A). As a result, this amphiphilic conformation induced large perturbations of the lipid 
bilayer, including membrane deformation, membrane area expansion, membrane thinning and 
enhanced membrane fluctuations (Figure 4.25B). Concomitant with these perturbations, the 
enhanced membrane permeability could be seen from water translocations across the 
membrane (Figure 4.25A). As a result, membrane organization was disrupted. Similar 
observations were obtained using MD simulations of compound 57 on a model bacterial 
membrane (Figure 4.26A). In contrast, 57 required a longer time to adsorb into the 
mammalian membrane, as compared to the bacterial membrane (Figure 4.26B). For instance, 
no amphiphilic conformations were observed for 57 on the mammalian membrane within the 
200 ns simulation time (Figure 4.26A). The lower density of negative charges on the 
mammalian membrane leads to weaker electrostatic interactions with amphiphilic xanthone 
derivatives. As a result, the surface concentration of these compounds on the mammalian 
membrane is much lower. Therefore, this differential interaction appears to be critical to the 













Figure 4.23. MD simulations of compound 4 (α-mangostin) on modeled bacterial membrane. 







Figure 4.24. MD simulation of xanthone derivatives without isoprenyl groups with modelled 
bacterial membrane. The configurations and locations of (a) Nine α-mangostin molecules and 















Figure 4.26. MD simulation of compound 57 on modelled bacterial and mammalian 
membranes. (A) Snapshots of conformations of 57 on bacterial and mammalian membrane. 













4.3.5 In vivo study of peptidic xanthone derivatives 
The toxicity of 57 and 61 were evaluated after topical application. Compounds 57 and 61 
were applied to the cornea (5 times/day) for four days at a concentration of 3 mg/mL (0.3% 
solution) without any deleterious effects on the mouse eyes, as determined by the 
examination of the living eye with a bio-microscope and by the inspection of histological 
sections. The rabbit corneal epithelial abrasion model of wound healing was also used to 
investigate corneal toxicity of 57 and 61 and to assess the potential adverse effects on normal 
physiological wound healing processes. Normal corneal clarity and transparency were 
observed after the application of 0.3% solutions of 57 and 61. There were no signs of corneal 
inflammation and no evidence of an inflammatory response or retardation of wound healing 
in the standard rabbit corneal epithelial abrasion model.
218
 No significant differences in the 
wound defect area (p-value > 0.05) compared to the control group (10 mM PBS at pH 7) 
were observed at all-time points (Figure 4.27). In summary, 57 and 61 had no adverse effects 
on normal corneas or on cornea wound healing when applied topically to the eye at typical 
therapeutic concentrations. 57 and 61 have much higher tolerated concentrations than 
compound 9 (400 µg/mL or 0.04% solution).  
Antimicrobials with good in vitro activity may be inactive in vivo. Therefore, the efficacy 
of 57 and 61 were further investigated in a mouse model of corneal infection (Figure 4.28A). 
The mouse cornea was infected with S. aureus ATCC29213 or MRSA ATCC700699. After 1 
day, antimicrobials were applied topically 5 times daily. As 0.3% solutions, compounds 57 
and 61 effectively reduced the number of viable bacteria by 2.56-log (99.7%) and 3.03-log 
(99.9%), respectively, in the cornea infection model (p-values < 0.001). By comparison, a 
0.3% solution of gatifloxacin produced a 2.06-log reduction in viable bacteria (p-value = 
0.037). By contrast, 9 induced a less than 1-log reduction at the tolerated concentration of 
0.02% in solution (p-value = 0.731). Encouragingly, 61 demonstrated a clear therapeutic 
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efficacy. The potency of 61 was also investigated in the mouse model of corneal infection 
using MRSA as the pathogen. As shown in Figure 4.28B, a 0.3% solution of 61 exhibited 
excellent in vivo efficacy (2.9-log reduction, p-value = 0.004) compared to a 5% solution of 
vancomycin (2.5-log reduction; p-value = 0.015). No significant different was observed for 
0.3% solution of 61 compared to 5% solution of vancomycin (p-value= 1.000). A high 
concentration of vancomycin is used in corneal infections due to its poor tissue penetration.
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The results of these studies confirm the appropriateness of our molecular design strategy for 
developing a new class of xanthone-based antibiotics with efficient therapeutic 
characteristics, as lower concentration of 61 could achieve similar therapeutic effects of 























Figure 4.27. Effects of 57 and 61 on wound healing in rabbit corneas. Left: Slit lamp 
photography after treatment with 57 and 61 as 0.3% solutions revealed no clinical signs of 
toxicity or corneal opacity. Right: The topical application of 57 and 61 as 0.3% solutions did 












Figure 4.28. Evaluation of the in vivo efficacy of selected antimicrobials in the killing of 
bacteria in an experimental infection in the mouse cornea. (A) Infection by S. aureus ATCC 
29213 (keratitis model). Concentration used: 9, 200 µg/mL, p-value= 0.731; 57, 61, and 
gatifloxacin (GAT), 0.3% solution. MIC: 9, 0.5 µg/mL; 57 and 61, 3 µg/mL. (B) Infection by 
MRSA ATCC700699. Concentration used: 61, 0.3% solution, MIC= 2 µg/mL; vancomycin 
(Van), 5% solution. PBS was used as a negative control. ***p < 0.001 compared to control, 
except gatifloxacin. **p-value = 0.004 compared to control, except vancomycin. The p-
values of gatifloxacin and vancomycin compared to the control are 0.037 and 0.015, 










4.3.6 Summary: Amphiphilic xanthone derivatives as potential therapeutic agents 
against Gram-positive bacteria 
The results from section 4.2 and this study identified three important structural components 
for the design of a successful small-molecule with properties similar to a CAMP. First, a rigid 
hydrophobic core with two or more aromatic rings is needed. A relatively small size and 
conformationally constrained structure likely facilitates the penetration of various physical 
barriers in the outer membrane of Gram-positive bacteria.
220
 Second, cationic moieties are 
required to form an amphiphilic structure and to discriminate the bacterial membrane from 
the mammalian membrane. We and others have previously demonstrated that amphiphilic 
structures are important for appropriate physical-chemical interactions between a membrane-
targeting molecule and the bacterial membrane.
154, 204a, 221
 These data revealed that a cationic 
group with a more dispersed positive charge, such as arginine, is preferred for enhanced 
selectivity. Cationic moieties are also critical to ensure rapid access to the cytoplasmic 
membrane via electrostatic interactions. Positively charged residues, particularly arginine, 
also facilitate peptide entry into cells.
222
 However, the hydrophobic core and cationic 
moieties are not sufficient for disruption of the membrane bilayer by xanthones. Therefore, a 
third component, a lipophilic chain in the form of an isoprenyl group or the reduced form of 
an isoprenyl group is needed to provide sufficient driving force for the penetration of the 
bulky xanthone into the cytoplasmic membrane. The promising antimicrobial activity, low 
toxicity in vivo and in vitro, and activity in a mouse model of corneal infection of xanthones 
57 and 61 suggest that these molecules have significant potential as new templates in the 
therapeutic pipeline against some of the most serious forms of Gram-positive bacteria, 




4.4 Antibacterial activities of amphiphilic xanthone derivatives against Gram-negative 
pathogens 
The antibacterial activities of amphiphilic xanthone derivatives against Gram-negative 
bacteria were also investigated. Table 4.17 shows that compound 4 was inactive against 
Gram-negative bacteria even at 200 µg/mL. By contrast, compound 9 had moderate 
antimicrobial activity with a MIC of 40 – 50 µg/mL against two strains of Gram-negative 
bacteria (P. aeruginosa ATCC27853 and K. pneumonia ATCC10031). Other amphiphilic 
xanthone derivatives displayed similar MIC values against Gram-negative pathogens (MIC≥ 
50 µg/mL).  
Two important phenomena were observed: First, appending a cationic charge moiety to a 
hydrophobic core broadens the antimicrobial spectrum. Work by Djouhri-Bouktab et al. also 
reported that using positive amine groups to modify squalamine analogues resulted in greater 
potency against Gram-negative bacteria.
204a
 The results clearly demonstrated that the cationic 
moiety of 9 was mandatory to complex or bind with the negatively charged LPS. Second, 
antibacterial activities of these xanthone derivatives were much weaker than those with 
Gram-positive bacteria.  
To assess the membrane targeting activities of the amphiphilic xanthone derivatives against 
Gram-negative bacteria, Sytox Green uptake and a calcein leakage assay were used.  As 
shown in Figure 4.29, compounds 9, 23 and 25 did not induce any Sytox Green uptake in E. 
coli ATCC8739, which was consistent with the poor antimicrobial properties of these 
xanthone derivatives against E. coli. In contrast, significant membrane permeabilization of S. 
aureus after treatment with 9, 23 and 25 could be observed at the same concentration. Calcein 
loaded liposomes composed of E. coli total lipid extract was also constructed to study the 
direct interaction of Gram-negative bacterial inner membrane with these xanthone derivatives. 
As shown in Figure 4.29, a strong lytic activity could be observed as significant amount of 
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calcein released was detected. For instance, at L/C ratios of 4, 8 and 16, 9 caused 95.9±1.1%, 
21.6±1.0% and 10.5±2.0% leakage respectively. For 23 and 25, lytic activity observed were 
101.9±1.2%, 22.1±2.1%, 5.0±1.7% and 99.4±1.2%, 47.8±3.3%, 16.4±0.1% respectively. In 
fact, cytoplasmic membrane of E. coli is rich in PE (80% PE and 15% PG) 
223
, which is 
similar to the liposome composition (75% DOPE) used in this study. Taken together, the 
results suggest that LPS is the barrier impeding the xanthone derivatives from reaching the 
inner membrane. The results are consistent with other reports, which indicate that LPS 
provides a very effective barrier to hydrophobic molecules.
224
 This result also demonstrated 
that, while disrupting the inner membrane is necessary for bacteria cell death, the outer 
membrane must be considered as a potential barrier as well. 
To further test the hypothesis that LPS is the main barrier to amphiphilic xanthone 
derivatives, a checkerboard assay was performed to investigate the synergistic interaction of 
the amphiphilic xanthone derivatives with selected antimicrobials with different antibacterial 
actions. Fractional inhibitory concentration index (FICI) was interpreted as follows:  FICI≤ 
0.5 denoted synergy, 0.5 ≤ FICI < 0.75 denoted partial synergism or additive and 0.75 ≤ FICI 
<  4 denoted indifference and FICI of ≥ 4 denoted antagonisms.225 In this experiment, 7 
antimicrobials were selected: eugenol, polymyxin B, daptomycin, vancomycin, gatifloxacin 
and EDTA.  
 Eugenol is the principal chemical component of clove oil from Eugenia aromatica with 
inner membrane disruption property.
226
 Eugenol also shows potent synergistic activity with 
antibiotics against Gram-negative bacteria.
227
 Table 4.18 shows that compound 9 did not 
synergize with eugenol against P. aeruginosa (FIC= 1) and E. coli (FIC= 0.75). The primary 
target of eugenol is the inner membrane. The outer membrane most likely was not perturbed. 
Therefore, eugenol did not interact with compound 9 synergistically as it could not facilitate 
9 to pass through bacterial outer membrane. Next, the synergistic action of 9 with polymyxin 
150 
 
B was analyzed. Polymyxin B is a polycationic lipopeptide isolated from Bacillus 
polymyxa.
228
 Polymyxin B is also known as a LPS permeabilization agent of Gram-negative 
bacteria.
228
 As shown in Table 4.18, combining 9 with polymyxin B displayed low FICI of 
0.3125 and 0.5 against P. aeruginosa and E. coli respectively. Compound 61, the 
intermediate to obtain compound 9 was used as a control in this experiment. Compound 61 is 
bromo-substituted, so this compound is neutral in charge. Synergy was not observed with 
polymyxin B in combination with compound 61. These results show that LPS was the main 
barrier to amphiphilic xanthone derivatives.  
Polymyxin B nonapeptide (PMBN) is a polymyxin B derivative which lacks the fatty acid 
residue and the terminal diaminobutyric acid. PMBN was reported to have antimicrobial 
properties that are drastically reduced against Gram-negative bacteria, but it was still 
remarkably active in sensitizing outer membrane of Gram-negative bacteria.
229
 The 
combination of polymyxin B nonapeptide (PMBN) with 9 was investigated. As PMBN was 
not active against both Gram-negative bacteria tested at 50 µg/mL, a sensitization index was 
used as an indicator to assess the synergistic interaction. As shown in Table 4.18, PMBN was 
found to have a good sensitization activity with compound 9 against P. aeruginosa 
ATCC27853. At PMBN concentrations of 25 µg/mL and 50 µg/mL, MIC of 9 reduced from 
50 µg/mL to 3.125 µg/mL and 1.56 µg/mL respectively. Sensitization index for the 
combination of PMXB with 9 against E. coli ATCC8739 was weaker. MIC of 9 was reduced 
from 50 µg/mL to 12.5 µg/mL. 
Ethylenediaminetetraacetic acid (EDTA) is another outer membrane active agent. EDTA is 
a chelator that removes the divalent cations from LPS, and results in the destabilization of the 
LPS.
230 
In the presence of TRIS as a potentiating agent, the effect of EDTA to permeabilize 
outer membrane will be stronger.
97b
 The FICI was 0.19 and 0.375 for the combination of 
EDTA-9 against P. aeruginosa and E. coli, respectively.  
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The synergistic interaction of gentamicin with 9 was also tested. Gentamicin is an 
aminoglycoside antibiotic that works by binding the 16S rRNA of the 30S bacterial 
ribosomal subunit and further interrupting protein synthesis.
231
 Gentamicin also interacts at 
divalent cations cross-bridge adjacent to polyanionic polymers in LPS.
232
  Table 4.18 shows 
that gentamicin partially synergized with 9 with FIC indices of 0.5. The synergistic 
interaction was weaker than the combination of 9 using polymyxin B. The result was also 
consistent with a review that the aminoglycoside is a weaker outer membrane 
permeabilizer.
97b
   
Finally, the combinations of 9 with daptomycin and vancomycin against Gram-positive 
bacteria were tested. They are also membrane targeting but with different membrane targets. 
Daptomycin is a 13-member amino acid cyclic lipopeptide antibacterial agent. Daptomycin 
undergoes oligomerization and depolarize the inner membrane to kill the bacteria.
233
 
Vancomycin is a glycopeptides antimicrobial that inhibits bacterial cell wall biosynthesis by 
binding the peptide terminus D-Ala-D-Ala of the peptidoglycan precursor.
234
 No synergisms 
were observed as FIC indexes were 1 for all the combinations tested. In general, only 
antimicrobials with outer membrane permeabilizing property could work synergistically with 
amphiphilic xanthone derivatives. 
In summary, LPS is the main barrier to impede amphiphilic xanthone derivatives to kill 
Gram-negative bacteria effectively. SARs to date did not result in a better amphihilic 
xanthoen derivative with satisfactory MIC value against Gram-negative pathogen (MIC ≤ 
6.25 µg/mL). Second, reagents with LPS permeabilization property are required to exert 
promising antibacterial activity. Future SARs could focus on coupling functional groups of 









P. aeruginosa ATCC27853 >200 50 
K. pneumonia ATCC10031 >200 40 
 
Table 4.18. The FIC index was calculated from combinations of 9 and its intermediate with 
different antimicrobials against Gram-negative bacteria. The intermediate is a bromo-
substituted xathone derivative modified with 1, 4-dibromobutane. 





P. aeruginosa E. coli 
Eugenol 1 - 
c 
- - 
Polymyxin B 0.31 0.5 1 1 
Daptomycin 1 - - - 
Vancomyxin 1 - - - 
Gentamicin 0.5 - - - 
EDTA 0.19 0.375 - - 
PMBN 16 – 32 d 4 - - 
a
 P. aeruginosa: P. aerugonosa ATCC 27853 
b 
E. coli: E. coli ATCC 8739 
c
 Not determine 
d 
Sensitization index is used instead of FIC index as polymyxin B nonapeptide was found 
inactive against both bacteria tested up to 50 µg/mL. Sensitization index is defined as the 






Figure 4.29. Membrane targeting properties of selected amphiphilic xanthone derivatives (9, 
23, 25) against Gram-negative bacteria. Sytox Green uptake and calcein leakage studies 
(using E. coli lipid extract) suggested that the outer membrane of Gram-negative bacteria is 
the main barrier to prevent amphiphilic xanthone derivatives to disrupt inner membrane. 



























5.1 SAR analysis of amphiphilic xanthone derivatives against mycobacteria 
Rifampicin, discovered 50 years ago is the last novel class of antibiotics introduced for the 
first-line treatment of Tb. Although bedaquiline has been approved by FDA as a part of 
combination therapy for MDR pulmonary TB treatment, the clinical pipeline for TB is still 
meager. To date, studies on membrane targeting TB drugs are rare compared to other Gram-
positive or Gram-negative pathogens. In this study, antimicrobial activities of amphiphilic 
xanthone derivatives against mycobacteria were investigated. Their membrane targeting 
properties were also examined. The focus of this study was to determine if amphiphilic 
xanthone derivatives possess significantly different antibacterial action from first-line TB 
drugs. 
In this study, amphiphilic xanthone derivatives were selected from different categories to 
investigate their anti-mycobacterial activities. Two representative mycobacterial strains were 
used: M. smegmatis and M. bovis. The results are presented in Table 5.1. Compound 9 
displayed potent anti-mycobacterial activities with MIC values of 2.5 µM and 7.5 µM against 
M. smegmatis and M. bovis respectively. Compounds 18, 19 and 27 showed intriguing results. 
Although they were inactive against Gram-positive bacteria (MIC> 50 µg/mL), they were 
active against mycobacteria. For instance, compounds 18 and 19, xanthone derivatives 
coupled with aliphatic amines of 6 carbon numbers, showed a MIC value of 3.2 µM against 
M. bovis. However, compound 18 was inactive against M. smegmatis. The MIC value 
was >30 µM. Compound 27, a xanthone derivative that was modified using low pKa 
morpholine, displayed anti-mycobacterial activities of 30 µM against both mycobacterial 
strains. The results showed that the pKa of amine moieties did not a play crucial role in anti-
mycobacterial activity.  
Compounds 38 and 39 showed similar MIC values to compound 9, suggesting that 
spacer length also exerted less effect on antimycobacterial activity. Compounds 49 and 50, 
156 
 
hydrogenated xanthone derivatives also have shown good inhibitory activity with MIC values 
of 6.4ug/ml against both strains. Compared to compound 9, hydrogenated compound 49 
showed a 3-fold reduction of inhibitory activity against M. smegmatis. Weak activity was 
observed for arginine modified derivative, 57 against M. smegmatis and M. bovis, with MIC 
values of > 30µM and 12.8 μM respectively. MIC values of first line-Tb drugs were also 
presented in Table 5.1. In general, different structural parameters were required for inhibitory 
action against mycobacteria compared to other Gram-positive bacteria. First, pKa and carbon 
number of amine moieties were not critical parameters for inhibitory effects. Second, an 
amino acid modified xanthone derivative was less active.  
Compounds 9 and 27 were independently evaluated by Quotient Bioresearch, UK for M. 
tuberculosis screening (Table 5.2). Their MIC90 against 10 strains of M. tuberculosis showed 
that the MIC range was conserved between isolates. Compounds 9 and 27 displayed MIC 
range of 2 – 8 µM. The isolates with known resistances to established anti-mycobacterial 
agents (isolate numbers of 01;005 and 01;104) did not have significantly higher MICs against 
compound 9 and 27, suggesting that there was no cross-resistance to established anti-
mycobacterial agents. This finding was important as 9 and 27 may have a therapeutic use 
against M. tuberculosis, including MDR strains due to the conserved susceptibility to these 
compounds.  
Time-kill kinetics of compounds 9, 19 and 27 against both M. smegmatis and M. bovis 
were also investigated (Table 5.3). For bactericidal compounds 9 and 19, the concentration 
required to achieve a 3-log reduction was in general 2-fold of the MIC values. 3 hours were 
required to achieve 3-log reductions against M. smegmatis at 2× and 4× MIC. It is noteworthy 
that compound 19 achieved a complete kill at 4x MIC in 3 hours. Complete kill is important 
as no persisters were left behind. Weaker bactericidal activity was observed in M. bovis, as 6 
– 9 hours were required. In contrast, no bactericidal activity of compound 27 was detected up 
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to 24 hours. Streptomycin and isoniazid were used as comparators in this study. Streptomycin 
and isoniazid both displayed low MIC values, but had poor bactericidal activity. Table 5.3 
shows that only streptomycin at 4x MIC displayed bactericidal activity against M. smegmatis. 




























Table 5.1. MIC90 of selected amphiphilic xanthone derivatives against mycobacteria. Strains 
used in this study: M. smegmatis and M. bovis. Maximum concentration tested= 30 µM. 
Compounds MIC values 
M. smegmatis M. bovis 
9 2.5 7.5 
18 ! 30 3.2 
19 3.2 3.2 
27  30 30 
38 3.2 6.4 
39 3.2 6.4 
49 6.4 6.4 
50 6.4 6.4 
53 ! 30 6.4 
57 ! 30 12.8 
Rifampicin 2.5 0.02 
Isoniazid 15 6.25 
Ethambutol 1.25 6.25 










Table 5.2. MIC values of compounds 9 and 29 against clinical isolates of M. tuberculosis. 
MIC values were determined by Quotient Bioresearch Ltd, UK. 
Isolate number MIC 
Compound 9 Compound 27 
01;001 4 4 
01;057 4 4 
01;064 8 4 
01;095 4 4 
01;092 2 4 
01;087 8 8 
01;111 4 4 
01;005a 8 8 
01;104b 4 4 
H37Rvc 2 4 
a
 Resistance: Rifampicin and streptomycin; Highly resistance: Ethambutol 
b
 Resistance: Ethambutol and streptomycin; Highly resistance: Isoniazid 
c









Table 5.3. Time-kill kinetics of compounds 9 and 19 against M. smegmatis and M. bovis. 
Streptomycin and isoniazid were used as comparators for M. smegmatis and M. bovis 
respectively. 
Compound Concentration Time required for 3-log reduction (h) 
M. smegmatis M. bovis 
9 1× MIC 24 24 
9 2× MIC 3 9 
9 4× MIC 3 ND
a 
19 1× MIC 24 > 24 
19 2× MIC 3 9 
19 4× MIC 3 (complete kill) 6 
27 1× MIC > 24 ND 
27 2× MIC > 24 ND 
27 4× MIC > 24 ND 
Streptomycin 1× MIC > 24 > 24 
Streptomycin 2× MIC 24 > 24 
Streptomycin 4× MIC 3 > 24 
Isoniazid 5× MIC ND > 24 
Isoniazid 10× MIC ND > 24 
a






5.2 Preliminary studies on anti-mycobacterial action of amphiphilic xanthone 
derivatives 
5.2.1 Amphiphilic xanthone derivatives impaired mycobacterial membrane integrity 
As amphiphilic xanthone derivatives 9 and 19 displayed strong bactericidal activities 
against mycobacteria, these compounds may also behave like a cationic antimicrobial peptide 
to disrupt the mycobacterial inner membrane. To test this hypothesis, the membrane integrity 
was directly measured using an assay based upon a pH-sensitive fluorophore, CMFDA, 
which is processed into a membrane-impermeable form following uptake. The bacteria were 
washed and placed in suspension buffered at an acidic pH of 5.5. As the intracellular pH of 
the CMFDA-labeled bacteria was neutral, the loss of membrane integrity could be measured 
as a shift in fluorescence upon exposure of the intracellular fluorophore to the extracellular 
acidic environment. The positive control used in this study was ionophore nigericin. 
Mycobacterial suspension treated with nigericin resulted in a drop of intracellular pH to 5.5 
(100% shift). In this study, M. bovis was used. Figure 5.1 shows that compound 9 induced 
rapid and significant pH drop of intracellular pH at 60 µM. A 3 hour treatment with 
compound 9 resulted in pH shift of 68.7±10.3%. At 30 µM, pH shift of 20.0±6.2% was 
observed. Identical treatment of the M. bovis with compound 19 induced stronger % of pH 
shift than 9.  For instance, at 30 µM and 60 µM, pH shifts of 76.6±8.8% and 61.6±4.7% were 
recoded respectively after 3 hours of treatment. Compound 27 induced the smallest amount of 
pH shift. Only around 30% of pH shift was recorded at 60 µM. Figure 5.1D shows that at 30 
µM, compound 19 induced the strongest pH shift, followed by compound 9 and 27. These 
experiments showed that treatment with compounds 9 and 19 resulted in exposure to external 
pH. The degree of impairment of membrane integrity induced by these xanthone derivatives 
correlated well with their MIC values against M. bovis. Unfortunately, this assay failed to 
work using M. smegmatis, as the standard curve could not be obtained to calculate the %pH 
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shift. A possible reason could be the membrane of M. smegmatis is more permeable than M. 
bovis. Consequently, the protons are much easier to establish equilibrium in between bacterial 
cells and external buffer. Thus, the standard curve was failed to be generated. 
Similar studies were performed using first-line TB drugs (isoniazid, rifampicin, 
ethambutol and streptomycin). Figure 5.2 clearly shows that no impairment of membrane 
integrity was detected even at 16×, suggesting that amphiphilic xanthone derivatives had a 
distinct different target compared to first-line anti-TB drugs. This observation is consistent 
with the former study on anti-tuberculosis activity that no cross-resistance was observed with 
the first-line TB drugs. 
Baclight assay was used as an alternative method to investigate the effect of amphiphilic 
xanthone derivatives on membrane integrity of M. smegmatis. Figure 5.3 shows that 
significant reduction of membrane integrity was observed for compound 9 at 4× MIC. A 
membrane integrity reduction of 62.5±2.0% was recorded after 24 hours of incubation. 
Compound 19 recorded stronger reduction of membrane integrity at 2× and 4× MIC, with % 
reduction of membrane integrity of 78.8±1.2 and 76.9±0.9 respectively. At 1× MIC, the 
reduction % was 28.0±10.0. For both compounds, negligible % reduction of membrane 
integrity was detected at 0.5×  MIC (< 15%).  
Interestingly, at 2× MIC and 4× MIC, both compounds displayed stronger reduction of 
membrane integrity after 3 hours of treatment (% reduction >80%). The previous study 
(Table 5.3) also indicated that both compounds 9 and 19 achieved 3-log reductions of viable 
cell counts against M. smegmatis in 3 hours. Therefore, it further supported the hypothesis 
that the reduction of membrane integrity induced by xanthone derivatives was the major 








Figure 5.1. Action of selected amphiphilic xanthone derivatives on intact M. bovis using 
CMFDA-labeled cells. pH drops were indicated by % of pH shift, in the presence of (A) 
compound 9 (B) compound 19 and (C) compound 27 at different concentrations. (D) 
Comparative effect of % of pH shift induced by compounds 9, 19 and 27 at 30 μM. 100% 
shift indicates the drop of pH to 5.5. The values represent the means ± standard deviations 






Figure 5.2. % of pH shift induced by first-line Tb drugs on M bovis. Concentration used was 
16x MIC. The values represent the means ± standard deviations from three independent 
experiments performed in duplicate. 
 
 
Figure 5.3. Effects of amphiphilic xanthone derivatives on membrane integrity of M. 
smegmatis at 0.5x – 4x MIC. Membrane integrity was measured using Baclight assay. The 
values represent the means ± standard deviations from two independent experiments 




To determine the extent of membrane disruption, the ability of amphiphilic xanthone 
derivatives to induce Sytox Green uptake was investigated. Figure 5.3 shows that compound 
9 induced strong and rapid Sytox Green uptake at 60 µM in 3 hours for both M. smegmatis 
(Figure 5.4A) and M. bovis (Figure 5.4B). By contrast, no significant Sytox Green uptake 
was observed for mycobacteria treated with 60 µM of rifampicin, streptomycin, ethambutol, 
isoniazid and pyrazinamide. The results further supported the former observation that 
amphiphilic xanthone derivatives have different targets from the first-line anti-TB drugs. 
A comparative study using Sytox Green uptake of compounds 9, 19 and 27 showed 
unexpected results (Figure 5.5). Unlike CMFDA and Baclight assays, compounds 19 and 27 
only induced negligible Sytox Green uptake compared to compound 9. Together with 
CMFDA assay, the findings suggest that compound 19 and 27 interacted with the 
mycobacterial membrane by alternating the proton motive force. In contrast, compound 9 
induced much greater membrane disruption as proven in Sytox Green assay. On the basis of 
the Sytox Green uptake data, calcein leakage assay was performed. Figure 5.6A shows that 
compound 9 had the strongest potency to induce leakage. Compound 19 showed weaker 
leakage, and no observable leakage was detected for compound 27 at all compound to lipid 
ratios. The results suggest that Sytox Green uptake determines membrane disruption more 
effectively than the Baclight assay. 
Consistent with the previous results obtained from CMFDA assay, no detectable leakage 







Figure 5.4. Membrane permeabilization or Sytox Green uptake induced by compound 9 on 
(A) M. smegmatis and (B) M. bovis. Rifampicin (RIF), streptomycin (STREP), ethambutol 
(ETH), isoniazid (INH) and pyrazinamide (PYR) were used as comparators. Concentration 




Figure 5.5. Sytox Green uptake of selected amphiphilic xanthone derivatives against M. 











Figure 5.6. Calcein leakage assay of (A) amphiphilic xanthone derivatives and (B) First-line 
Tb drugs on artificial liposome with composition of Cl:DOPG:DOPI= 4:3:3. The values 












5.2.2 Effects of amphiphilic xanthone derivatives on respiratory ATP production in 
mycobacteria 
Bacteria require energy to survive. Respiratory ATP synthesis is required for growth as 
mycobacteria cannot gain enough energy by substrate-level phosphorylation.
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 Respiratory 
ATP synthesis takes place in the respiratory chain, located on the cytoplasmic membrane.  
On the basis of membrane targeting data, which suggested a possible connection to 
respiratory ATP synthesis via interaction with the inner membrane, time-course studies were 
performed to examine the effect of amphiphlic xanthone derivatives on ATP levels in M. 
smegmatis. The effect on cellular ATP content was examined using thenoyltrifluoroacetone 
(TTFA) and dicyclohexylcarbodiimide (DCCD) as comparators. TTFA is a respiratory 
complex II inhibitor while DCCD is an ATP synthase-specific inhibitor. Compounds 9 and 
19 could inhibit the production of respiratory ATP. Streptomycin, isoniazid and rifampicin at 
4× MIC were also evaluated. As shown in Figure 5.7, after 1 hour of treatment, TTFA, 
DCCD, compound 9 and compound 19 resulted in a rapid loss of ATP. % of ATP remaining 
in cells reduced to 36.8%, 7%, 5.8% and 5.9% for TTFA, DCCD, 9 and 19 respectively. In 
contrast, streptomycin and ethambutol only resulted <25% declined in ATP after 9 hours of 
treatment. Compound 27 induced ATP loss was slow. % of ATP remaining in cells was 
50.2%, 26.8%, 18.9% and 11% at 1 h, 3 h, 6 h and 9 h respectively. In addition, extracellular 
ATP content was also measured. Figure 5.8 shows large amounts of extracellular ATP was 
detected in cells treated with compounds 9 and 19. In contrast, no significant amount of 
extracellular ATP was measured in cells treated with both TTFA and DCCD. The results 
signified that, ATP leakage could be the main reason that 9 and 19 caused significant ATP 




Next, distribution of extracellular and intracellular ATP in bacteria treated with 
amphiphilic xanthone derivatives was tabulated. Tables 5.4A and 5.4B show the distribution 
of ATP measured as intracellular ATP or extracellular ATP for M. smegmatis and M. bovis 
respectively. Extracellular ATP% is an indicator of ATP leakage. In general, for M. 
smegmatis treated with compounds 9 and 19 at 2× MIC and 4× MIC, more than 90% of the 
ATP measured was found to be extracellular after 1 hour of treatment. In contrast, for M. 
smegmatis treated with compound 27, ATP leakage occurred slower. For instance, as shown 
in Figure 5.9, % of extracellular ATP found was 30.4%, 63.4%,76.7% and 84.4% at 1 h, 3 h, 
6 h and 9 h respectively. At 4x MIC, 91.3% of ATP was distributed as extracellular ATP after 
6 h of treatment. The results also supported the previous observation that compounds 9 and 
19 were stronger membrane targeting agents than 27. Moreover, as ATP could be detected in 
the extracellular environment, it also suggested that 19 and 27 could induce membrane 
damage that allowed the leakage of ATP. ATP has a molecular weight of 507.18 g/mol and 
Sytox Green has molecular weight of > 600. Thus, the membrane damage caused by 
compound 9 and 27 was sufficient to allow leakage of ATP but not Sytox Green. As 
compound 9 induced the slowest ATP leakage, the ascending order of these compounds to 
induce membrane disruption was 9> 19> 27. Similar observations were obtained when the 
cells were treated at 1× MIC with most of the ATP found in the extracellular environment. 
ATP distribution was also investigated for cells treated at 0.5x MIC. As shown in Table 5.4A, 
most of the ATP was detected in the bacteria. For instance, after 9 hours of treatment, the 
percentage of intracellular ATP detected was 76.8%, 66.5% and 73.5% for cells treated with 
9, 19 and 27 respectively.  
Results with M. bovis showed (Table 5.4B) that the extent of ATP leakage in treated M. 
bovis was weaker and slower as compared to M. smegmatis. For instance, M. bovis treated 
with 2× MIC and 4× MIC of compound 19, only 63.2% and 69.7% of ATP were found in 
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extracellular environment after 9 hours of treatment. In contrast, >80% of ATP was detected 
in treated M. smegmatis. Compound 27 also induced much weaker ATP leakage at all 
concentrations. Figure 5.9 (right) clearly shows that the %ATP in supernatant (black bar) 
increased slower than M. smegmatis. This result was also consistent with the time-kill data, 
which showed that longer times were required to achieve a 3-log reduction against M. bovis 
(6 – 9 hours). Similarly, no significant ATP leakage was detected for cells treated with 0.5x 
MIC of all compounds. Overall, the results suggested that membrane permeabilization led to 





















Figure 5.7. Comparative effects of respiratory inhibitors and anti-mycobacterial agents on 
ATP concentration in M. smegmatis. The % of ATP in cells treated at different time-point 
was calculated relative to the ATP content measured at time 0. The dashed line (100%) 
indicates the ATP percentage at time 0 for each treatment. Data points represent the means ± 
standard deviations from two independent experiments performed in triplicate. Compound 










Figure 5.8. Time-course of the effect of the amphiphilic xanthone derivatives and respiratory 
inhibitors on extracellular ATP in M. smegmatis. The values represent the means ± standard 
deviations from two independent experiments performed in triplicate. Compound codes: 







Figure 5.9.  Comparative effects of compounds 9, 19 and 27 on ATP distribution in M. 
smegmatis and M. bovis. Black bar indicates %ATP in supernatant or extracellular ATP and 
red bar indicates %ATP in cells or intracellular ATP. High percentage of ATP in supernatant 
indicates ATP leakage from the cell. Time points studied: 0, 1 h, 3 h, 6 h, 9 h and 24 h. These 
values were tabulated based on the total ATP detected in supernatant and in cells at the 
specific time point. The chart was plotted based on the values tabulated in Tables 5.4A and 
5.4B. The results for the concentration of 2x MIC are shown as representative. Refer to 
Tables 5.4A and 5.4B for the complete data on ATP distribution induced by these compounds 






Table 5.4A. Comparative effects of amphiphilic xanthone derivatives on %ATP distribution 
of M. smegmatis in cell and supernatant. Concentrations of compound 9, 19 and 27 used were 
0.5x MIC – 4x MIC. Time points studied: 0, 1 h, 3 h, 6 h, 9 h and 24 h.  
Compound Conc. 
ATP distribution (%) 





S C S C S C S C S C 
9 0.5x MIC 0 100 6.8 93.2 16.4 83.6 12.2 87.8 23.2 76.8 66.7 33.3 
 1x MIC 0.8 99.2 42.1 57.9 88.0 12.0 79.9 20.1 82.4 17.6 44.4 55.6 
 2x MIC 1.3 98.7 95.6 4.4 97.3 2.7 96.8 3.2 96.6 3.4 86.7 13.3 
 4x MIC 1.3 98.7 97.4 2.6 97.5 2.5 96.7 3.3 97.3 2.7 97.3 2.7 
19 0.5x MIC 0 100 24.7 75.3 39.0 61.0 30.6 69.4 33.5 66.5 53.6 46.4 
 1x MIC 2.3 97.7 88.5 11.5 91.8 8.2 88.0 12.0 89.4 10.6 88.1 11.9 
 2x MIC 4.0 96.0 97.2 2.8 97.4 2.6 96.1 3.9 96.1 3.9 95.3 4.7 
 4x MIC 4.3 95.7 94.3 5.7 91.1 8.9 83.5 16.5 84.3 15.7 88.0 12.0 
27 0.5x MIC 0 100 2.2 97.8 5.9 94.1 13.2 86.8 26.5 73.5 47.5 52.5 
 1x MIC 2.3 97.7 6.5 93.5 44.7 55.3 36.3 63.7 58.6 41.4 88.7 11.3 
 2x MIC 3.0 97 30.4 69.6 63.4 36.6 76.7 23.3 84.4 15.6 94.7 5.3 
 4x MIC 3.8 96.2 42.7 57.3 55.3 44.7 91.3 6.7 92.1 7.9 95.5 4.5 
a 
Percentage of ATP in supernatant 
b








Table 5.4B. Comparative effects of amphiphilic xanthone derivatives on %ATP distribution 
of M. bovis in cell and supernatant. Concentrations of compound 9, 19 and 27 used were 0.5x 
MIC – 4x MIC. Time points studied: 0, 1 h, 3 h, 6 h, 9 h and 24 h. 
Compound Conc. 
ATP distribution (%) 





S C S C S C S C S C 
9 0.5x MIC 0 100 20.8 79.2 27.4 72.6 22.9 77.1 47.2 52.8 34.7 65.3 
 1x MIC 2.0 98.0 24.9 75.1 66.1 33.9 70.7 29.3 85.3 14.7 86.4 13.6 
 2x MIC 3.6 96.4 42.4 57.6 83.6 16.4 91.9 8.1 92.8 7.2 94.1 5.9 
 4x MIC 10.5 89.5 66 34 89.6 10.4 93.3 6.7 94.5 5.5 93.2 6.8 
19 0.5x MIC 0 100 25.1 74.9 20.1 79.9 28.0 72.0 25.4 74.6 15.6 84.4 
 1x MIC 2.5 97.5 13.2 86.8 24.2 75.8 30.4 69.6 48.5 51.5 37.5 62.5 
 2x MIC 2.2 97.8 10.1 89.9 44.2 55.8 63.2 36.8 75.3 24.7 70.5 29.5 
 4x MIC 9.4 90.6 16.8 83.2 42.1 57.9 69.7 30.3 84.0 16.0 85.2 14.8 
27 0.5x MIC 0 100 20.2 79.8 8.6 91.4 8.6 91.4 7.3 92.7 4.8 95.2 
 1x MIC 4.7 95.3 11.5 88.5 7.7 92.3 14.4 85.6 13.5 86.5 4.5 95.5 
 2x MIC 8.1 91.9 16.7 83.3 20.0 80.0 27.4 72.6 33.1 66.9 50.2 49.8 







In summary, this chapter has shown that amphiphilic xanthone derivatives killed 
mycobacteria via different mechanism from the current first-line TB drugs. This preliminary 
study has also shown that the inner membrane may be the main target of the amphiphilic 
xanthone derivatives. Membrane disruption led to ATP leakage and depletion, resulted in 
rapid cell death. However, the structural parameters required were very different from those 
active against other Gram-positive bacteria. Future studies could investigate the role of 
mycolic acid in anti-mycobacterial action of amphiphilic xanthone derivatives. In general, 
xanthone derivatives are potential therapeutic candidates for treating mycobacterial infections 



































6.1 Peptides design, sequences and nomenclature 
Antimicrobial peptides (AMPs) are naturally occurring molecules produced by both 
prokaryotic and eukaryotic cells and involved in several host defense mechanisms.
138, 236
 Up 
to date, hundreds of AMPs have been isolated and identified. AMPs have been extensively 
investigated for possible clinical applications as they have broad-spectrum activity against 
multiple pathogens, including drug-resistant strains.
153a, 225
 Humans have a family of ten 
molecules called defensins, which are one of the main families of AMPs with molecular 
weights between 3–6 kDa and about 45 amino acids in length.211a They are classified into α- 
and β-defensins, based on the spatial distribution of the three cysteine intramolecular 
bonds.
211a
 Defensins show potent and useful antibacterial properties, such as rapid time kill, 
broad spectrum of activity and low rate in selecting resistant mutants in vitro.
141
 
Our group has previously modified and identified 10 amino acids (AA) C-terminal analogs 
of human-β-defensins 3 to obtain monomeric and dimeric forms of the peptide. The 10 AA  
C-terminal molecule has an amino sequence of RGRKVVRRKK (coded as B1088) with a net 
charge of +7.
237
 Its covalent dimeric form, V2-peptide-dimer [(RGRKVVRR)2KK] (coded as 
B2088) (18 AA, net charge = +12), adopts a compact structure in which the hydrophobic 
residues occupy the core position and the cationic charged residues distribute on the surface 
disrupting bacterial membranes.
140a
 The V2-peptide-dimer retains its rotational molecular 
mobility and its high molecular mobility enables it to permeate through the bacterial outer 
membrane and LPS, and accumulates on the cytoplasmic membrane disrupting it.
140a
 V2-
peptide-dimer has considerable advantages over conventional antibiotics, such as rapid 
killing of bacteria, promising selectivity to discriminate the bacterial membrane and low 






In the previous sections, xanthone derivatives displayed potent antimicrobial activities 
against Gram-positive pathogen. However, their activities against Gram-negative pathogens 
were not satisfactory. The aim of the current study was to design novel antimicrobials based 
on the B2088 template, to obtain potent compounds against Gram-negative pathogens. The 
design idea was arisen from polymyxin B. Polymyxin B is a small cyclic lipopeptide with 
potent LPS neutralization activity. Polymyxin B nonapeptide, a polymyxin B analogue 
without a lipid chain, binds with comparable affinity to LPS but is not effective at 
neutralizing LPS, thus demonstrating the importance of lipid insertion of polymyxin B into 
the LPS layer for activity.
238
 LPS is an amphiphilic molecule with an anionic portion and six 
lipid tails. Strong interactions with LPS could lead to larger perturbations of the LPS layer. 
Therefore, I hypothesize that conjugating two fatty acid tails at the N-terminus of the peptide 
dimer, such that the cationic segment and the fatty acid chains of the N-lipidated-peptide 
could interact complementarily with the anionic moiety and the lipid tails of the LPS 
molecule. 
Herein, I disclose the efforts towards designing a novel class of potent N-lipidated 
peptide-dimers, C8-B2088 and C8-B2099, with all the desired antimicrobial properties, such 
as promising MIC values, good membrane selectivity, non-toxic and be able to permeabilize 
the Gram-negative outer bacterial membrane effectively. In addition, the relationship(s) 
between the lipid length of these peptides on selectivity, toxicity, outer and inner membrane 
interactions will be described and assessed. The prospects of synergy between the N-lipidated 
peptide-dimers and the conventional antibiotics were also studied. These data pave the way 
and provide unique insights into developing a new group of N-lipidated peptides for 
therapeutic use against multidrug resistant Gram-negative bacteria, including the deadly CRE. 
At the end of this chapter, antimicrobial activities of N-lipidated peptides against Gram-
positive are also described.  
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In this study, 2 peptides were used: the V2-peptide-monomer with a sequence of 
RGRKVVRRKK and the less hydrophobic G2-peptide- monomer with a sequence of 
RGRKGGRRKK. The branched peptide-dimers, V2-peptide-dimer and G2-peptide-dimer 
used in this study were derived from their corresponding V2- or G2- peptide-monomer and 
had sequences of (RGRKVVRR)2KK and (RGRKGGRR)2KK respectively. For N-lipidated 
peptides, both peptide-monomers and peptide-dimers were further modified using fatty acids 
with varied carbon numbers, Cn ranging from n= 2 to 16: acetic acid (2 carbons), butyric acid 
(4 carbons), hexanoic acid (6 carbons), octanoic acid (8 carbons), decanoic acids (10 carbons), 
lauric acid (12 carbons), myristic acid (14 carbons) and palmitic acids (16 carbons). All N-
lipidated peptides were amidated at their N-terminals. The net charges of the peptide-
monomers and peptide-dimers were +7 and +12 respectively. To maintain consistency in the 
peptide series nomenclature, we identified V2-peptide-monomer and G2-peptide-monomer as 
B1088 and B1099 respectively, while V2-peptide-dimer as B2088 and G2-peptide-dimer as 
B2099. A N-lipidated peptide is prefixed with Cn, where n indicated the number of carbon of 
the attached fatty acid. The sequence and structure of the peptides used in this study are 
















Figure 6.1. Sequences of parent peptide-dimers, monomers and their N-lipidated peptides 
used in this study. Fatty acid with variable lipid length was conjugated at N-terminus of 
peptide-dimers B2088 and B2099 or peptide-monomer B1088 and B1099. V= valine and G= 











6.2 In vitro antimicrobial activities and hemolytic activities of the peptides   
The antimicrobial activities of N-lipidation of B1088 and B1099 were first explored. The 
MIC values of all these peptides against K. peumoniae, P. aeruginosa and E. coli are shown 
in Tables 6.1A and 6.1B for Cn-B1088, Cn-B2088, Cn-B1099 and Cn-B2099. Both B1088 and 
B1099, and their short fatty acid conjugations (n= 2 – 6) displayed poor antibacterial 
activities (MIC ≥ 10 – 80 µM) against all the strains tested. Conjugations with longer lipids, 
from C10-B1088 up to C14-B1088, gradually enhanced bacterial inhibition. For example, C14-
B1088 showed MIC values at 6 µM (K. pneumoniae and E. coli) and 10 µM (P.aeruginosa). 
Reduced antimicrobial activities were observed when the lipid length further increased to n= 
16. MIC values of ≥ 40 µM were observed for C16-B1088 against K. pneumoniae and P. 
aeruginosa. Similar trends were observed for N-lipidated B1099.  
Next, the dimeric forms of these peptides were considered. The antibacterial activities of 
the N-lipidated peptide-dimers were also lipid length-dependent. In general, antibacterial 
activities were gradually enhanced when the lipid length increased up to n= 12 (MIC values 
of ≤ 6 µM). The opposite effect was observed at longer lipid lengths from n= 12 to n= 16 
(MIC values of ≥ 6 µM). The results showed that N-lipidation with carbon units of ≥14 
generally resulted in less activity, for example, C16-B2088 had MIC values >40 µM against K. 
pneumonia and P.aeruginosa. In summary, C8-B2088 and C10-B2088 displayed the most 
potent antibacterial activities. The results also showed that there was no significant impact on 
the antibacterial activities when the hydrophobic amino acid residues (valine) were replaced 
with the non-hydrophobic residues (glycine) in both peptide-monomers and peptide-dimers 
(except C16-peptide-dimers). 
The hemolytic activities, where the concentration needed to induce 10% of hemoglobin 
released are listed in Tables 6.1A and 6.1B. All peptides with lipid carbon number of ≤ 10 
were non-hemolytic up to the highest concentrations tested at 10,000 µg/mL. The hemolysis 
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substantially increased at longer lipid lengths from 12 to 16 carbon numbers. For instance, 
C12-B2088, C14-B2088 and C16-B2088 had HC10 values of 543 ± 53, 252 ± 5 and 114 ± 38 
µg/mL respectively. The findings are consistent with other reports, which demonstrated that 




Encouraged by the potent antimicrobial activities and non-hemolytic properties of C8-
B2088, C10-B2088, C8-B2099 and C10-B2099, the antibacterial activities of these N-lipidated 
peptides against a panel of 10 strains of P. aeruginosa were further evaluated (Table 6.2). 
B2088 and B2099 were used as reference peptides. Gatifloxacin and gentamicin were used as 
comparators. The data revealed that C8-B2099 and C8-B2088 displayed a 2- or 3-fold 
enhanced inhibition against most of the strains tested respectively, as compared to their 
parent dimers B2088 and B2099 respectively. An overall improvement of 85% (17 in 20) and 
65% (13 in 20) were observed for C8-modified peptide-dimers and C10-modified peptide-
dimers respectively. In contrast, several P. aeruginosa strains displayed significant resistance 
against gatifloxacin and gentamicin, with MIC values of > 16 µM. In summary, C8-modified 
peptide-dimers (C8-B2088 and C8-B2099) displayed the most potent antibacterial activities 
against a panel of P. aeruginosa strains, including those displayed resistant against 
gatifloxacin and gentamicin.  
The MIC values of C8-B2088 and C8-B2099 against CRE strains were also tested. Table 
6.3 shows that both peptides displayed MIC value of 3 µM against K.  pneumoniae DS16260. 
In contrast to non-CRE strains of E. coli and K. pneumoniae, higher MIC values (6 – 10 µM) 
were observed for CRE strains. It is noteworthy that the MIC values were stable among all 
the CRE strains tested. The CRE strains displayed different levels of resistance against 
levofloxacin and gentamicin. For example, only K. pneumoniae DU31158 was susceptible to 
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levofloxacin. Other CRE strains displayed MIC values range from 10 to > 100 µM against 






























Table 6.1A. In vitro antibacterial activity (µM) and hemolytic activity (HC10) of N-lipidated 
peptide-monomers, Cn-B1088  and Cn-B1099.  










A B C A B C 
0 >10000 >80 80 10 >10000 >80 >80 20 
2 >10000 >80 >80 40 >10000 >80 >80 20 
4 >10000 >80 >80 40 >10000 80 80 40 
6 >10000 80 80 10 >10000 >80 >80 20 
8 >10000 >80 10 6 >10000 40 10 6 
10 >10000 80 20 6 >10000 20 10 10 
12 >10000 20 10 6 8602±1269 10 6 6 
14 8896.5 ± 853.5 6 10 6 6670±29 10 6 6 
16 5481.0 ± 32.6 40 80 10 5064±37 80 80 10 
a 
Values represent the means and standard deviations obtained from two independent 
experiments. 
b









Table 6.1B. In vitro antibacterial activity (µM) and hemolytic activity (HC10) of N-lipidated 
peptide-dimers, Cn-B2088  and Cn-B2099.  










A B C A B C 
0 > 10000 6 6 3 >10000 3 6 6 
2 > 10000 6 6 6 >10000 3 6 1.5 
4 > 10000 6 10 3 >10000 6 6 3 
6 > 10000 6 6 3 >10000 3 3 3 
8 > 10000 3 3 6 >10000 3 3 3 
10 > 10000 3 3 6 >10000 3 3 6 
12 543 ± 53 6 6 6 517 ± 66 6 6 6 
14 252 ± 5 10 3 1.5 82 ± 5 10 6 10 
16 114 ± 38 > 40 > 40 10 64± 5 10 10 10 
a 
Values represent the means and standard deviations obtained from two independent 
experiments. 
b









Table 6.2. MIC (µM) of selected N-lipidated peptide-dimers against 10 strains of P. 
aeruginosa (Pa). Gatifloxacin and gentamicin were used as comparators. 
Organism Gatifloxacin Gentamicin 
Cn-B2088 peptide-dimers Cn-B2099 peptide-dimers 
n= 0 n= 8 n= 10 n=0 n= 8 n= 10 
Pa DR18531 8 30 3 1.5 1.5 3 3 6 
Pa DM4150R 2 0.5 3 3 1.5 6 3 6 
Pa DM23257 2 0.5 3 3 3 10 6 6 
Pa DM23376 4 0.5 6 3 3 6 3 6 
Pa DU14476 64 25 6 3 3 6 3 3 
Pa DR5790 64 25 10 3 3 6 3 3 
Pa DR4877 32 > 60 6 3 6 6 3 6 
Pa DM23155 4 1 6 3 3 6 3 3 
Pa ATCC9027 2 0.25 6 3 3 6 3 6 
Pa ATCC27853 4 0.5 6 3 3 6 3 3 
Improvements a - - - 8/10 8/10 - 9/10 5/10 
a










Table 6.3. MIC (µM) of C8-B2088 and C8-B2099 against CRE strains of E. coli (Ec) and K. 
pneumoniae (Kp). Levofloxacin and gentamicin were used as comparators.  
Organism Levofloxacin Gentamicin C8-B2088 C8-B2099 
Ec DS19963 20 0.5 6 10 
Ec DS17232 20 1 10 10 
Ec DM17528 80 < 0.25 10 10 
Kp DS07955 > 100 > 60 10 10 
Kp DS16260 10 2 3 3 
Kp DU31158 0.03 < 0.25 10 10 














6.3 Aggregation behavior of N-lipidated peptides 
The ANSA fluorescence probe was used to determine the degree of aggregation of the N-
lipidated peptides-dimers. The fluorescence intensity of ANSA increases when the dye binds 
to the non-polar regions of a protein. The emission maximum of ANSA will be blue shifted 
when it binds to the complex. Figure 6.2 showed no evidence for self-assembly states for N-
lipidated peptide-dimers up to a carbon unit of n=10. C12-B2099 underwent aggregation 
gradually in the solution when the concentration increased from 20 to 300 µM. At 300 µM, 
the degree of aggregation was 62.5 ± 1.8%. C12-B2088 showed some self-assembled in the 
solution (27.6 ± 2.6% at 300 µM). C14-B2088, C16-B2088, and C14-B2099 and C16-B2099 
were found to aggregate at much lower concentrations. At 20 µM, they reached a degree of 
aggregation of 50 – 60%, and 100% at 100 µM. In addition, the emission maximum was 
gradually blue shifted from 510 nm to 490 nm when the lipid length increased. The data 
revealed that the reduced activities of C16-B2088 and C16-B2099 against bacteria may arise 
from their aggregated states. For N-lipidated peptide-monomers, no apparent aggregation was 
observed, including C16-B1088 and C16-B1099 (Figures 6.2C and 6.2D).  
The structure of the cluster formed by these N-lipidated peptide-dimers was investigated 
using coarse-grained molecular dynamics simulations. Figures 6.3A, 6.3B and 6.3C show that 
C4-B2088 and C8-B2088 existed mostly as monomers. In contrast, Figure 6.3D shows a 
strong aggregation of C16-B2088. The results also revealed that the aggregate formed due to 
the lipid tails buried inside the folded peptide while the cationic groups faced outwards 
forming a micelle-like structure (Figure 6.3D). 
The antibacterial activity of the N-lipidated peptide-monomers and peptide-dimers 
demonstrated an intriguing finding. The MIC values displayed a “U” shape behavior with the 
lipid length of (8 - 10 carbon units) showed an optimal MIC level against Gram-negative 
bacteria. Optimal lipid lengths for peptide-dimers and peptide-monomers were 8 – 10 and 12 
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– 14 carbon units respectively. There are some reports showing a similar “U” shape behavior 
of N-lipidated peptides against Gram-negative bacteria.
240
  
Aggregations and interactions with the membranes are two important parameters that 
contribute to the “U” shape pattern for antimicrobial activities of these N-lipidated peptides. 
From the activity data, the reduced antimicrobial activity at longer lipid lengths may be 
primarily related to the self-assembly of the fatty acid conjugated peptides, as shown in 
Figure 6.2. This observation complements a number of previous studies.
144, 192, 197
 Malina and 
Shai reported that the enhanced oligomerization of N-lipidated peptides increased their 
volume in solution, which made it difficult for them to penetrate through the bacterial cell 
wall.
198
 Consequently, their ability to reach and disrupt the cytoplasmic membrane was 
limited, which is reflected in their poor antimicrobial activity. In contrast, no significant 
aggregation was observed for N-lipidated peptide-dimers with carbon units of 0 – 10. The 
data suggests that these potent N-lipidated peptide-dimers existed in a monomeric state in 
solution, which was corroborated in the MD simulation study (Figure 6.3). Simulation results 
further suggested that the aggregation of the N-lipidated peptide-dimers was a result of a 
subtle balance of electrostatic and hydrophobic interactions. For the N-lipidated peptide-
dimers with short lipid lengths, the electrostatic repulsion interactions dominate, so they 
mainly existed as monomeric state. On the other hand, if the carbon unit of the conjugated 
fatty acid was too long, the hydrophobic interactions between lipid lengths dominated, 
resulting in aggregation.  However, it should be noted that the self-assembly of a lipopeptide 
does not always lead to reduced activity. Shankar et al. reported that a short hybrid E-
vinylogous lipopeptide with a moderate hydrophobicity and high electrical potential of self-







Figure 6.2. Degree of aggregation of (A) Cn-B2088 and (B) Cn-B2099 (C) Cn-B1088 and (D) 
Cn-B1099 in water. Data points in panels A and B represent the means ± standard deviations 




























Figure 6.3. Aggregation of N-lipidated peptide-dimers with different lipid lengths was 
studied using molecular dynamic (MD) simulation. (A) The number of clusters formed 
during the MD simulations. (B) The snapshot of clustered formed by C4-B2088. (C) The 











6.4 Outer membrane studies 
6.4.1 Interaction of N-lipidated peptides with LPS 
Next, the binding strength of the N-lipidated peptide-dimers to LPS was investigated using 
a rapid and robust high-throughput fluorescence displacement assay. The occupancy of 
dansylcadaverine (DC) displacement followed a dose-response function, where the maximum 
displacement was achieved at 15 – 30 µM for all the peptides. I reasoned that the DC 
displacement was proportional to the binding strength. The apparent binding strengths of the 
N-lipidated peptide-dimers were computed from the displacement curve are shown in Figure 
6.4. The results (Table 6.4) show that in general, the binding strength to the LPS gradually 
increased with the lipid length. For example, the binding strength of C2-B2088 was 75.7 ± 1.5 
(arbitrary units), and this value increased to 151.0 ± 3.7 for C16-B2088. The N-lipidated 
peptide-dimers also displayed stronger binding strength than their monomeric conjugates. C8-
B1088 and C10-B1088 demonstrated binding strengths of 84.2 ± 0.6 and 101.6 ± 1.4 
respectively (Table 6.4). In contrast, the binding strengths of 121.0 ± 2.3 and 131.3 ± 0.9 
were observed for C8-B2088 and C10-B2088 respectively. The results revealed that the N-
lipidated B2088 had stronger binding strengths as compared to the N-lipidated B2099. This 
finding was in accordance to previous reports which demonstrated that hydrophobic groups 












Table 6.4. Summary of outer membrane studies in this study for Cn-B2088 and Cn-B2099. 
Carbon units, n  NC50 (µM)
a




G2-Peptide V2-Peptide G2-Peptide V2-Peptide G2-Peptide 
0 > 1000 > 1000 84.8 ± 1.6 82.4 ± 1.4 1.9 ± 1.6 
2 > 1000 > 1000 56.1 ± 1.8 75.7 ± 1.5 1.6 ±1.5 
4 768.9 > 1000 72.4 ± 1.4 93.4 ± 0.9 2.5 ± 3.0 
6 413.4 ± 7.4 187.3 ± 5.6 86.4 ± 0.4 100.2 ± 0.4 10.5 ± 1.9 
8 117.4 ± 3.5 73.4 ± 3.7 112.2 ± 1.4 121.0 ± 2.3 20.0 ± 5.2 
10 141.7 ± 5.1 38.1 ± 0.5  122.0 ± 2.0 131.3 ± 0.9 44.3 ± 1.5 
12 62.8 ± 1.4 29.0 ± 1.2 126.5 ± 2.4 129.6 ± 0.8 55.9 ± 1.2 
14 35.31 ± 0.8 32.1 ± 1.7 124.2 ± 1.4 135.0 ±4.0 39.2 ± 3.8 
16 43.0 ± 1.1 47.9 ± 9.3 105.9 ± 0.9 151.0 ± 3.7 36.5 ± 0.3 
C8-B1088/99 > 1000 > 1000 69.9 ± 1.3 84.2 ± 0.6 ND 
c
 
C10-B1088/99 565.9± 5.1 > 1000 78.0 ± 1.2 101.6 ± 1.4 ND 
a 
NC50 of peptides using LPS from E. coli serotype 0111:B4  
b








6.4.2 In vitro LPS neutralization by N-lipidated peptides 
Binding to LPS is not a necessary requisite for biological neutralization of endotoxic 
activity.
242a
 In this study, the LPS neutralization potency of N-lipidated peptides was 
determined by LAL assay. Figure 6.5A shows that N-lipidated peptide-dimers with short lipid 
lengths of carbon units of 0 – 4 were not able to neutralize LPS of E. coli effectively (NC50 > 
1000 µM). To neutralize E. coli LPS, the critical lipid length for N-lipidated peptide-dimers 
was 6, as the NC50 of C6-B2088 and C6-B2099 sharply reduced to 187.3 ± 5.6 µM and 413.4 
±7.4 µM respectively. Thereafter, the NC50 decreased gradually with longer lipid lengths. For 
example, C8-B2088, C10-B2088 and C12-B2088 exhibited NC50 values of 73.4 ± 53.7 µM, 
38.1 ± 0.5 µM and 29.0 ± 1.2 µM respectively. Previous reports have shown that inactivation 
of LPS is accompanied by a change in the aggregated structure of LPS or lipid A into a 
multilamellar form.
243
 Thus, a long lipid length is needed to provide sufficient strength to 
bind and change the structure of LPS into a multilamellar form. A similar trend, but with 
higher NC50, was observed when P. aeruginosa LPS was used instead of E. coli LPS (Figure 
6.5B). The exception was C4-B2099, which displayed a higher potency in P. aeruginosa LPS 
neutralization, with NC50 value of 344.8 ± 11.2 µM. 
The N-lipidated peptide-monomers did not exhibit LPS inhibitory activity in a significant 
way. As compared to the N-lipidated peptide-dimers, the NC50 of N-lipidated peptide-
monomers were generally higher. Almost no neutralization (NC50 > 1000) was observed 
from B1088 and or B1099 up to C8-B1088 and C8-B1099 (Figure 6.5A). It may be also 
worthwhile to consider that the LPS neutralization correlated with dye displacement assay 
results using LPS as mentioned above. In summary, the interaction between N-lipidated 
peptide-dimers and LPS increased with the lipid length, and the N-lipidated peptide-dimer 
with a carbon unit ≥ 6 displayed LPS neutralization activity. In contrast, N-lipidated peptide-
monomers required longer carbon chains (up to 10 and 12) to achieve the same level activity. 
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6.4.3 NPN assay: Outer membrane permeabilization 
Next, the NPN uptake induced by N-lipidated peptide-dimers was investigated to assess the 
ability of these compounds to permeabilize LPS layer of Gram-negative bacteria. NPN is a 
hydrophobic fluorescence probe; its fluorescence emission is enhanced when it relocates in a 
glycerophospholipid environment.
244
 Hence, increased fluorescence values of NPN indicates 
a loss of organization of the structure of the outer membrane of Gram-negative bacteria. As 
shown in Figure 6.6, C0-B2099, C2-B2099 and C4-B2099 induced negligible outer membrane 
permeabilization up to 400 µM. As NPN is similar to the LPS neutralization assay, a 6-
carbon lipid was the critical lipid length to observe the NPN uptake, which further increased 
with the increase of lipid length, reaching a maximum at C12-B2099. After that, the outer 
membrane permeabilization of N-lipidated peptide-dimers decreased with carbon lengths of n 
= 12 to n = 16, as indicated in the smaller panel inserted in Figure 6.5.   
Overall, the outer membrane studies using the approaches discussed above clearly indicate 
that N-lipidated peptide-dimers with longer lipid lengths of C6-12 interacted more strongly 
with LPS. Combining all factors including antibacterial activity, hemolytic activity and outer 
membrane permerbilization, N-lipidated Cn-B2088 or Cn-B2099 with carbon units of 8 and 













Figure 6.4. Maximum achievable displacement of Bodipy TR cadaverine (BC) from the LPS 
from E. coli serotype 0111:B4. Values presented were relative to the displacement of BC at 
40 µM of polymyxin B. The values represent the means ± standard deviations from two 











Figure 6.5. Calculated concentration necessary to neutralize 50% of LPS (NC50) by N-
lipidated peptides using the LAL assay. Note that 1000 µM was the highest concentration 
tested, and NC50 > 1000 µM was represented as 1000 µM in the graph for ease of comparison. 
Please refer to Table 6.4 for the NC50 values for all peptides tested. The values represent the 













Figure 6.6. % 1-N-phenylnaphthylamine (NPN) uptake of P. aeruginosa DM23155 induced 
by Cn-B2099. For clarity, the % NPN uptake curve of Cn-B2099 with n = 12, 14 and 16 were 
displayed in the smaller panel, which showed that the % uptake decreased at longer acyl 
lengths. The values represent the means ± standard deviations from two independent 










6.5 Time-kill kinetics of N-lipidated peptide-dimers 
The bactericidal properties of C0-B2088, C8-B2088, C0-B2099 and C8-B2099 were 
compared at 1 and 2 multiples of the MIC values against a representative strain of P. 
aeruginosa (DM23155). Figure 6.6 shows that both N-lipidated peptide-dimers, C8-B2088 
and C8-B2099 displayed concentration-dependent effects, demonstrating a faster killing 
kinetics at higher concentrations. Interestingly, although both C8-B2088 and C8-B2099 only 
showed a 2-fold improvement of MIC value as compared to C0-B2088 and C0-B2099, both 
C8-B2088 and C8-B2099 had more rapid bactericidal kinetics. For example, both C8-B2088 
(Figure 6.7A) and C8-B2099 (Figure 6.7B) achieved a 3-log reduction (99.9% reduction) in 
viable counts in 30 minutes at 2× MIC. In contrast, the time-kill kinetics of C0-B2099 at 2× 
MIC was 10-fold slower, as 5 hours were required. A 3-log reduction could not be achieved 
for C0-B2088. It is also noteworthy that C8-B2099 at both concentrations managed to reduce 
the viable count by a 6.7-log reduction, achieving a complete kill at 24 hours of incubation. 
For comparison, a complete kill was only achieved at 2× MIC of C0-B2099. Regrowth 
occurred when the strain was incubated with 1× MIC of C0-B2099 at 24 hour, and only 2.7-
log reduction was achieved at 5 hours. For B2088 series, only C8-B2088 at 2× MIC could 
achieve a complete kill at 24 hours. In summary, the results demonstrated that C8-B2088 and 











Figure 6.7. Time-kill kinetics of (A) C0-B2088 (parent peptide-dimer B2088) and C8-B2088 
at 1× and 2× MIC and (B) C0-B2099 (parent peptide-dimer) and C8-B2099 against a 
representative strain of P. aeruginosa (DM23155). MIC values (μM): C0-B2088 and C0-













6.6 Inner membrane studies 
6.6.1 Depolarization of bacterial membrane by N-lipidated peptide-dimers 
C8-B2088 and C8-B2099 displayed rapid killing action at 2× MIC. From this observation, 
the interaction of the selected N-lipidated peptide-dimers with cytoplasmic membrane was 
also investigated. Figure 6.8A showed that the addition of N-lipidated peptide-dimers, C8-
B2088, C10-B2088 and C12-B2088 at 4× MIC to P. aeruginosa DM23155 caused a rapid 
increase in the fluorescence intensity of DiSC3-5, indicating a loss of membrane potential to a 
high extent. In contrast, N-lipidated B2088 with shorter lipid lengths (carbon units of 2 to 6) 
induced slower and less significant membrane depolarization. Figure 6.8B showed that Cn-
B2099 also displayed similar lipid length dependent manner in reducing the membrane 
potential. In contrast, C8-B1099, a N-lipidated peptide-monomer, at 4× MIC only dissipated 
negligible membrane potential, as compared to peptide-dimer, C8-B2099 at 4× MIC.   
6.6.2 Cytoplasmic membrane permeabilization induced by N-lipidated peptide-dimers 
The ability of the N-lipidated peptide-dimers to induce membrane disruption was further 
investigated. Inner membrane depolarization, as shown in Figure 6.8, does not necessarily 
lead to the membrane disruption.
139
 Please note that membrane disruption was measured as % 
membrane integrity in this experiment. Figure 6.9 shows that Cn-B2088 and Cn-B2099 did 
not lead to significant pore formation at 1× MIC or 2× MIC (% integrity > 80%) from n= 0 to 
10. An exception was C10-B2088 at 2 × MIC, which reduced the membrane integrity to 51.1 
± 1.1%. Strong membrane disruption was only observed for C12-B2088, C14-B2088 and C16-
B2088 at 1x and 2x MIC (% integrity < 50%). These data revealed that the inner membrane 
disruption was not a crucial event to exhibit bacterial inhibition and bactericidal activities for 
C8-B2088 and C8-B2099. 
Together with outer membrane studies, the antimicrobial action of N-lipidated peptides can 
be interpreted as follows: Initially, the positively charged arginine and lysine of the peptides 
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are attracted to the negative charges of the inner core of the LPS. Then, the hydrophobic lipid 
tails of N-lipidated peptide-dimers, with appropriate lengths of C8-C10, bind optimally to the 
lipid A moiety of the LPS (Figures 6.3 and 6.4). In support of this, David et al. has also 
suggested that a clear segregation of cationic and apolar domains are crucial in designing a 
molecule for LPS sequestration.
245
 However, it is also noteworthy that the binding is 
necessary but not sufficient for neutralization.
246
 As reported in Figure 6.5, despite all the N-
lipidated peptide-dimers displaying binding properties to LPS, only lipid lengths with carbon 
units ≥ 8 revealed efficient LPS neutralization. This result emphasizes the necessity of 
conjugating a longer lipid length to insert into the LPS layers as high-potency neutralizers. It 
appeared possible that the peptide-dimers with longer lipid lengths inactivated the LPS by a 
change in the aggregate structure of lipid A or LPS into a multi-lamellar form.
247
 Importantly, 
the resulting LPS neutralizing effect will allow access of additional peptide molecules into 
the cytoplasmic membrane. This “self-promoting uptake” concept, results in the introduction 
of defects into the packing of lipid A moieties of the outer membrane layer. This concept is 
widely supported in the literature. 
248
 This “self-promoting uptake” mechanism also enhanced 
the antibacterial activity of the N-lipidated peptide-dimers at their optimized lipid lengths of 
C8-C10. 
6.6.3 Membrane selectivity studies of N-lipidated peptide-dimers using calcein leakage 
assay 
In order to gain a better insight into membrane selectivity, the N-lipidated peptide-dimers 
were investigated for their ability to induce calcein release from large unilamellar vesicles. 
Liposomes with compositions of DOPE/DOPG= 75/25 and DOPC mimic the membrane 
composition of bacteria and mammalian cells respectively. The data revealed that a direct 
correlation between the leakage ability of these peptides on model membranes and their 
corresponding selectivity. Figure 6.10 showed that all N-lipidated peptide-dimers displayed 
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significant ability to damage the target bacterial membrane at a high ratio of compound to 
lipid of 1:32. In contrast, a disruption of DOPC liposomes (shown in red bar) was only 
observed at longer lipid lengths, notably from C8- to C16-B2088 or B2099. The fact that the 
DOPC liposomes were disrupted by the N-lipidated peptide-dimers with longer lipid tails, 
suggested that a longer lipid would result in decreasing selectivity, which was also associated 






















Figure 6.8. N-lipidated peptide-dimers induced membrane depolarization of Gram-negative 
bacteria. Both (A) Cn-B2088 and (B) Cn-B2099 showed lipid-length dependent manner to 
reduce the bacterial membrane potential.  
 
Figure 6.9. Percent (%) integrity of inner membrane after P. aeruginosa was treated with 1× 
and 2× MIC of Cn-B2099, measured by LIVE/DEAD Baclight bacterial viability kit. The 
values represent the means ± standard deviations from two independent experiments 









Figure 6.10. Effect of N-lipidated peptide-dimers (A) Cn-B2099 and (B) Cn-B2088 at 
different concentrations on calcein released from model membranes. DOPE/DOPG= 75/25 












6.7 Synergistic effect of N-lipidated peptide-dimers 
The outer membrane is known as a permeability barrier to most antibiotics. As the results 
show that N-lipidated peptide-dimers with carbon units of ≥ 6 could bind and neutralize LPS 
effectively, the checkerboard antibacterial assays were used to determine the synergistic 
effect of C6-B2088, C6-B2099, C8-B2088 and C8-B2099 with selected antibiotics against P. 
aeruginosa and E. coli. The FICI index of 1 is defined as an indicator without synergy, FICI 
of 0.5 < FICI< 0.75 indicates a partial synergy and FICI≤ 0.5 indicate an increasing degree of 
synergy.
225
 The lowest FICIs for the combinations of the compounds were shown in Tables 
6.5A and 6.5B. C6-B2099 and C8-B2099 demonstrated 5 of 10 and 4 of 10 combinations 
(with an overall 45% of synergistic actions, 9 in 20) indicating synergy with FICIs of ≤ 0.5. 
Partial synergy with FICIs of 0.75 was observed between the combinations of C6-B2099 with 
nalidixic acid and erythromycin against E. coli. C6-B2088 showed significant synergy effect 
with all the five antibiotics tested (100%). FICs ≤ 0.5 were observed in 16 of 20 combinations 
(80%) for both C6-B2088 and C8-B2088. Other 20% (4 in 20) combinations displayed partial 
synergy with FICI value of 0.56. In general, C6-B2088 and C8-B2088, which are more 
hydrophobic than C6-B2099 and C8-B2099 respectively, displayed improved synergy effect 
(FICIs of ≤ 0.5) from 45% to 80%. 
Polymyxin B is a small cyclic lipopeptide with potent LPS neutralization activity. Earlier 
studies have shown that the lipid insertion of polymyxin B into the LPS layer is important 
since polymyxin B nonapeptide, a polymyxin B analogue without a lipid chain, binds with 
comparable affinity to the LPS but it is not effective in its neutralization..
238, 249
 This 
observation further supports the argument that a lipid chain with an appropriate length (n= 8 
in our studies) is important in the LPS neutralization. It should also be noted that the LPS is 
also known as endotoxin, the primary cause of septic shock.
250
 Lipid A is the endotoxic 
principle of LPS that serves as the minimal biological active unit of LPS. Therefore, LPS 
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neutralization is important in lowering the chance of triggering an immune response.
251
 
However, as LPS neutralization is not the main focus in this study, this issue will not be 
further discussed in details. The results are encouraging as they are comparable to the gold 
standards, polymyxin B and polymyxin E (colistin), which are frequently used in 
combination therapy to improve its antibacterial activity. Several groups have reported that 
the combination using polymyxin B or colistin shows a highly variable synergy (14–100%) 
for P. aeruginosa.
252
 Synergy is important to reduce the dose of each drug in the combination, 
and such combination therapy is also well known to prevent the development of resistance in 
bacteria.
253
 Note that the major concerns of polymyxin B and colistin used therapeutically are 
their nephrotoxicity and neurotoxicity.
252a
 Thus, the N-lipidated peptide-dimers might be a 













Table 6.5A. FIC index of C6-B2088 and C8-B2088 with selected antibiotics against P. 
aeruginosa DM23155 and E. coli ATCC25922. 
Antibiotics 
P. aeruginosa  E. coli  
C6-B2088 C8-B2088 C6-B2088 C8-B2088 
Nalidixic Acid 0.38 0.50 0.50 0.50 
Gentamicin 0.25 0.38 0.38 0.31 
Erythromycin 0.38 0.56 0.38 0.56 
Streptomycin 0.38 0.56 0.38 0.31 
Kanamycin 0.31 0.56 0.50 0.31 
 
 
Table 6.5B. FIC index of C6-B2099 and C8-B2099 with selected antibiotics against P. 
aeruginosa DM23155 and E. coli ATCC25922. 
Antibiotics 
P. aeruginosa  E. coli  
C6-B2099 C8-B2099 C6-B2099 C8-B2099 
Nalidixic Acid 0.63 0.56 0.75 0.56 
Gentamicin 0.31 0.38 0.56 0.38 
Erythromycin 0.56 0.38 0.75 1 
Streptomycin 0.50 0.56 0.38 0.50 






6.8 Evaluation of in vitro and in vivo toxicity of C8-B2088 
The most potent compound, C8-B2088, which displayed promising antibacterial activity, 
LPS disruption and rapid time-kill, progressed into the preliminary in vitro toxicity 
evaluation. Toxicity to the eukaryotic cells is always a concern when working with 
membrane-targeting antimicrobials. Table 6.6 shows that both cell viability assay and 
cytotoxicity assays indicated that C8-B2088 induced negligible toxicity at 2000 µM towards 
human corneal fibroblast cells. Precise effective concentrations to induce 50% cytotoxicity 
and reduce cell viability were impossible to obtain as excessively high concentrations were 
needed. Preliminary acute toxicity of C8-B2088 was tested by topical, intraperitoneal (i.p.) 
and intravenous (i.v.) administration. Studies with animals showed no evidence of toxicity 
after a corneal topical application at 3 mg/ml. Tolerated concentrations for bolus injections 
were at 100 mg/kg ip and 6.25 mg/kg iv for 24 h.  
The membrane selectivity of a membrane-targeting antimicrobial is one of the major issues 
that has by far, prevented its transformation into a clinical application. While the current 
results, as well as results from other groups, demonstrate the usefulness of lipidation in 
improving the antimicrobial activity of AMPs, lipidation also has limitations. For example, 
lipidation usually correlates with higher hemolytic properties.
197, 254
 Most of the lipidated 
AMPs at their optimized carbon unit display strong hemolytic activity at micro-molar 
concentration,
24b, 33c, 42b, 43
 as increasing the lipophilicity enhances peptide binding to the 
neutral mammalian membrane. However, the optimized N-lipidated peptide-dimers (C8-
B2088 and C8-B2099) as shown here were non-hemolytic up to 10 mg/mL. In addition, no 
deleterious effects on human corneal fibroblasts were observed in the in vitro cell viability 
and cytotoxicy assay, and there was no evidence of toxicity in animal studies. Overall, the 






Table 6.6. In vitro and in vivo toxicity of C8-B2088. 
In vitro  In vivo  
HC50 > 10 mg/mL Topical ≥ 3 mg/kg 
LDH
a 
> 2000 µM i.v. 6.25 mg/kg 
ATP
a
 > 2000 µM i.p. 100 mg/kg 
a 




















6.9 Antibacterial activities of N-lipidated peptides against Gram-positive pathogens 
Next, the ability of N-lipidated B2088/99 to inhibit the proliferation of MSSA and MRSA 
was investigated (Table 6.7). For Cn-B2088 derivatives, all peptides with n= 0 to 14 
displayed MIC values ranging from 3.125 – 12.5 µg/mL against the MSSA strain tested. 
Antibacterial activity of C16-B2088 was significantly poorer, as reflected by its low MIC 
value of 50 - 100 µg/mL. For Cn-B2099 series, in general, their antibacterial activities were 
2-fold poorer than Cn-B2088 series (MIC values= 6.25 – 12.5 µg/mL). Similarly to Cn-B2088 
series, C16-B2099 also exhibited low activity in the Cn-B2099 series, with MICs of 50 – 100 
µg/mL. In summary, C8- and C10 conjugated peptide dimers resulted in an enhanced and 
optimized antibacterial potency for both MSSA and MRSA. As C8-B2088/99 and C10-
B2088/99 displayed the most remarkable MICs, the antimicrobial activities of these N-
lipidated peptides with a diverse group of MSSA and MRSA were further determined, as 
shown in Table 6.8. MIC results show that all of the MSSA and MRSA strains tested were 
susceptible to both C8-B2088/99 and C10-B2088/99 at low MICs, ranging from 3.125 µg/mL 
to 6.25 µg/mL. C8-B2099 displayed a slightly higher MIC value of 12.5 µg/mL against 4 
strains of MSSA tested: DM4299, DM4400R, MSSA ATCC29737 and MSSA ATCC29213.  
Next, the bactericidal kinetics of N-lipidated peptides against Gram-positive bacteria 
were evaluated. Figure 6.11 shows that C8-B2088 and C8-B2099 both killed MRSA in a dose-
dependent manner and exhibited fast killing kinetics. C8-B2088 achieved 3-log reductions of 
viable cell count (99.9 % killing) in 2 h and 1 h at 2× and 4× MIC respectively (Figure 
6.11A). In contrast, negligible killing was observed at 0.5× and 1×MIC after 24 h of 
incubation. Figure 6.11B shows that C8-B2099 displayed faster killing kinetics. At 1×, 2× and 
4× MIC, 3-log reductions were recorded at 30 min, 1 h and 2 h respectively. Similar to C8-
B2088, at 0.5× MIC, C8-B2099 no remarkable bacterial killing was observed. It is 
noteworthly that T=the detection limit for the time-kill assay was 100 CFU/mL (Log 
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survivor= 2). Thus, the re-growth signified that C8-B2099 at 2× MIC could not eradicate the 
bacteria completely. The compound might start to degrade after 5 hours, as stability is one of 
the major limitations of the antimicrobial peptides. Emergence of bacterial resistance was less 
likely, as the multi-step passage resistance selection study using C0-B2088 has proven that no 
4-fold increase of MIC was observed for 17 passages.
140a
 
To investigate the preliminary effect of lipid length on bacterial cytoplasmic membrane, 
DiSC3-5 assay was performed. Figure 6.12 showed that C0-B2088 and C2-B2088 induced 
negligible membrane depolarization. C4-B2088 and C6-B2088 at 8× MIC caused a very 
modest depolarization within 40 min of incubation. When the carbon number of fatty acid 
increased to 8, significant membrane depolarization was detected. The depolarization 
occurred in time-dependent manner. The kinetics were somewhat slower than C10-B2088, 
causing a maximal depolarization of the cytoplasmic membrane in around 1200 s. C12-B2088 
displayed very strong and rapid membrane depolarization. C14-B2088 and C16-B2088 were 
not tested as precipitation was observed. In summary, the results suggest that C8-B2088 killed 
the bacteria via a membrane targeting pathway and depolarization increased with carbon unit 















Table 6.7. In vitro antimicrobial activities of N-lipidated peptide-dimers used in this study 
against clinical isolates MSSA DM4001 and MRSA DM9808R. 
Peptides  MIC (µg/mL) Peptides MIC (µg/mL) 
Cn-B2088 MSSA MRSA Cn-B2099 MSSA MRSA 
B2088 12.5 6.25 B2099 12.5 12.5 
C2-B2088 12.5 6.25 C2-B2099 12.5 12.5 
C4-B2088 6.25 6.25 C4-B2099 12.5 12.5 
C6-B2088 6.25 3.125 C6-B2099 12.5 6.25 
C8-B2088 6.25 3.125 C8-B2099 6.25 6.25 
C10-B2088 6.25 3.125 C10-B2099 6.25 6.25 
C12-B2088 12.5 12.5 C12-B2099 6.25 12.5 
C14-B2088 6.25 6.25 C14-B2099 12.5 12.5 
















Table 6.8. MIC values of C8-B2088, C8-B2099, C10-B2088 and C10-B2099 against six strains 
of MSSA and eight strains of MRSA.  
Strains C8-B2088 C10-B2088 C8-B2099 C10-B2099 
MSSA DM 4583R 3.125 3.125 6.25 6.25 
MSSA DM4299 3.125 12.5 12.5 6.25 
MSSA DM4400R 6.25 6.25 12.5 3.125 
MSSA 29737 3.125 3.125 12.5 3.125 
MSSA 29213 6.25 6.25 12.5 3.125 
MSSA 6538 3.125 3.125 6.25 3.125 
MRSA DR42412 3.125 3.125 6.25 6.25 
MRSA DM21455 3.125 3.125 6.25 3.125 
MRSA DB57964 3.125 3.125 3.125 6.25 
MRSA DB68004 3.125 3.125 6.25 6.25 
MRSA DB21595 6.25 6.25 6.25 6.25 
MRSA DB6506 3.125 3.125 3.125 6.25 
MRSA 43300 3.125 3.125 6.25 6.25 







Figure 6.11. Time-kill curves of C8-B2088 and C8-B2099 against MRSA DM9808R. 
Bacterial killing kinetics of (A) C8-B2088 and (B) C8-B2099 at 0.5× – 4× MIC measured at 
various time points. Control was MHB only. 3-log reduction was defined as 99.9% reduction 




Figure 6.12. B2088 and its N-lipidated conjugates induced membrane depolarization. 





In summary, N-lipidated peptide-dimers could be broad-spectrum antibiotics for Gram-
positive and Gram-negative infections. N-lipidated peptides kill Gram-negative pathogens 
through outer-membrane permeabilization and inner membrane disruption. The optimized 
lipid length, in the range of n = 8- 10, displayed promising antimicrobial activities with 
maximum selectivity. Moreover, a synergism study showed that C6- and C8-B2088 might be 
used in combination therapy. In this study, C8-B2088 and C8-B2099 have been successfully 
identified as the most potent compounds. Thus, the design of the N-lipidated peptide-dimers 
with excellent toxicity profile represents a promising class of peptide candidates in combating 


































Increasing antibiotic resistance is a critical healthcare issue and it has led to the failure of 
current antimicrobial therapies. There is an urgent medical need for a sustainable supply of 
new, effective, safe antimicrobials without cross-resistance with currently used antibiotics. In 
this study, two novel types of natural product-derived antimicrobials were designed and 
explored: amphiphilic xanthone derivatives and N-lipidated peptides.  
Design principles for amphiphilic xanthone derivatives with a molecular structure 
consisting of a rigid, hydrophobic core derived from a natural product were demonstrated. In 
this study, SAR was optimized and a set of crucial components were identified: cationic 
moieties with high pKa value, moderate spacer length and isoprenyl groups. The amphiphilic 
xanthone derivatives displayed potent antimicrobial activity against Gram-positive bacteria 
including MRSA, acceptable selectivity, rapid time-kill, avoidance of antibiotic resistance 
and no observable in vivo topical toxicity. In addition, modifying the xanthone core with 
cationic amino acids and lipophilic chains produced a compound with an optimal set of 
characteristics with good in vivo activity. Biophysical studies revealed that amphiphilic 
xanthone derivatives target the bacterial inner membrane.  
This study has also shown that amphiphilic xanthone derivatives were active against 
mycobacteria. Amphiphilic xanthone derivatives demonstrated a different anti-mycobacterial 
mechanism from the current first-line TB drugs. Similar to their action on Gram-positive 
bacteria, amphiphilic xanthone derivatives also target the mycobacterial inner membrane. 
Membrane disruption leads to ATP leakage and depletion, resulting in rapid cell death.  
One of the most challenging issues of membrane targeting antimicrobials is systemic 
toxicity. Thus, the future work on amphiphilic xanthone derivatives will be focusing on SAR 
analysis of systemic toxicity (both i.v. and i.p. injections). In addition, their potential on oral 
application will be investigated too. Thus, their SAR analysis of in vitro ADME (absorption, 
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distribution, metabolism, and excretion) profiles would be also crucial to investigate. The 
absolute oral bioavailability of the optimized compound will be studied. 
This study also demonstrated the design of N-lipidated peptide-dimers could be potential 
candidates for Gram-negative infections through outer-membrane permeabilization. The 
optimized lipid length, in the range of n = 8- 10, displayed promising antimicrobial activities 
with maximum selectivity. Moreover, the synergistic study also showed that C8-B2088 might 
be used in combination therapy. Moreover, N-lipidated peptide-dimers also displayed potent 
activities against Gram-positive bacteria.  
The major limitations of the the current N-lipidated peptide-dimers are stability and the 
cost of synthesis, as many amino acids were involved. Thus, the future work will be focusing 
on truncated form of N-lipidated peptide-dimers. In this study, the minimum amino acids 
required to display similar antimicrobial activities to their parents (N-lipidated peptide-dimers) 
will be investigated. The potent activities, such as good MIC values and fast-time kill must be 
retained. In addition, truncated peptide-dimers are expected to display improved stability as 
there will be lesser cleavage sites to inactive the peptides. A summary Table with general 
properties of the amphiphilic xanthone derivatives and N-lipidated peptide-dimers are 
Tabulated on next page. 
Taken together, the design considerations to obtain and improve selectivity of membrane 
targeting antimicrobials provided in this study may be useful to address the critical need for 
new antimicrobials to combat the increasing prevalence of different type of resistant 
pathogens. These molecules have significant potential as new templates in the therapeutics 
pipeline against some of the most serious forms of Gram-positive bacteria, Gram-negative 
bacteria and mycobacteria, including MRSA, CRE and tuberculosis. They also show 




Summary Table: General properties of the amphiphilic xanthone derivatives and N-lipidated 
peptide dimers used in this study. 
Parameters Amphiphilic xanthone derivatives N-lipidated peptide-dimers 
Gram-positive Gram-negative Mycobacteria Gram-positive Gram-negative 
Antimicrobial properties 
MIC Cationic:  
0.39– 6.25 µg/mL 
Neutral/High carbon number: 
Inactive 
 




2.5–7.5 µM   
Cn≤ 14  3–6 µM 
Cn=16=Less active 
 
Cn ≤ 12  3–6 µM 
Cn ≥14 Less active 
 
Time-kill  
(at 2× or 4× MIC) 
30 min–2 h NAa M. smegmatis: 3 h 
M. bovis: 9 h 
C0= 5 h 
30 min–2 h 
C0= 5 h 
30 min 
Bacterial resistance No NA Not determine No No 
Synergistic study Outer membrane targeting 
agent: Yes 
NA Not determine Not determine Yes 
















Better MIC, faster 
Time-kill 
Mechanism of Action 
Inner membrane studiesb 
DisC3-5/  
CMFDA assay 
Positive NA Positive Positive Positive 
SYTOX Green Positive NA 9: Positive 
19, 27: Negative 
Not determine Not determine 
ATP leakage Positive NA Positive Not determine Not determine 
Baclight assay Positive NA Positive Not determine Positive: Cn≥ 12 
Calcein leakage Positive NA Positive Positive Positive 
Outer membrane studiesb 
LAL assay NA NA NA NA Negative: Cn≤ 4 
Positive: Cn≥ 6 
BC assay NA NA NA NA Positive 
Increase from Cn= 0 
to 12. Decrease from 
Cn=12 to 16 
NPN assay NA NA NA NA Positive  
Increase from Cn= 0 
to 12. Decrease from 
Cn=12 to 16 
Toxicity 
In vitro toxicity 
Hemolysis HC50 of non-peptidic xanthone derivatives < Peptidic xanthone 
derivatives 
Non-hemolytic: Cn≤ 10 
Hemolytic: Cn≥ 12 
ATP assay Not determine C8-B2088/99: > 2000 µM 
LDH assay Not determine C8-B2088/99 > 2000 µM 
In vivo toxicity 
Topical 9: 400 µg/mL 
57: > 3 mg/mL 
61: > 3 mg/mL 
C8-B2088/99: > 3 mg/mL 
Wound Healing 9: > 3 mg/mL 
57: > 3 mg/mL 
61: > 3 mg/mL 
C8-B2088/99: > 3 mg/mL 
i.v. 9: 25 mg/kg 
57: 6.25 mg/kg 
61: 12.5 mg/kg 
C8-B2088: 6.25 mg/kg 
i.p. 9: 50 mg/kg 
57: > 200 mg/kg 
61: > 200 mg/kg 
C8-B2088: 100 mg/kg 
In vivo efficacy 
Corneal Infection 9: Inactive 
57: Active 
61: Very active 
57: Active Not determine Not determine Not determine 
a
 Not applicable          
b 
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1 98.7 31 96.0 
2 99.2 32 97.3 
3 98.8 33 99.7 
4 99.8 34 98.4 
5 99.0 35 99.3 
6 98.3 36 99.2 
7 99.4 37 97.4 
8 99.4 38 98.5 
9 95.4 39 99.5 
10 99.1 40 97.9 
11 95.4 41 95.7 
12 96.0 42 99.1 
13 98.8 43 99.3 
14 96.9 44 98.8 
15 98.7 45 94.6 
16 98.4 46 98.6 
17 97.4 47 98.2 
18 96.8 48 96.5 
19 97.9 49 98.2 
20 98.2 50 98.7 
21 97.0 51 95.1 
22 97.6 52 96.0 
23 97.1 53 96.5 
24 95.9 54 > 95 
25 96.7 55 > 95 
26 95.4 56 > 95 
27 97.9 57 > 95 
28 99.5 58 > 95 
29 99.4 59 > 95 
30 95.1 60 > 95 
  61 > 95 
a 
Compounds 1–53: The purity of the compounds was checked by analytical reverse phase 
HPLC on a Shimadzu LC-20AP with a C18 column (Phenomenex, 150 4.6 mm, 3 μ, 110 Å), 
with a flow rate of 0.7 mL/min, and UV detection at 254 nm. A mixture of water and 












C0-B1088 98.4% C0-B2088 97.8% 
C2-B1088 99.1% C2-B2088 97.0% 
C4-B1088 98.9% C4-B2088 95.2% 
C6-B1088 98.2% C6-B2088 95.9% 
C8-B1088 98.0% C8-B2088 95.2% 
C10-B1088 98.3% C10-B2088 97.7% 
C12-B1088 98.4% C12-B2088 97.8% 
C14-B1088 98.6% C14-B2088 99.8% 
C16-B1088 99.1% C16-B2088 96.6% 
C0-B1099 98.4% C0-B2099 95.6% 
C2-B1099 97.9% C2-B2099 95.1% 
C4-B1099 98.0% C4-B2099 95.4% 
C6-B1099 98.0% C6-B2099 95.7% 
C8-B1099 99.4% C8-B2099 97.3% 
C10-B1099 98.2% C10-B2099 95.9% 
C12-B1099 98.0% C12-B2099 97.8% 
C14-B1099 95.2% C14-B2099 98.5% 
C16-B1099 98.1% C16-B2099 98.9% 
a
 Purity was determined using HPLC. Solvent A: 0.1% Trifluoroacetic in 100% Acetonitrile; 
Solvent B: 0.1% Trifluoroacetic in 100% Water 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
